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GENERAL INTRODUCTION
Current clinical guidelines for the diagnosis and treatment of kidney disease focus mainly on 
renal function as a guiding parameter for detecting and monitoring disease progression 1–4. 
However, kidney damage in the form of tissue remodeling such as fibrosis can be found prior 
to renal function decline, making tissue remodeling a promising subject in finding more precise 
and earlier predictors of disease progression 5–7. Therefore this thesis focusses on (tubulo-
interstitial) tissue remodeling as a signature of renal damage (Figure 1). First, we aim to evaluate 
different triggers of tissue remodeling such as sodium intake, proteinuria and blood pressure. 
Next, tissue remodeling as a whole is dissected into pathways of inflammation, fibrosis and 
lymphangiogenesis, and their interplay is being investigated as possible targets for treatment. 
Finally, we evaluate the possibilities to clinically monitor tissue remodeling by detecting renal 
damage in an early stage and preventing further renal deterioration . 
Triggers of tissue remodeling in kidney disease 
The definition of tissue remodeling is the reorganisation or renovation of existing tissues, which 
can be both physiological and pathological. In chronic kidney disease (CKD) pathological tissue 
remodeling plays an important role in disease progression. In order to unravel this desastrous 
pathway leading to end-stage renal disease (ESRD), the identification of the triggers, which can 
induce tissue remodeling, is key. 
Among the clinical inducers of tissue remodeling, proteinuria is a plausibile cause. Proteinuria 
can lead to a progressive decline in kidney function, worsening to CKD and end-stage renal 
disease (ESRD), and eventually the need for dialysis or renal transplantation 8. Since proteinuria 
is independently associated with a decline in renal function, anti-proteinuric treatment (mainly 
RAAS intervention, eventually in combination with reduced salt intake) comprises a major 
cornerstone in renal medicine. Nevertheless, complete annihilation of proteinuria is often not 
possible, and many patients slowly progress towards renal failure. Forced titration of proteinuria 
by dual RAAS intervention (ONTARGET trial) or ACE-inhibition (ACEi) under very low salt conditions 
worsened renal outcomes or interstitial fibrosis 9.  Even under rather low proteinuria values 
kidneys deteriorate over time. This indicates the need for additional treatment modalities. We 
previously showed that proteinuria can promote renal lymphangiogenesis that concomitantly 
occurs with a profibrotic response and tubular activation 10, and accordingly, this pathway might 
be a target for intervention downstream of proteinuria.
Next to proteinuria, dietary sodium and blood pressure form important life style-related 
inducers of developing tissue remodeling.  It has been shown that dietary sodium restriction 
enhances the response to ACEi, with an optimal antiproteinuric response in humans as well 
as in experimental renal disease 11. The exact mechanisms of this protective response of salt 
restriction are unknown, but seem to be at least partly independent of the classical correlate 
of sodium, namely blood pressure (BP). It has been shown that salt promotes hypertension and 
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Figure 1. Signature of renal function decline. Studies on triggers of tissue remodeling (Chapters 
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effects as well. The other way around; high salt intake increases organ damage that cannot be 
prevented by control of BP 12. The BP-independent effects of sodium are not fully investigated 
yet. We hypothesize that high salt intake induces tissue remodeling such as inflammation, 
lymphangiogenesis and fibrosis in CKD, (partly) independent of BP.
To understand how sodium can induce tissue remodeling independent of BP, we have to 
investigate the underlying mechanisms. By the groundbreaking work by Titze et al. we know that 
sodium can be stored subcutaneously in an osmotically inactive manner, and that this process is 
associated by salt-induced lymphangiogenesis 13–18. Of note, lymphangiogenesis is an important 
component of fibrotic and inflammatory responses 10,19–22. This raises the possibility that sodium 
promotes lymphangiogenesis by its effect on inflammatory cells, eg vascular endothelial 
growth factor C (VEGF-C) production by sodium-activated macrophages. As part of the process 
of sodium-induced lymphangiogenesis, VEGF-C is released by macrophages under high salt 
conditions inducing osmotic stress and therefore nuclear factor of activated T-cells 5 (NFAT5) 
induction 23,24. VEGF-C then binds to the VEGFR3 receptor, which induces lymphangiogenesis 
25. We have recently shown that circulating VEGF-C is modified by sodium intake, in healthy 
subjects and CKD patients, and thus could serve as a biomarker for activation of the pathway 
of non-osmotic sodium storage 21,26. Further support for this focus comes from an earlier study 
in our group by Kramer et al. who showed that low sodium diet could reduce macrophage 
influx, α-SMA (a marker for myofibroblast accumulation) and focal glomerulosclerosis (FGS) 
independent of blood pressure 27. 
Alternatively, this pathway of sodium storage could affect inflammation by modifying 
proteoglycans. The non-osmotic subcutaneous storage of sodium occurs likely by binding 
of sodium by glycosaminoglycans, the polysaccharide side chains of proteoglycans, in the 
interstitium of the skin and of cartilage 28–30. Proteoglycans are (a.o) components of the extracellular 
matrix that can act as docking platforms for growth factors, cytokines, and most prominently 
chemokines. Dependent on the strength of the proteoglycan – chemokine interaction, by 
regulation of the sulfation of their glycosaminoglycan side-chains, proteoglycans can stabilize 
or weaken chemokine gradients, and orchestrate leukocyte migration. Thus, proteoglycans can 
modulate inflammation, but the effect of the binding of excess sodium by proteoglycans on 
their functional properties has not been investigated.
Taken together, more focus on these different triggers of tissue remodeling, such as blood 
pressure, proteinuria and high sodium diet is warranted. This approach could have important 
clinical consequences, as it might explain induction of tissue remodeling and disease progression 
in CKD. Therefore it might serve to design adjunct preventative treatment strategies in different 
patient populations 31. 
Dissection of Tissue Remodeling Components in Kidney Disease.
In order to understand tissue remodeling in renal diseases, we need to focus on the components 




Processed on: 17-4-2019 PDF page: 14
14
have shown increased inflammatory parameters in CKD patients, such as an increased influx 
of macrophages and T-cells, complement activation and mediators of inflammation like MCP-1, 
E-Selectin, P-Selectin, ICAM and VCAM32–36. It has been shown that, in CKD patients, selective 
epithelial injury in the proximal tubules causes interstitial inflammatory and fibrotic responses, 
eventually leading to glomerulosclerosis and end stage renal disease (ESRD) 37. Macrophages play 
a key role in both inflammation and in lymphangiogenesis 10,38. Studies have shown that under 
osmotic stress, macrophages are able to upregulate the transcription factor, tonicity enhancer 
binding protein (TonEBP, also termed nuclear factor of activated T-cells 5, NFAT5) and VEGF-C, 
resulting in lymphangiogenesis by interacting with the VEGF receptor 3 (VEGFR3) 20,23,39,40.
Lymphatic remodeling plays a major role in the interstitial microenvironment of all organs, 
and specifically in the kidney 41,42. Therefore, macrophages might not only remove foreign micro-
organisms from the body, they also play an important role in maintaining tissue homeostasis by 
ensuring lymphangiogenesis in times of different types of stress, including osmotic stress. 
Lymphangiogenesis has been shown to be closely related to fibrogenesis in different organs 
including the kidney 22,43,44. In the early stages of lung fibrosis, Meinecke et al. has showed that 
activated lymphendothelial cells stimulate PDGFR-ß receptor-expressing mural cells, by secretion 
of platelet derived growth factor-B (PDGF-B), recruiting them around lymphvessles (LVs) and 
then by attaching to LVs, impeding their drainage capacity leading to fibrotic processes45. 
In renal interstitial fibrosis, there is an increased production and deposition of extracellular 
matrix (ECM), which eventually leads to a progressive loss of kidney function 46. In terms of 
synthesis, (myo)fibroblasts with an activated phenotype expressing smooth muscle actin 
(α-SMA) are considered to be the main source of the increased deposition of ECM 47–51. Earlier 
studies showed that interstitial fibrosis is the result of an increase in important ECM components, 
such as collagen type I, collagen type III, fibronectin and proteoglycans 52–54. 
In conclusion, tubulo-interstitial tissue remodeling comprises a complex set of mechanisms 
and pathways, eventually leading to renal interstitial fibrosis and tubular atrophy (IFTA) as the 
final common pathway and which is directly correlated to loss of renal function 7. Therefore, 
dissecting the pathways involved in tissue remodeling and investigating their interplay, may lead 
to possible targets for intervention. 
Clinical monitoring of tissue remodeling.
Finally, detecting tissue remodeling in an early stage and to be able to monitor disease 
progression is of key importance to prevent further renal damage. At the moment, renal 
biopsies are the gold standard in determining actual tissue remodeling and therefore disease 
progression in kidney disease. However, this method is invasive and therefore does not form 
an easy access parameter to detect or monitor disease progression in kidney patients. While 
the body of literature in the renal field on tissue remodeling biomarkers is increasing rapidly 
over the last decade, implementation in clinical practice is not yet achieved. The ‘actionability’ 
of these biomarkers remains unknown and more research on their ‘actionability’ is warranted. 
Especially, to investigate whether longitudinal availability of tissue remodeling biomarkers next 
chapter 1
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to metabolic biomarkers of renal (dis-)functioning such as creatinine, albuminuria, vitamin K, 
FGF23 and uric acid might improve treatment of the patients.
Scope of the thesis
The aim of this thesis is to investigate new and promising ways to prevent and detect renal 
function decline with a focus on renal tissue remodeling events. Proteinuria is independently 
associated with a decline in renal function and structural damage of renal interstitial tissue. 
When we are able to detect the first signs of structural renal damage, we can act on this. One 
of the preventative measures doctors can prescribe to their patients is reducing their sodium 
intake. Earlier studies have shown that salt promotes hypertension and thereby induces damage 
to different organs in the body. This ongoing organ damage, especially in heart and kidneys, is 
however also seen despite adequate control of blood pressure, raising the question whether 
salt has a direct pro-inflammatory effect and what mechanisms play a role in this possible 
inflammatory pathway. The present thesis attempts to expand the current knowledge on 
the triggers leading to tissue remodeling in kidney disease and investigates the interplay of 
tissue remodeling components such as lymphangiogenesis, inflammation and fibrosis. Finally 
these findings are used to find actionable biomarkers to be able to detect tissue remodeling 
throughout the course of renal damage, in order to prevent further renal damage. 
Part A of this thesis investigates triggers of tissue remodeling in kidney disease. In Chapter 
2, we aimed to identify the effect of high dietary salt intake on renal tubulo-interstitial 
lymphangiogenesis, inflammation and fibrosis. High salt has been shown to aggravate renal 
damage in different models of induced renal damage. We also tried to identify if these tissue 
remodeling events are mediated via renal proteoglycans. Under various inflammatory conditions, 
renal proteoglycans convert from non-inflammatory into pro-inflammatory molecules by 
upregulation their sulfation degree, thereby increasing affinity for many chemokines, growth 
factors and some other mediators. We hypothesized that high dietary salt intake increases the 
degree of proteoglycan sulfation in the kidney and that the renal tissue remodeling events are 
related to sodium homeostasis and proteoglycan changes. In Chapter 3, we measured dermal 
sodium content and associated these findings with dermal proteoglycan variables in renal 
patients prior transplantation. In this chapter we tried to associate dermal inflammation, fibrosis 
and lymphangiogenesis with changes in dermal proteoglycans and compared our findings in 
healthy subjects (the donors) and renal patients who are preemptive recipients or have been 
on dialysis. In this final chapter of part A, we thus aimed to translate our experimental findings 
to the clinic.
Part B focuses on the dissection of (tubulo-)interstitial tissue remodeling components such 
as lymphangiogenesis, inflammation and fibrosis, and their interplay. In Chapter 4, we tried 
to identify the role and possible interaction of intrarenal tubulo-interstitial lymphangiogenesis, 
inflammation and fibrosis under proteinuric conditions by targeted intervention strategies in a 
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Part C of this thesis focusses on the translational aspects of experimental tissue remodeling 
findings towards clinical application by investigating possible biomarkers to monitor tissue 
remodeling.  Chapter 5 provides an extensive overview of current renal biomarkers for both 
acute kidney injury and chronic kidney disease. Interestingly, most biomarkers are related to 
tissue remodeling events. Biomarker studies have been performed extensively over the last years, 
however, we aimed to categorize renal biomarkers according to their actionability, in terms of 
a documented response to treatment in relation to outcomes. In Chapter 6, the final chapter, 
we investigated a promising class of biomarkers for renal fibrosis in rats. Collagen degradation 
products are excreted in the urine, and therefore could function as non-invasive early markers 
for progressive renal fibrosis and therefore renal function decline. 
After Parts A, B and C, I conclude my thesis with general conclusions and future perspectives.
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ABSTRACT 
Background. High dietary sodium aggravates renal disease by affecting blood pressure and 
by its recently shown pro-inflammatory and pro-fibrotic effects. Moreover, pro-inflammatory 
modification of renal heparan sulfate (HS) can induce tissue remodeling. We aim to investigate if 
high sodium intake in normotensive rats converts renal HS into a pro-inflammatory phenotype, 
able to bind more sodium and orchestrate inflammation, fibrosis and lymphangiogenesis.
Methods. Wistar rats received a normal diet for 4 weeks, or 8% NaCl diet for 2 or 4 weeks. Blood 
pressure was monitored, and plasma, urine and tissue collected. Tissue sodium was measured by 
flame spectroscopy. Renal HS and tubulo-interstitial remodeling were studied by biochemical, 
immunohistochemical and qRT-PCR approaches. 
Results.  High sodium rats showed a transient increase in blood pressure (week 1; p<0.01) and 
increased sodium excretion (p<0.05) at 2 and 4 weeks compared to controls. Tubulo-interstitial 
T-cells, myofibroblasts and mRNA levels of VCAM1, TGF-β1 and collagen type III significantly 
increased after 4 weeks (all p<0.05). There was a trend for increased macrophage infiltration 
and lymphangiogenesis (both p=0.07). Despite increased dermal sodium over time (p<0.05), 
renal concentrations remained stable. Renal HS of high sodium rats showed increased sulfation 
(p=0.05), increased L-selectin binding to HS (p<0,05), and a reduction of sulfation-sensitive anti-
HS mAbs JM403 (p<0.001) and 10E4 (p<0.01). Hyaluronan expression increased under high salt 
conditions (p<0.01) without significant changes in the chondroitin sulfate proteoglycan versican. 
Statistical analyses showed that sodium-induced tissue remodeling responses partly correlated 
with observed HS changes.
Conclusion. We show that high salt intake by healthy normotensive rats convert renal HS 
into high sulfated pro-inflammatory glycans involved in tissue remodeling events, but not in 
increased sodium storage. 
renal effects of high sodium diet
2
530678-L-bw-Hijmans
Processed on: 17-4-2019 PDF page: 26
26
INTRODUCTION
High sodium intake is known to aggrevate renal disease 1–3. We previously showed that high 
dietary sodium can cause tissue remodeling and a decline in kidney function 4–7. Moreover, 
moderate sodium restriction has shown to have a protective effect in chronic kidney disease 
(CKD) and combining sodium restrictive dietary measures with common treatment regimens 
for CKD and proteinuria, enhanced the therapeutic effects 4,5,8. The mechanism of this 
renoprotective effect of sodium restriction has always been ascribed to the decrease in blood 
pressure 9–11. Although this “dietary sodium – blood pressure” pathway of causative renal damage 
is well-known and is thoroughly documented, new research also suggests involvement of a 
“dietary sodium – blood pressure independent” pathway as well, leading to renal damage 12. 
Nonetheless, the exact mechanisms behind this blood pressure independent pathway are still 
unknown. Titze et al. showed that excess sodium can be stored in the skin, becoming osmotically 
inactive, thereby creating a buffering option during high sodium conditions 13. Furthermore, 
they showed that osmotically inactive Na+ storage in the skin is an active process characterized 
by an increased glycosaminoglycan (GAG) content and sulfation in the reservoir tissue, leading 
to dermal tissue remodeling demonstrated by increased lymphangiogenesis and macrophage 
and T-cell influx 14,15. Proteoglycans (PGs) are glycoconjugates consisting of a protein core, to 
which highly anionic GAGs are covalently attached 16. They are abundantly expressed and can 
be found in extracellular matrix and on cell membranes 17. Dictated by their sulfation pattern, 
GAGs interact with various proteins and orchestrate biological processes like cell-cell and cell-
matrix interactions, growth factor signaling cascades, chemokine and cytokine activation, tissue 
morphogenesis, cell migration and proliferation, and wound healing 18. Proteoglycans act as 
a scaffold/platform for growth factors, cytokines, and most prominently chemokines 16,19. In 
previous studies, we have shown that critical pro-inflammatory modifications of renal heparan 
sulfate (HS) proteoglycans result in tissue remodelling responses (inflammation and fibrosis) after 
ischemia/reperfusion, renal transplantation and proteinuria 20–22. Furthermore, scarce information 
suggests that the amount and type of cations bound to glycosaminoglycans modulate its 
3D-structure and biological properties 23–25. We assume that HS changes also might occur upon 
high dietary sodium intake. We therefore hypothesize that high dietary sodium intake convert 
renal HS into a pro-inflammatory phenotype, able to bind more sodium and orchestrate influx of 
inflammatory cells, fibrosis and lymphangiogenesis. To this end normotensive healthy male rats 
were fed with a high sodium diet and compared to sex- and age-matched rats on control diet, 
followed by evaluation of renal HS proteoglycans, sodium content and renal tissue remodelling. 
Here, we report an increased sulfation of renal HS upon high salt diet, resulting in the conversion 
of renal HS into pro-inflammatory glycans involved in tissue remodeling events, however not 
functioning as a storage depot for sodium. 
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MATERIALS AND METHODS
Experimental design of the animal experiment 
Fifteen three-month old male normotensive salt-insensitive Wistar rats were randomly divided 
into three groups. Rats included in the first group (N=5) served as healthy controls and received 
normal rat chow diet for four weeks and were sacrificed afterwards. Rats in the second and third 
group (N=5 each) received normal chow containing 8% NaCl (AB diets, Arie Blok B.V., Woerden, The 
Netherlands) and 1% NaCl in drinking water for two weeks and four weeks prior to sacrifice. Body 
weight and blood pressure was measured at baseline, 1 week, 2 weeks, 3 weeks and 4 weeks 
with the Cardiocap/5 (Datex-Ohmeda, Newark, USA). We used the non-invasive blood pressure 
recordings by the Cardiocap/5 device using the tail cuff method in awake rats. The rats were 
trained for two weeks before the experiment started and underwent the measurements during 
the experiment without stress and restrainers. Rats were sacrificed by cervical dislocation under 
general anesthesia. At the moment of sacrifice, organs were harvested after saline perfusion. 
Kidneys, abdominal skin and ears of all fifteen rats were taken and cryo-preserved. The kidneys 
were used for immunohistochemistry, binding assays, sodium measurements and qRT-PCR. The 
abdominal skin and the ears were used for sodium measurement. Blood plasma was collected 
at 2 weeks and 4 weeks, urine at baseline, 2 weeks and 4 weeks. At baseline, 2 and 4 weeks rats 
were placed in metabolic cages for 24 hour urine collection and the measurement of food and 
water intake. Creatinine in plasma and urine was measured by an enzymatic UV assay (Roche 
Modular P). 
The experiment was carried out under a protocol, which was approved by the Animal Care 
Committee of the University of Groningen (licence number 6318A). 
Immunohistochemistry 
Staining was performed on 3-μm-thick formalin-fixed paraffin sections after deparaffinization in 
xylene and rehydration in alcohol series. Antigen retrieval was done for 15 min in a microwave 
oven in Tris/EDTA buffer pH:9.0, citrate buffer pH:6.0, or overnight at 80°C in Tris/HCl buffer pH:8.0. 
Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide. Sections were 
incubated for 1 h or overnight at 4°C with the following primary antibodies: mouse anti-human 
α-SMA (clone 1A4, Sigma-Aldrich, St Louis, USA), goat anti-collagen III (cat. no. 1330-01, Southern 
Biotech, Birmingham, USA), rabbit anti-rat CD3 (clone A0452, Dako, Glostrup, Denmark) for T cells, 
mouse anti-rat CD68 (clone ED1, AbD Serotec, Oxford, UK) for macrophages and mouse anti-rat 
podoplanin (cat. no. 11-035, Angio Bio, Del Mar, USA) for lymphatic vessels. After this step, the 
sections were incubated with secondary and tertiary antibodies diluted in PBS/1% BSA and 1% 
normal rat serum. We used rabbit anti-mouse Ig horseradish peroxidase (HRP), goat anti-rabbit Ig 
HRP, goat anti-mouse Ig HRP, rabbit anti-goat Ig HRP and swine anti-rabbit Ig HRP (all from Dako, 
Glostrup, Denmark). As negative controls, the primary antibodies were replaced by PBS/1% BSA. 
Bound antibodies were visualized by aminoethylcarbazole (AEC) or by 3,3’-diaminobenzidine 
(DAB) (Sigma-Aldrich, St Louis, USA) and then counterstained with diluted hematoxylin. Tissue 
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sections were scanned by a NanoZoomer HT (Hamamatsu Photonics K.K., Shizuoka Pref., Japan). 
ED1+ macrophages, CD3+ T-cells and podoplanin+ lymphvessels were manually counted in 30 
cortical interstitial fields per kidney. The expression of collagen type III was measured by using 
an automatic quantification method using ImageJ 1.41 (Rasband, W.S., U.S. National Institutes of 
Health) and expressed as a % positively stained area.
Immunofluorescence 
In order to investigate eventual changes in structure of renal HS by high salt diet, ligand binding 
assays for MCP-1 and L-selectin were performed. These two proteins recognize two different 
binding sites of HS. To detect the changes in capacity of renal proteoglycans to bind with 
MCP-1 and L-selectin, 4μm thick renal cryosections were fixed by paraformaldehyde, followed 
by incubation with MCP-1 (4ug/ml, Peprotech, Rocky Hill, USA) and L-selectin-Fc (1:100, 26) in 
PBS+0.2M NaCl and TBS (final NaCl concentration is 0.18M) respectively 26. Salt concentration was 
adjusted to achieve critical binding in control tissue in order to detect loss or gain of binding in 
kidneys from sodium-fed rats. Mouse anti human MCP-1 (1:400, Peprotech, Rocky Hill, USA) was 
used as the primary antibody and rabbit anti mouse IgG HRP (1:100, DAKO, Heverlee, Belgium) 
was used as the secondary antibody for the MCP-1 binding assay. Similarly, rabbit anti human 
IgM HRP (1:100, DAKO) was used as the conjugated antibody for L-selectin binding assay. For 
the immunohistochemistry analysis of hyaluronan and versican 4μm thick renal cryosections 
were fixed with acetone and endogenous peroxidase activity was blocked with 0.03% hydrogen 
peroxide. Endogenous biotin binding sites were blocked by an Avidin/Biotin blocking step in 
case of hyaluronan. Sections were incubated for 1 hour with biotinylated hyaluronan binding 
protein (1:20, HABP, Seikagaku, Tokyo, Japan) and Versican (1:8000, ITK Diagnostics B.V., Uithoorn, 
the Netherlands), respectively. Streptavidin-C3Y (1:50, Invitrogen, Carlsbad, USA) and goat anti-
rabbit HRP (1:100, DAKO, Heverlee, Belgium) were used as conjugates for these stainings. 
We performed a double staining for L-selectin/IgM (2004; 1:25, 26) and JM13 (1991; 1:50, 27). 
After washing with TBS, tissues were incubated with rabbit anti-human IgM HRP and goat anti-
mouse IgM FITC conjugates (both 1:100, DAKO, Heverlee, Belgium). HRP activity was visualized 
using the TSATM Tetramethylrhodamine System (PerkinElmer LAS Inc., Waltham, USA). DAPI 
solution was applied to the sections and incubated for 10 minutes for nuclear staining. The 
same protocol was used for negative controls, however the L-selectin-Fc or MCP-1 incubation 
step was omitted. Stainings for hyaluronan and versican, and binding of L-selectin and MCP-1 
was evaluated on a Leica DM4000B equipped for immunofluorescence, and with a DFX345FX 
camera using a LAS software package. Eight pictures at 200x magnification per kidney were 
taken followed by digital quantification by ImageJ 1.41 (Rasband, W.S., U.S. National Institutes of 
Health) and expressed as a % positively stained area.
For anti-HS mAbs JM403 and 10E4, we randomly selected 10 glomeruli per kidney and 
measured the intensity of the staining of the glomerulus (JM403) and Bowman’s capsule (10E4) 
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Measurements of renal and dermal sodium 
Cortical renal tissue was obtained by cutting a triangular shaped sample from the cortical area 
of the kidney. Abdominal skin tissue was obtained and shaved before sodium measurements. 
Samples were cut in half and the wet weight of each part was measured. Per sample, both 
halves were dried overnight at 80 0C, dry weight was measured and one of the halves solved 
in pure nitric acid (Sigma-Aldrich, St Louis, USA) for sodium measurements. The second half of 
the sample was used to calculate the amount of protein per sample by measuring the nitrogen 
content according to Dumas using the Gerhardt Dumatherm Nitrogen/Protein analyser (C. 
Gerhardt UK Ltd, Northamptonshire, UK). Sodium concentrations were measured by atomic 
absorption (flame) spectrometry (Thermo M Series AA Spectrometer, Thermo Fisher Scientific, 
Waltham, USA) and expressed per dry weight and per nitrogen content.
Extraction and purification of GAGs from renal samples
From each rat, ~30 mg frozen kidney tissue was collected. The five renal samples per group 
were pooled, resulting in three pooled samples (control, 2 weeks high sodium diet and 4 weeks 
high sodium diet). Extraction and purification of HS was performed as described previously 28–30. 
Briefly, renal tissues were re-suspended in 50 mM Tris Buffered Saline (TBS), 2 mM EDTA, 6M Urea 
and mechanically disrupted with a Potter grinder. After recovery of the supernatant, the pellet 
was washed again in 50 mM TBS, 2 mM EDTA, 6M urea and centrifuged. Both supernatants were 
pooled and dialysed against 25 mM Tris, 5 mM EDTA pH 7.8. Proteins were then degraded by 
pronase digestion (2 mg/ml of pronase, final concentration, incubation for 24h at 37°C), and 
precipitated by addition of ice-cold trichloroacetic acid (TCA, 5% v/v final concentration) and 
incubated at 4°C for 1h. The samples were centrifuged, the pellets were treated again with 
TCA. Supernatants from both TCA treatments were collected, pooled, and supplemented with 
diethylether (50% v/v final concentration). After shaking, the organic upper phase was discarded 
and diethylether washing was repeated 4 times. The pH from the recovered aqueous phase 
was then adjusted to 7 by addition of 1M sodium carbonate, and residual diethyl ether was 
eliminated by leaving the samples overnight in a low-pressure environment. 
The sample was then applied to a DEAE-Sephacel column (2 mL) equilibrated in 20 mM 
phosphate pH 6.5. After extensive washing with 20 mM phosphate, 0.3 M NaCl pH 6.5, GAG 
chains were step-eluted with 20 mM phosphate, 1 M NaCl pH 6.5. Recovered samples were 
desalted over a Pd-10 column, lyophilized, and stored at − 20 °C prior to analysis.
Disaccharide analysis of HS by reverse-phase ion-pair high-performance 
liquid chromatography (RPIP-HPLC) analysis
GAG samples were dissolved in 100 mM sodium acetate, 0.5 mM CaCl
2
, pH 7.1 and HS was 
exhaustively digested into disaccharides by incubation with heparinase I (10 mU, Grampian 
enzymes, Orkney, UK) overnight at 30 °C, followed by a second incubation with heparinase II 
and heparinase III (10 mU each, Grampian enzymes) for 24 h at 37 °C. Compositional analysis 
was performed by RPIP-HPLC, as described previously 31. Samples were applied to a Luna 5µ 
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C18 reversed phase column (4.6 × 150 mm, Phenomenex) equilibrated at 0.5 mL/min in 1.2 mM 
tetra-N-butylammonium hydrogen sulfate and 8.5% acetonitrile, and then resolved using a NaCl 
gradient (0–8 mM in 10 min, 8–30 mM in 1 min, 30–56 mM in 11.5 min, 56–106 mM in 1.5 min, 
and 106 mM for 6 min) calibrated with disaccharide standards (Iduron, Alderley Edge, UK). On-
line post-column disaccharide derivatization was achieved by the addition of 2-cyanoacetamide 
(0.25%) in NaOH (0.5%) at a flow rate of 0.16 mL/min, followed by fluorescence detection 
(excitation 346 nm, emission 410 nm). Disaccharide analyses of each pool were performed in 
triplicate.
Statistical analyses
Statistical analysis was performed using SPSS 23.0 (SPSS Inc., Chicago, IL, USA) and GraphPad 
Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA) was used to construct graphs and figures. 
Statistical differences between two groups were tested using Mann-Whitney-U test. Kruskall-
Wallis test was used to compare multiple groups at the same time point. Correlations between 
independent variables were tested using Spearman Rank correlation. Partial correlation was used 
to correct for possible confounders. Statistical differences of p<0.05 were considered significant. 
RESULTS
Rats who received a high sodium diet (N=10 at two weeks and N=5 at four weeks) did not 
differ in body weight compared to control rats (N=5; Table 1), despite the fact that high sodium 
rats ate more. High sodium rats did not show significant differences in blood pressure over 
time compared to controls (AUC blood pressure), although a short hypertensive peak could be 
observed after the one-week diet, suggesting that the high sodium rats restored stable blood 
pressure and plasma sodium, by increasing their sodium excretion. High salt rats increased their 
water intake and urine production (for all these parameters, see Table 1). Importantly, there were 
no significant differences in creatinine clearance and proteinuria between high sodium rats 
and control rats up to four weeks, indicating that within this time frame renal function is not 
influenced by high dietary sodium intake (Table 1).  
High sodium diet induces tubulo-interstitial remodeling
In order to investigate to which extent high sodium diet affects tubulo-interstitial remodeling 
responses, we first evaluated a regular PAS staining. No apparent tubulo-intersitial or 
glomerular fibrotic responses were noted, however in the high salt fed rats we observed quite 
some accumulation of cells in the tubulo-interstitial areas (Fig.1).  To better evaluate tubulo-
interstitial tissue remodeling, we specifically evaluated markers for inflammation, fibrosis and 
lymphangiogenesis. In terms of inflammation, the influx of ED1+ macrophages showed an 
increasing trend over time in high sodium rats compared to controls (Fig 2A; p<0.07). The influx 
of CD3+ T-cells is increased in high sodium rats at four weeks compared to controls (p<0.05) and 
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N=10 at T0, T1, T2
N=5 at T3, T4
P-value
Body weight (g)
T0 386 [369-392] 383 [353-404] 0.759
T1 394 [380-408] 390 [361-417] 0.500
T2 426 [414-446] 413 [381-442] 0.125
T3 428 [408-443] 430 [408-445] 0.402
T4 444 [424-455] 440 [413-445] 0.209
Food intake (g/24h)
T0 1.0 [0.8-7.6] 1.0 [0.8-9.8] 0.806
T2 0.0 [0.0-4.9] 3.5 [0.4-11.4] 0.041
T4 0.5 [0.4-14.1] 7.4 [5.6-14.2] 0.076
Systolic blood pressure (AUC in arbitrairy units)
T0-2 17.5 [10.5-19.5] 10.5 [5.0-39.2] 0.624
T0-4 30.8 [14.2-43.8] 35.3 [24.0-61.2] 0.347
Systolic blood pressure (mmHg)
T0 152 [138-158] 155 [113-167] 0.624
T1 132 [125-160] 164 [143-190] 0.007
T2 143 [140-147] 148 [124-180] 0.297
T3 150 [141-162] 155 [130-203] 0.754
T4 153 [125-168] 172 [155-192] 0.076
Water intake (ml/24h)
T0 11.7 [4.7-25.6] 9.6 [4.5-27.6] 0.713
T2 11.4 [1.4-20.5] 23.6 [14.7-35.7] 0.020
T4 17.7 [2.7-26.3] 28.2 [13.6-36.8] 0.076
Urine production (ml/24h)
T0 14.0 [5.0-26.0] 13.0 [9.5-19.0] 1.000
T2 16.0 [8.0-26.0] 25.5 [14.0-29.5] 0.057
T4 21.0 [11.5-22.0] 26.0 [16.0-31.0] 0.047
Sodium excretion (mmol/24h)
T0 0.56 [0.31-0.95] 0.67 [0.37-2.09] 0.440
T2 0.67 [0.60-0.74] 5.34 [2.41-9.06] 0.002
T4 0.62 [0.29-2.52] 6.21 [1.90-9.67] 0.016
Plasma sodium (mmol/L)
T2 140.0 [138.0-141.0] 140.5 [137.0-143.0] 0.352
T4 141.0 [137.0-142.0] 142.0 [140.0-144.0] 0.242
Creatinine clearance (mL/min)
T2 4.8 [4.6-4.9] 3.9 [3.5-4.7] 0.052
T4 3.9 [1.7-4.5] 4.8 [3.8-8.3] 0.117
Albuminuria (mg/24h)
T0 6.8 [1.4-65.5] 7.3 [0.9-56.0] 0.806
T2 8.7 [2.2-95.4] 12.8 [1.9-101.0] 0.739
T4 5.4 [1.7-84.9] 17.6 [2.9-137.6] 0.251
Measurement of general parameters in controls rat on normal chow diet (N=5 at all time-points) and in rats on high 
salt diet (N=10 on T0, T1, T2; N=5 on T3, T4). Time-points represent weeks. Values are expressed in median [range] and 
statistical testing was done by performing Mann-Whiney-U test. P<0.05 is considered to be a significant difference 
between groups at a certain time-point.
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compared to high sodium rats at two weeks (Fig 2A; p<0.05). Focusing on fibrosis, an increased 
accumulation of α-SMA+ myofibroblasts was found in high sodium rats at both two (NS; p=0.12) 
and four weeks (Fig 2B; p<0.05).  The high salt diet did not have any effect on renal collagen 
type III protein expression after two or four weeks (Fig 2B). Podoplanin+ lymph vessels showed 
an increasing trend over time in high sodium rats compared to controls, however there were no 
significant differences between the 3 groups (Fig 2C; p<0.07 ).
In addition, we analyzed tubulo-interstitial remodeling phenomena in renal tissue by mRNA 
expression levels of inflammatory and fibrotic markers. While changes in tissue remodeling 
(Fig 2) were predominantly apparent after 4 weeks, we already found most changes on mRNA 
level after 2 weeks. MCP-1 showed no significant differences between groups (Fig 3A). VCAM1 
showed a significant increase in high sodium rats at two weeks compared to controls (p<0.05) 
and a significant return in the high sodium rats at four weeks compared to high sodium rats at 
two weeks (Fig 3B; p<0.05). 
Although at the protein level collagen type III expression was not different in high sodium 
rats compared to controls, on mRNA expression level, both TGF-β and collagen type III expression 
was increased compared to controls (Fig 3C and 3D; both p<0.05). TGF-β expression significantly 
decreased in high sodium rats at four weeks compared to high sodium rats at two weeks (p<0.01) 
and collagen type III mRNA expression apparently remained increased at four weeks compared 
to controls (NS; p<0.08).  
Dermal and renal sodium content
Since Titze et al. showed that excess sodium could be stored non-osmotically in the skin 13, 
we aimed to measure dermal and renal sodium. Dermal sodium concentrations expressed 
per mg dry weight in ear skin of high sodium rats did not significantly differ from controls at 
Figure 1. PAS staining of kidney of a control rat (left) and high salt fed rat (right). No apparent 
fibrosis was observed upon high salt feeding, however, we noted quite some accumulation of 
tubulo-interstitial cells (arrows) in the high salt kidneys. Scale bar represents 50 µm.
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Figure 2. Influence of high salt diet on renal tubulo-interstitial inflammation (A), fibrosis (B) 
and lymphangiogenesis (C). IHC was done for ED1+ macrophages (A), CD3+ T-Cells (A), α-SMA+ 
myofibroblasts (B), collagen type III (B) and podoplanin+ lymphvessels (C). Scale bar represents 50 
or 100 µm. Statistical differences between groups (N=5/group) were tested using Kruskall-Wallis 
test. *p<0.05.
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Figure 3. Influence of high salt diet on the mRNA expression of inflammatory (A, B) and 
fibrotic markers (C, D). mRNA expression relative to GAPDH was measured for inflammatory 
markers (A; MCP-1, B; VCAM1) and fibrotic markers (C; TGF-β, D; collagen type III) and expressed 
as fold increase to control diet. Statistical differences between groups (N=5/group) were tested 
using Kruskall-Wallis test. *p<0.05.
Figure 4. Sodium concentrations in ear skin (A), abdominal skin (B) and cortical kidney 
tissue (C). Sodium concentrations were measured by flame spectrometry and expressed in mmol 
sodium per mg dry weight. Statistical differences between groups (N=5/group) were tested using 
the Kruskall-Wallis test. *p<0.05 and **p<0.01.
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baseline, however, increased over time, (Fig 4A; week 4 vs week 2: p<0.01). We also measured 
dermal sodium concentrations in abdominal skin, which showed significantly higher sodium 
concentrations expressed per dry weight in high sodium rats compared to controls at four weeks 
(p<0.05) and over time in high sodium rats (Fig 4B; p<0.01). When we compared these findings 
with cortical renal sodium content (Fig 4C), no significant differences between high sodium rats 
and controls or significant differences over time were found. The same findings were obtained 
when sodium concentrations were expressed per mg protein as calculated form nitrogen 
content of the samples (data not shown).
Therefore, we found no evidence that excess sodium is being stored in the kidney in contrast 
to dermal tissue .  
Structural and functional HS changes by high salt diet
Quantification of HS from renal cortex showed a small but significant increase after two weeks of 
high salt diet and a significant decrease upon four weeks high salt diet (both compared with 2 
weeks high sodium and with baseline) (Fig 5A; all p=0.05). Disaccharide profiling of renal cortical 
HS revealed a substantial increased sulfation after high salt feeding, both after 2 and 4 weeks (Fig 
5B; both p=0.05 ). From Table 2, where all individual disaccharides are depicted, it becomes clear 
that upon high salt feeding, all HS sulfation, including N-sulfation, 2-O-sulfation and 6-O-sulfation 
increased. This is mirrored by the mRNA expression values of the N- and O-sulfotransferases 
(Table 2) although differences among the groups did not reach statistical significance. From 
qRT-PCR analysis, data suggest a short up-regulation of 6-O-desulfating enzyme Sulf2 at two 
weeks in the high sodium group, however, the structural analysis clearly indicate an increase of 
6-O-sulfation upon high salt feeding, both at disaccharide and at 6-OST1 mRNA levels, especially 
at 4 weeks high sodium feeding (Table 2 ).
Figure 5. High salt diet induced changes in amount and sulfation of renal cortical HS. Total 
renal cortical content of HS (A) and total sulfation of HS (B) were measured three times in pooled 
extracts from 5 rats per group (controls, high sodium rats 2 weeks and high sodium rats 4 weeks). 
Statistical differences between groups (N=3/group) were tested using the Kruskall-Wallis test. 
*p<0.050.
renal effects of high sodium diet
2
530678-L-bw-Hijmans
Processed on: 17-4-2019 PDF page: 36
36
Table 2. Disaccharide composition of renal cortical HS chains and mRNA expression levels of 
enzymes involved in HS (de)sulfation. 
Relative expression of 
disaccharides and of 
(de)sulfation enzymes
Control rats Rats fed with high salt for 2 weeks
Rats fed with high salt 
for 4 weeks
∆UA-GlcNac 41.6 [41.1-41.8] 36.8 [36.5-36.9] 38.2 [38.1-38.2]
∆UA-GlcNS 18.7 [18.7-18.8] 20.2 [19.3-20.6] 18.9 [17.5-19.2]
∆UA-GlcNac.6S 13.8 [13.8-14.1] 14.5 [13.9-14.7] 14.1 [14.1-14.2]
∆UA-GlcNS.6S 6.1 [6.1-6.3] 7.1 [6.9-7.3] 6.6 [6.5-7.4]
∆UA.2S-GlcNac 0.7 [0.7-0.8] 0.7 [0.0-0.8] 0.6 [0.4-0.8]
∆UA.2S-GlcNS 10.9 [10.7-11.0] 12.7 [12.1-12.8] 13.2 [12.7-13.8]
∆UA.2S-GlcNS.6S 8.2 [7.9-8.4] 8.7 [8.7-8.9] 8.6 [8.4-8.6]
Total N-sulfation 43.9 [43.7-44.2] 48.5 [47.9-48.8] 47.0 [47.0-47.3]
Total O-sulfation 48.0 [47.2-48.7] 51.9 [51.6-52.6] 51.4 [51.3-52.9]
NDST1 0.9 [0.5-1.9] 2.2 [0.6-22.2] 0.6 [0.2-71.6]
2-OST 0.8 [0.6-1.8] 1.6 [1.4-2.4] 1.1 [0.6-1.8]
6-OST1 0.9 [0.8-1.3] 1.0 [0.9-4.5] 1.2 [0.8-4.3]
HSPE 1.1 [0.3-1.5] 1.7 [1.6-5.8] 1.1 [0.8-3.2]
SULF2 1.1 [0.8-1.1] 1.3 [1.0-4.8] 1.0 [1.0-4.6]
Disaccharides are expressed as percentage of total disaccharides (N=3/group of pooled kidneys). Enzymes involved in HS (de) 
sulfation (N=5/group) are adjusted for GAPDH expression and expressed as fold increase compared to control rats (which 
mean value is set to one). Values are expressed in median [range]. Abbreviations used are frequently used in the proteoglycan 
field 19.
Furthermore, we evaluated structural changes in renal HS by using monoclonal anti-HS 
antibodies and L-selectin and MCP-1 binding to HS followed by quantification (Fig 6).  In previous 
studies, anti-HS mAbs JM403 and 10E4 are known to lose their intensity under different disease 
conditions. In high sodium fed rats, the glomerular staining intensity of JM403 was significantly 
decreased compared to controls at both two (p<0.01) and four weeks (p<0.001). For 10E4, the 
staining intensity of Bowman’s capsule decreased in high sodium rats as well compared to 
controls at both two weeks (p<0.06) and four weeks (p<0.01). Finally, we investigated the ability 
of HS to bind L-selectin and found that high sodium fed rats showed a significant increase of 
L-selectin binding compared to controls at both two (p<0.05) and four weeks (p<0.05). We found 
the same results for MCP-1 binding to HS (data not shown). Since the binding of L-selectin mainly 
depends on O-sulfation, we performed the L-selectin binding to heparan sulfate in a double 
staining with anti-heparan sulfate mAb JM-13, which is critically dependent on 2-O-sulfation 
32. Also JM-13 staining increased under high salt feeding conditions. Altogether, these data 
corroborate increased sulfation of renal cortical HS by high salt feeding. Next to heparan 
sulfate, we also evaluated and quantified tubulo-interstitial hyaluronan (by specific binding 
of biotinylated hyaluronan binding protein) and versican, an interstitial chondroitin sulfate 
proteoglycan. Interestingly, high salt diet also induced hyaluronan accumulation, maily in the 
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Figure 6. High dietary salt intake induced changes in staining intensity of anti-HS JM403 
and 10E4, and HS-dependent L-selectin binding. Staining intensity is expressed compared to 
control group.. L-selectin binding was done in a double staining with anti-HS mAb JM13, which is 
critically dependent on 2-O-sulfation. As can be seen, under high dietary salt conditions, staining 
intensity of L-selectin binding as well as JM13 increased, whereas anti-HS mAbs JM403 and 10E4 
was partially lost, indicative for increased sulfation of HS under high dietary salt conditions. Scale 
bar represents 50 µm. Statistical differences between groups (N=5/group) were tested using the 
Kruskall-Wallis test. *p<0.05; **p<0.01; ***p<0.0001. 
renal effects of high sodium diet
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Figure 7. High dietary salt induced hyaluronan accumulation and apparent loss of versican. 
High dietary sodium increased hyaluronan especially in the cortico-medullary region (top), 
whereas versican tended to be reduced in the same areas (bottom). Scale bar represents 50 µm. 
Statistical differences between groups (N=5/group) were tested using the Kruskall-Wallis test. 
*p<0.05; **p<0.01; ***p<0.0001. 
cortico-medullary region (Fig.7; top; p<0.01). Versican, on the other hand seem to reduce by 
the high salt feeding conditions (Fig. 7B; bottom; NS). These data suggest, that high salt diet 
mainly induced increased heparan sulfate sulfation and hyaluronan content in the renal tubulo-
interstitium.
Associations between sodium excretion, renal tissue remodeling parameters 
and HS parameters
In order to investigate the chain of events and associations between changes in sodium 
excretion, changes in HS and tubulo-interstitial remodeling, we calculated Z-scores and 
correlated our findings (Table 3). In these analyses, we combined all three groups of rats.  Urinary 
sodium excretion as a measure for salt intake correlated negatively with the intensity of 10E4 
HS and positively with binding of L-selectin to HS. We next evaluated the association between 
HS changes and tubulo-interstitial remodeling. Loss of 10E4 and JM403 HS both correlated with 
an increased number of lymphvessels. Furthermore, JM403 intensity also inversely correlated 
with the influx of myofibroblasts and increased mRNA expression of collagen type III and MCP-1. 
The binding of L-selectin with HS correlated with lymph vessel density and mRNA expression 
of collagen type III and VCAM1. Finally, L-selectin binding was positively correlated with the 
influx of macrophages and increased expression of TGF-β. Finally, sodium excretion correlated 
with lymph vessel formation, and mRNA expression of collagen type III and VCAM1. Moreover, 
when adjusted for HS measures (10E4, JM403 and L-selectin binding), the association of sodium 
chapter 2
530678-L-bw-Hijmans
Processed on: 17-4-2019 PDF page: 39
39
excretion with lymph vessels and VCAM mRNA expression was lost, however this was not the 
case for the association between sodium excretion and Coll III mRNA expression. This suggests 
that (part of) the correlation found between sodium excretion and both lymph vessel formation 
and VCAM1 mRNA expression is mediated via changes in HS function. However, the correlation 
between sodium excretion and collagen type III mRNA expression is independent of high 
sodium-induced HS changes.
Table 3. Correlations between sodium excretion (as a measure of sodium intake) and changes 
in HS (A), changes in HS and tubulo-interstitial remodeling (B), sodium excretion and tubulo-
interstitial remodeling (C) and correlations of sodium excretion with tubulo-interstitial remodeling 
after partial correction for changes in HS (D). 
A. Sodium excretion correlates with changes in HS
Variables R p-value
Sodium excretion vs. L-selectin binding 0.586 0.022
Sodium excretion vs. 10E4 -0.674 0.006
B. Changes in HS correlate with tubulo-interstitial remodeling
Variables R p-value
L-selectin binding vs. lymphvessels 0.549 0.034
L-selectin binding vs. macrophages 0.514 0.050
L-selectin binding vs. TGF-β mRNA expression 0.550 0.034
L-selectin binding vs. collagen type III mRNA expression 0.624 0.013
L-selectin binding vs. VCAM1 mRNA expression 0.689 0.004
10E4 vs. lymphvessels -0.731 0.002
JM403 vs. lymphvessels -0.547 0.035
JM403 vs. α-SMA -0.607 0.016
JM403 vs. collagen type III mRNA expression -0.774 0.001
JM403 vs. MCP-1 mRNA expression -0.575 0.025
C. Sodium excretion correlates with tubulo-interstitial remodeling
Variables R p-value
Sodium excretion vs. lymphvessels 0.774 0.001
Sodium excretion vs. collagen type III mRNA expression 0.654 0.008
Sodium excretion vs. VCAM1 mRNA expression 0.539 0.038
D. Correlations of sodium excretion with tubulo-interstitial remodeling after partial correction for 
changes in HS (L-selectin binding, 10E4 and JM403)
Variables R p-value
Sodium excretion vs. lymphvessels 0.520 0.083
Sodium excretion vs. collagen type III mRNA expression 0.669 0.017
Sodium excretion vs. VCAM1 mRNA expression 0.316 0.317
Spearman Rank correlation was performed on the Z-score of the variables in all rats (N=15) and p<0.05 is considered to be a 
significant correlation.
renal effects of high sodium diet
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DISCUSSION
For the first time, we have shown that a high sodium diet increases sulfation of renal HS in salt-
insensitive, normotensive healthy rats, and is associated with renal tissue remodelling events. 
Interestingly, these tubulo-interstitial changes are not associated with increased sodium content 
of the kidneys. 
After receiving a high sodium diet for 1 week, the rats showed a marked increase in blood 
pressure. However, this peak was transient and the blood pressure dropped to control values 
after two weeks. Evaluation of the blood pressure over time by determining and comparing 
the AUC per group, revealed that the rats in our experiment were capable of maintaining a 
stable blood pressure during the course of the study, independent of the sodium content of 
their diet. Our data showed that they compensated this sudden increase of sodium intake 
by increasing their sodium excretion, water intake and urine production. In addition to the 
stable blood pressure, plasma sodium concentrations remained constant in both controls and 
high sodium rats. Studies by the group of Titze suggested that sodium could be stored non-
osmotically as glycosaminoglycans in the skin. In this way, the skin can function as an extra 
buffering compartment for sodium in the body, in order to compensate for high sodium intake 
13,15,33. However, this non-osmotic sodium storage had not been investigated in the kidney yet. 
We therefore measured renal tissue sodium concentrations and compared these to dermal tissue 
sodium concentrations as a positive control. We measured dermal sodium content in both ear skin 
and abdominal skin, since studies have shown differences in distribution of sodium throughout 
the body 34. In both ear and abdominal skin we confirmed a significant increase in the sodium 
concentration over time. However, we did not find this for renal sodium concentrations. This 
indicates that non-osmotic sodium storage does not occur in the kidney. A possible explanation 
might be that HS is the predominant GAG present in kidney tissue, while hyaluronan, chondroitin 
sulfate and dermatan sulfate are the important GAGs in the skin 35, suggesting that the process of 
non-osmotic sodium storage may be specific for certain GAGs present in various tissues. 
Interestingly, despite the fact that HS did not show increased sodium binding properties, the 
high salt diet has profound effects on the amount of HS expressed in the kidney and the degree 
of sulfation. When we analyzed the polysaccharide sulfation patterns after the different diets, 
we found that N-sulfation, 2-O-sulfation and 6-O-sulfation increased in high sodium rats. These 
findings were also reflected by the expression values of the N- and O-sulfotransferases. Previous 
studies clearly showed close ties between 6-O-sulfation, 6-O-sulfotransferases and the sulfatases 
Sulf1 and Sulf2 36–40. In this study, we found an up-regulation of 6-O-desulfating enzyme Sulf2 at 
two weeks; however, the structural analysis clearly indicated an increase of 6-O-sulfation upon 
high salt feeding after 4 weeks, which could suggest a delayed effect or a restoration of function. 
Lamanna et al. showed through knockout models that loss of Sulf2 caused a decrease in N- and 
2-O-sulfation, while loss of Sulf1 had no significant effect. Furthermore, loss of both Sulfs resulted 
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in an increase in these sulfate moieties 41. This suggests a dynamic interplay between Sulf activity 
and the HS biosynthetic machinery, which is not completely understood yet.  
While changes in the disaccharide composition are apparently modest in our high sodium rats 
compared to their controls, the functional consequences of seemingly small structural changes 
and an increased sulfation of HS can be critical 19. Next to the analysis of the disaccharide 
composition, anti-HS antibodies can be used as an alternative way to study the fine structure 
of HS.  Previous studies by our group, showed that a decreased staining intensity with anti-
HS antibodies, specifically for the JM403 and 10E4 epitopes, are associated with increased 
renal damage and worsening of disease conditions 21,42,43. In this study we used three different 
antibodies/L-selectin to profile changes in heparan sulfates. We used anti-heparan sulfate mAb 
JM403 of which its specific epitope is dominated by an N-unsaturated GlcN unit (free amino 
group) in low sulfated heparan sulfates 42,44). JM-403 strongly recognizes heparan sulfates in the 
glomerular basement membranes, in Bowman’s capsule, and in some tubular en endothelial 
basement membranes. The epitope of mAb 10E4 is characterized by a mixed N-acetylated/N-
sulfated sequence in low sulfated heparan sulfates, mainly present in Bowman’s capsule and 
some tubular basement membranes 42. Both mAbs JM403 and 10E4 loose reactivity with heparan 
sulfates upon increased sulfation 42. Finally, we demonstrate heparan sulfate by its interaction with 
recombinant L-selectin-IgM. The binding of L-selectin with heparan sulfate is critically dependent 
on (6-)O-sulfation 45. Based on the characterization one can predict that upon increased sulfation 
of heparan sulfates, the binding of JM403 and 10E4 will decrease, while the binding of L-selectin 
with heparan sulfates will increase as what happened in our study (Fig 6).  In order to investigate 
the binding of L-selectin to sulfated HS we also performed a double staining of anti-heparan 
sulfate mAb JM13 (which is critically dependent on 2-O sulfation as shown by van den Born et al. 
42 with the L-selectin binding assay. It shows co-localization in tubular basement membranes as 
has been shown before by our group 26,45. Consequently, we show that the increased binding of 
L-selectin to heparan sulfates after high salt diet is accompanied by an increased JM13 staining 
intensity, which is an extra prove of increased sulfation of heparan sulfate upon high salt diet.
Previous studies in more severe models for kidney damage, showed that changes in L-selectin 
and MCP-1 binding can lead to influx of immune cells and tubulointerstitial remodeling, however 
HS changes secondary to high sodium intake have never been studied before. 22,46–48. In order 
to investigate the effects on proteoglycans other than HS, we investigated hyaluronan and 
versican. Hyaluronan is frequently used as a marker for water handling by the skin because of 
their significant water-binding capacity and we show that a high sodium diet, also leads to higher 
expression of hyaluronan 49. On the other hand, versican shows no significant change over time 
while it has been known to be associated with lymphangiogenesis and tissue remodeling 49,50 
during regeneration and renal transplantation. Apparently, the GAG/proteoglycan response to 
various noxi is not uniform, rather context dependent. 
HS is found in the matrix (mainly basement membranes) and on cell surfaces 19. In our analytical 
renal HS analysis (disaccharide composition) we purified HS from kidney homogenates, so did 
renal effects of high sodium diet
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not discriminate between matrix and cellular HS. Multiple studies however, have shown that 
the majority of HS is found in basement membranes 42,44,51. This is also corroborated by our HS 
visualization in Fig 6 where anti-HS mAb JM403 stained the glomerular basement membranes 
(and some other basement membranes), anti-HS mAb 10E4 stained Bowman’s capsule (and some 
other basement membranes). The double staining of anti-HS mAb JM13 with L-selectin binding 
to HS, shows that JM13 and L-selectin both recognize HS mainly in tubular basement membranes. 
These data do not deny the presence of extracellular surface layer HS, rather demonstrate that by 
far the majority of renal tissue HS is in the basement membranes and that the cell surface HS is 
below detection limit of the immunohistochemistry procedures. We previously showed cellular 
HS on tubular epithelial cells in renal tissue of transplant recipients using anti-HS mAb 10E4 52, 
and on the apical cell membranes of hepatocytes in liver tissue, by various anti-HS mAbs 43, which 
shows that cellular HS can be demonstrated by anti-HS mAbs. So, based on these considerations, 
we conclude that our data (analytical HS analyses and immunofluorescence stainings with anti-
HS mAbs and L-selectin) refers largely to matrix-associated (=basement membrane-associated) 
HS. In our study, no albuminuria is evoked, suggesting that the glomerular filtration barrier is not 
adversely influenced by high salt intake. 
These changes in HS function and structure were already found after 2 weeks, while changes 
in tubulo-interstitial remodeling (i.e. influx of macrophages, T-cells and myofibroblasts and 
increased lymph vessel formation) became apparent only after 4 weeks. On an mRNA level, 
VCAM1, MCP-1, TGF-β and collagen type III expression increased after 2 weeks, VCAM1 and TGF-β 
normalized after 4 weeks. Also the mRNA expression levels of most HS sulfotransferases peaked at 
2 weeks high sodium diet, and reversed thereafter. Therefore, the changes in renal HS (mainly at 
week 2) and the tubulo-interstitial remodeling responses on a mRNA-level (also at week 2) could 
be induced by the peak in blood pressure at week 1, and in their turn led to tubulo-interstitial 
remodeling on a tissue level after 4 weeks. We therefore speculate that the high sodium diet-
induced changes in renal HS structure and tubulo-interstitial remodeling could be transient in 
normotensive rats, as we showed that the rats could compensate for a rise in blood pressure by 
increasing their sodium excretion and their non-osmotic dermal sodium storage. Importantly 
however, this also suggests that if this process is disturbed in salt-sensitive rats and patients, 
high dietary salt intake could lead to progressive renal damage from 2 to 4 weeks onwards. An 
alternative blood pressure-independent explanation for the renal damage found after the high 
sodium intake in our study can possibly be found in the studies of Oberleithner et al., where they 
show that only a small increase of the plasma sodium concentration (5%) is enough to stiffen the 
endothelial cells by 25%, leading to cellular dysfunction. Next to this, it has been demonstrated 
by surface measurements that the endothelial glycocalyx detoriates when sodium is elevated 
53–55. The concentration in our study of 8% sodium in the diet is very high, however did not lead 
to observable adverse reactions to the diet by the rats. Moreover, the high sodium diet did not 
lead to a lower body weight. It might be that exposure to lower sodium content in the diet finally 
lead to the same finding, eventually after longer time frames.
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Finally, it was interesting to investigate potential links between all phenomena described. We see 
a clear time-dependent association between sodium excretion as a reflection of sodium intake 
and workload for the kidney, functional changes in HS and tubulo-interstitial remodeling events, 
(lymphangiogenesis and mRNA expression of collagen type III and VCAM1), which is being 
covered by statistical correlation. To correct for confounders, partial correlation was performed, 
which confirmed that at least VCAM1 mRNA expression and lymphangiogenesis increases 
when the sodium excretion increases, which is probably due to changes in HS function, since 
its significance disappeared after correction. Previous studies by our group in different disease 
models have shown that conversion of heparan sulfate into pro-inflammatory glycans can 
conttribute to renal tissue worsening. Upon renal ischemia/reperfusion, subendothelial heparan 
sulfates become converted into glycans able to bind L-selectin and MCP-1 and contribute to 
the influx of macrophages into the kidney 46. In another study we showed that upon renal 
transplantation, vascular and glomerular heparan sulfates convert into profibrotic glycans that 
bind FGF2 and contribute to glomerulosclerosis and neointima formation 56. In a third study, 
we showed that in mice which were knocked down for the basement membrane associated 
heparan sulfate proteoglycans Coll XVIII and Coll XV (which are hybrid collagen/proteoglycan 
molecules) the influx of neutrophils and macrophages in response to renal ischemia/reperfusion 
was completely prevented, and renal function (serum urea) and renal tubular injury was 
significantly improved 57. In the last study we also provided extensive in vitro evidence that the 
MCP-1 driven migration of monocytes is crucially dependent on heparan sulfates. Studies have 
previously shown links between changes in HS function and increased proliferation and influx 
of fibroblasts and lymphocytes, however, for the first time we show that an increased sodium 
excretion could induce pro-inflammatory conversion of HS, ultimately contributing to tubulo-
interstitial remodeling 21,58,59. 
At present, mechanisms by which high dietary sodium increased renal HS sulfation remain 
unknown. To evaluate a direct sodium effect on renal HS and tissue remodeling, we conducted an 
in vitro study on precision-cut mouse kidney slices and titrated different sodium concentrations 
into the medium 60. We did not see any changes in VCAM1, MCP-1, SULF2 and TGF-β mRNA 
expression levels at 24 hours after the addition of 40 and 80 mmol NaCl compared to controls 
(two independent experiments in triplicate; data not shown). This suggests that the sodium 
effect on these markers as observed in vivo (Fig 3 and Table 2) thus might be influenced by 
physiological processes. We speculate that high working load of proximal tubular epithelial cells, 
increased RAAS and/or sympathetic activity, increased release of vasoactive mediators such as 
endothelin and vasopressin, or cytokine release by inflammatory cells might play a role, however 
this has not been studied in detail yet. 
In conclusion, we deliver here a detailed description of a mechanistic pathway, in which 
a high sodium intake by healthy normotensive rats converts renal HS into high sulfated pro-
inflammatory glycans. HS is not involved in sodium binding, however the modifications to 
HS caused by the high sodium diet are associated with tubulo-interstitial remodeling in the 
renal effects of high sodium diet
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kidney. We also provide further evidence to the emerging view that blood pressure independent 
mechanisms also play an important role in aggravation of renal diseases by high dietary 
sodium intake. Further research will be needed to investigate the exact mechanism leading 
to the conversion of HS into pro-inflammatory glycans by a high sodium diet. Since these 
data show harmful renal effects of excess dietary sodium, most likely independent of blood 
pressure, we propose better monitoring of sodium intake and sodium excretion in renal patients 
independent of their response to blood pressure medication. Furthermore, our study underlines 
the importance of limiting sodium intake in healthy persons as well, since the effects of high 
sodium intake could already been seen after a 4 week high salt diet in otherwise healthy rats. 
This could be a highly relevant decree for the prevention of renal disease in general population. 
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ABBREVIATIONS
CD68/ED1:  Cluster of Differentiation 68, Pan-Macrophage Marker
CD3:  Cluster of Differentiation 3 (T-cell)
eGFR:  Estimated Glomerular Filtration Rate
N-Sulfation:  Nitrogen-Sulfation
O-Sulfation:  Oxygen-Sulfation
ESRD:  End-Stage Renal Disease
RRT:  Renal Replacement Therapy
CKD:  Chronic Kidney Disease
GAG:  Glycosaminoglycan
HS:  Heparan Sulfate
XYLT-1:  Xylosyltransferase 1 
HD:  Hemodialysis
OR:  Operation
WMO:  Wet Maatschappelijke Ondersteuning (Dutch law)
METc:  Medisch Etische Toetsings Commissie (Dutch Ethical Committee)
HLA:  Human Leukocyte Antigen
PBS/BSA:  Phosphate Buffer Saline/ Bovine Serum Albumin
α-SMA:  Alpha-Smooth Muscle Actin
HABP:  Hyaluronan Binding Protein
JM403: Anti-Heperan Sulfate Antibody
MCP-1/CCL: Monocyte Chemoattractant Protein-1 
Ig HRP:  Immunoglobulin Horseradish Peroxidase
DAB/AEC:  Aminoethylcarbazole/ Peroxidase Substrate 3,3’-Diaminobenzidine
DAPI:  4’,6’-Diamidino-2-Phenylindole Hydrochloride 
RT:  Reverse Transcriptase
VCAM1:  Vascular Cell Adhesion Protein 1
VEGF-C:  Vascular Endothelial Growth Factor C
CS:  Chondroitin Sulfate
DS:  Dermatan Sulfate
HA:  Hyaluronic Acid
NDST1:  N-deacetylase, N-sulfotransferase-1
HS6OST1:  Heparan Sulfate 6-O-sulfotransferase-1
CHST11:  Chondroitin 4-O-sulfotransferase-1 or Carbohydrate sulfotransferase-11
CHSY1:  Chondroitin Sulfate Synthase 1
UST:  Uronyl 2-sulfotransferase
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ABSTRACT
Background. Excess dietary sodium is not only excreted by the kidneys, but can also be stored 
by non-osmotic binding with glycosaminoglycans in dermal connective tissue. Such storage has 
been associated with dermal inflammation and lymphangiogenesis. We aim to investigate if skin 
storage of sodium is increased in kidney patients and if this storage is associated with clinical 
parameters of sodium homeostasis and dermal tissue remodeling. 
Methods. Abdominal skin tissue of 12 kidney patients (5 on hemodialysis) and 12 healthy 
kidney donors was obtained during surgery. Skin biopsies were processed for dermal sodium 
measurement by atomic absorption spectroscopy, and evaluated for CD68+ macrophages, 
CD3+ T-cells, collagen I, podoplanin+ lymph vessels, and glycosaminoglycans by qRT-PCR and 
immunohistochemistry. 
Results. Dermal sodium content of kidney patients did not differ from healthy individuals, 
but was inversely associated with plasma sodium values (p<0.05). Compared to controls, 
kidney patients showed dermal tissue remodeling by increased CD68+ macrophages, CD3+ 
T-cells and Collagen I expression (all p<0.05). Also, both N- and O-sulfation of heparan sulfate 
glycosaminoglycans were increased (all p<0.05), most outspoken in hemodialysis patients. 
Plasma and urinary sodium associates with dermal lymph vessel number (both p<0.05), whereas 
loss of eGFR, proteinuria and high systolic blood pressure associated with dermal macrophage 
density (all p<0.05). 
Conclusion. Kidney patients did not show increased skin sodium storage compared to healthy 
individuals. Results do indicate that kidney failure associates with dermal inflammation, whereas 
increased sodium excretion and plasma sodium associate with dermal lymph vessel formation 
and loss of dermal sodium storage capacity.
Trial registration. The cohort is registered at clinicaltrials.gov as NCT (september 6, 2017). NCT, 
NCT03272841. Registered 6 September 2017 – Retrospectively registered, https://clinicaltrials.
gov.
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BACKGROUND
Over the past decades, the classical paradigm of sodium handling by the human body has been 
widely questioned 1–3. New evidence suggests that besides via regulation of sodium excretion 
by the kidneys, sodium can also be stored in a non-osmotic manner in bone, cartilage and 
skin tissue 2,4. Especially skin has been shown to function as an extra compartment for sodium 
storage 5. 
In a previous animal study, we showed increased dermal sodium concentrations in rats who 
received a high sodium diet for 4 weeks 6. However, human dermal tissue remodeling responses 
such as lymphangiogenesis, fibrosis and inflammation have not been investigated, especially 
not in relation to dermal sodium concentrations. A recent study showed that the sodium storage 
in human tissues, such as arteries, skin and muscle, is mediated by glycosaminoglycans (GAGs) 7. 
While it has been shown that XYLT-1, an enzyme involved in the synthesis of GAGs, is increased, 
that study did not investigate in greater detail, which GAGs are involved.
In previous studies, our group showed that upon various noxi, renal proteoglycans and their 
covalently attached GAG side chains (such as heparan sulfate, HS) can be converted into pro-
inflammatory mediators orchestrating macrophage influx, T-cell influx, and contribute to fibrosis 
and lymphangiogenesis 6,8. Our studies, among others, have shown that this conversion can also 
be induced by a high sodium diet 6,9–11.
In order to investigate these phenomena, we focused on the growing group of patients with 
end stage renal disease (ESRD) and who were in need of renal replacement therapy (RRT) 12. These 
patients are suffering from CKD and are matched up with healthy renal transplant donors. While 
early tranplantation (CKD above stage 5; preemptives) has several benefits in terms of patient 
and grafts survival 13,14, the majority of patients suffering from ESRD are dialysis dependent and 
awaiting renal transplantation. Multiple studies have shown high cardiovascular morbidity and 
mortality in dialysis patients, mainly associated by systemic inflammation which can be induced 
by uremia, the underlying renal disease, dialysis-related factors and comorbidities 15–17. 
In order to decrease cardiovascular morbidity and mortality, the driving forces of systemic 
inflammation in patients with chronic kidney disease, and especially in dialysis patients, need 
further investigation
In this study, we aim to investigate whether skin storage of sodium is increased in kidney 
patients (i.e. both hemodialysis patients and preemptive patients), comparing them to healthy 
individuals (kidney donors). Second, we hypothesize that skin storage of sodium is associated 
with clinical parameters of sodium homeostasis, such as plasma sodium regulation and sodium 
excretion. Next, we hypothesize that dermal sodium storage is associated with tissue remodeling 
responses such as changes in GAGs, inflammation, lymphangiogenesis and fibrosis. 
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For this study, full thickness skin biopsies were obtained from 12 healthy controls (kidney donors) 
and 12 kidney patients at the time of renal transplantation (recipients), undergoing surgery at 
the University Medical Center Groningen (UMCG) between 14th February and 22nd March 2017. 
Of the 12 kidney patients, 5 were on hemodialysis (HD). From all patients, blood and urine were 
analyzed for sodium (Ion Selective Electrode by Roche Modular, Roche, Mannheim, Germany) 
and creatinine concentration (Roche Modular Enzymatic method, Roche, Mannheim, Germany). 
For all renal patients, clinical data were obtained from electronic patient files and the urine 
and plasma were collected on the day of the operation (OR) or one day before the OR. For the 
healthy donors, clinical data were also obtained from their electronic files. Urine and plasma 
were collected one day before OR or a week before OR. All study participants provided written 
informed consent prior to study and are enrolled in the Transplantlines Biobank and Cohort 
study (TXLINES01). The cohort is registered at clinicaltrials.gov as NCT03272841.
The study protocol is in accordance with the Dutch Medical Research Involving Human 
Subjects Act (WMO), and approved by the Medical Ethics Committee of the University Medical 
Center Groningen (METc 2014/077). All procedures were conducted in accordance with the 
declarations of Helsinki and Istanbul.
Study protocol 
Pre-operatively, both kidney donors and kidney patients received intravenous antibiotic 
profylaxis (2 gram Cefalozine and 500 mg Metronidazole) 30 minutes prior to the OR. Next to 
this all patients received 200 mL of intravenous 15% Mannitol at the time of induction. Renal 
patients (recipients) also received intravenous immunosuppressive medication pre-OR (40 mg 
Solumedrol®, 0.075 mg/kg Tacrolimus, 2000 mg Cellcept® and 20 mg Basiliximab). In case of 
identical HLA-typing, the Basiliximab was not given. All patients who were on dialysis received 
HD one day before surgery. One of the patients received plasmapheresis the day before the OR 
for immuno-absorption because of ABO-incompatibility. Of the 5 patients on hemodialysis, 1 
received ultrafiltration to 1 kg above goal weight during the last dialysis. Abdominal full-thickness 
skin tissue was obtained from kidney donors and kidney patients during transplant surgery after 
incision. Immediately after skin biopsies were taken under dry and sterile conditions, they were 
placed in a tin container kept cool on ice (0 degrees Celcius) with the precaution of avoiding any 
contact of the skin with water or saline. The skin samples were then transported to the research 
laboratory for processing. There, the skin tissue was pinned on a sterile, flat surface and 1 or 2 
biopsies (depending on size of harvested skin) were taken with a biopsy punch (Stiefel Biopsy 
Punch, 6mm; SmithKline Beecham, UK) for immunohistochemistry. The remainder of the tissue 
was divided in halve and the halves were placed in two sterile Eppendorf tubes for future qPCR 
and sodium measurements after which all processed skin samples were stored in a minus 80 
degree Celcius freezer. 
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Measurement of dermal sodium
The skin samples for determination of sodium content were cut into two equal parts and wet 
weights were measured. Both halves were then dried overnight in an oven at 80 degrees Celsius 
after which their dry weight was measured. One of the samples was then dissolved in a destruction 
solution made up of a 4:1 mixture of perchloric acid and pure nitric acid (Sigma-Aldrich, St Louis, 
USA) at 60 degrees Celsius for 3 hours. To 0.5 mL sample solution, 4.5 mL of water was added to 
obtain a 5 mL stock sample solution. The sample solution was then diluted 1:1000 after which the 
sodium content was measured by atomic absorption (flame) spectrometry using the Thermo M 
Series AA Spectrometer (Thermo Fisher Scientific, Waltham, USA). The second half of the sample 
was used to calculate the amount of protein per sample by measuring the nitrogen content using 
a Dumas method (Dumatherm Nitrogen/Protein analyser, C. Gerhardt UK Ltd, Northamptonshire, 
UK). Sodium concentrations were expressed as µmol sodium per mg protein. 
Immunohistochemistry
Immunohistochemical staining was performed on 4-μm-thick cryo sections cut from skin 
biopsies with a Leica CM1950 cryostat (Leica Biosystems, Wetzlar, Germany) followed by acetone 
or 4% paraformaldehyde fixation for 10 minutes. Endogenous peroxidase activity was blocked 
by incubating with 0.03% hydrogen peroxide (in phosphate buffered saline; PBS). Endogenous 
biotin binding sites were blocked by an Avidin/Biotin blocking step in case of biotin-labeled 
reagents. Skin cryo sections were incubated for 1 hour with the following primary antibodies/
reagents: mouse anti-human α-smooth muscle actin (SMA; clone 1A4, Sigma-Aldrich, St Louis, 
USA), rabbit anti-human CD3 (clone A0452, Dako, Glostrup, Denmark), biotinylated hyaluronan 
binding protein (HABP, Seikagaku, Tokyo, Japan), mouse anti heparan sulphate mAB JM403 18, 
mouse anti-human podoplanin (Clone D240, ThermoFisher, Rockford, USA), mouse anti-human 
CD68 (clone ED1, AbD Serotec, Oxford, UK), rabbit anti-versican (ITK Diagnostics, B.V., Uithoorn, 
The Netherlands) and mouse anti-human MCP-1 (Peprotech, Rocky Hill, USA) diluted in PBS/1% 
Bovine Serum Albumin (BSA). Binding of primary antibodies was detected by incubating the 
sections for 30 minutes with either a secondary or both secondary and tertiary antibodies 
diluted in PBS/1% BSA (and 1% normal human serum in some cases). We used rabbit anti-mouse 
Ig horseradish peroxidase (HRP), goat anti-rabbit Ig HRP, goat anti-mouse Ig HRP, rabbit anti-
goat Ig HRP, (all from Dako, Heverlee, Belgium) in PBS/1% BSA. As negative controls, the primary 
antibodies were replaced by PBS/1% BSA and were all found to be negative. Bound antibodies 
were visualized by aminoethylcarbazole (AEC) counterstained with diluted hematoxylin or by 
the TSA TM tetramethylrhodamine system (PerkinElmer Life Sciences Inc., Waltham, USA) (10 
min) for HRP antibodies. In the detection of CD3 antigen immunoreactivity was visualized using 
3,3’-diaminobenzidine (DAB) solution. Biotinylated HABP was visualized using Cy3 conjugated 
streptavidin (Invitrogen, Carlsbad, USA). DAPI solution (Vector laboratories, Burlingame, USA) was 
applied to the sections and incubated for 10 minutes for nuclear staining and subsequently 
mounted in either Citifluor mounting medium (fluorescence) or Aquatex mounting medium. 
The whole staining procedure was carried out at room temperature. 
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Quantification of immunohistochemistry
Stainings were evaluated on a Leica DM4000B (Leica Biosystems Wetzlar, Germany) equipped 
for immunofluorescence, and with a DFX345FX camera using a LAS software package. At least 5 
pictures at 20x magnification per skin sample were taken followed by digital quantification using 
ImageJ 1.46r (Rasband, W.S., U.S. National Institutes of Health) and expressed as % positively 
stained area (for macrophages, glycosaminoglycans and collagen I). D2-40 podoplanin positive 
lymphvessles and CD3-positive T-cells were quantified manually by two independent researchers 
and the mean of both scorings were used, expressed per standardized tissue area.
Gene expression
RNA was isolated from frozen skin tissue by the FavorPrep Tissue Total RNA Mini Kit (Favorgen 
Biotech Corp, Vienna, Austria) according to the manufacturer’s protocol. The total amount of 
RNA after isolation was measured by a nanodrop UV-spectrometer (Nanodrop Technologies, 
Wilminton, DE, USA) at 260/280nm.
From 700ng RNA, cDNA was synthesized using the Quantitect reverse transcription kit 
(Qiagen, Venlo, the Netherlands) in accordance with the manufacturer’s protocol. The following 
solutions were added to 1 ng/µL RNA: 2 µl genomic DNA wipeout buffer, 1 µL Quantiscript 
Reverse Transcriptase (RT), 4 µL 5X RT Buffer, 1 µL RT Primer Mix and RNase-free water (up to 20 
µL). The samples were placed in a MyCycler™ Thermal Cycler (Bio-Rad Laboratories) to start the 
cDNA synthesis with 1 cycle of 42°C/15 min and 95°C/3 min. Afterwards, the cDNA samples were 
diluted with 130 µL of RNAse-free water and stored at 4°C (for use shortly). For quantitative reverse 
transcription-polymerase chain reaction (qRT-PCR), 3µL cDNA (diluted 3x from stock) and 7µL 
SYBR Green-Primer- Water mix (consisting of 5 µL SYBR Green Supermix (BioRad, Veenendaal, The 
Netherlands), 0.08 µL gene specific primer set (0.5 mM) and 1.92 µL MilliQ water) were pipetted into 
a 384 wells plate (Applied Biosystems, Foster City, CA). All reactions were performed in triplicate. The 
plate was covered with an adhesive cover and centrifuged for 30 seconds. Primers were ordered 
from Sigma and the sequences of the oligonucleotides are shown in Table 1 below. Amplification 
was performed using an ABI7900HT Thermal cycler (Applied Biosystems) with the cycle procedure 
as follows: 10 min at 95°C, with 40 repeats of a 15s denaturation step at 95°C and a 40s extension 
and annealing step at 60°C. Data analysis was performed using science detection software 2.4 
(Applied Biosystems). To determine differences in expression of gene of interest, Ct-values were 
normalized against mean Ct-values of β-Actin as housekeeping gene.
Statistics
Data are shown as median (interquartile range) and comparisons between groups were 
performed by Mann-Whitney U test. Spearman Rank correlation coefficient on the Z-scores of 
various parameters was used for association studies. Statistical analysis were performed using 
SPSS 23.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5.0 (GraphPad Software Inc., La 
Jolla, CA, USA) was used to construct graphs and figures. P values below 0.05 were considered 
statistically significant. 
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Table 1. Gene-specific qPCR primers and their respective PCR fragment lengths.
Primer Forward sequence Reverse sequence
A. Inflammation
CCL2 5’-AGACTAACCCAGAAACATCC-3’ 5‘-ATTGATTGCATCTGGCTG-3’ 
VCAM 5’-TCCTGAGCTTCTCGTGCTCTATT-3’ 5‘-TGACCCCTTCATGTTGGCTT-3’ 
B. Fibrosis
COL1A1 5’-GGGATTCCCTGGACCTAAAG-3’ 5‘-GGAACACCTCGCTCTCCA-3’ 
C. Lymphangiogenesis
VEGFC 5’-CTGGCTCAGGAAGATTTTATG-3’ 5’-TGTTTTTACAGACACACTGG-3’ 
PDPN 5’-AAGATGGTTTGTCAACAGTG-3’ 5’-GTACCTTCCCGACATTTTTC-3’ 
D. Proteoglycan related
VCAN 5’-CCAGTGTGAACTTGATTTTG-3’ 5‘-CAACATAACTTGGAAGGCAG-3’ 
NDST1 5’-CGTGACGCGACCTAGCGA-3’ 5‘-TCATAGGTGGAGTGATTTGACTGG-3’ 
HS6ST1 5’-AGGAAGTTCTACTAACATCACC-3’ 5’-CCCATCACACATATGCAAC-3’ 
HSPE 5’-CCTTGCTATCCGACACCTTT-3’ 5’-GGCTGACAGGCCCAATTTA -3’ 
CHYSY1 5’-AGACTTTCAGCAAAATCCAG-3’ 5’-GTTTGAGAGAAAGGACAAGG-3’ 
HAS1 5’-TCCACTGTGTATCCTGCATC-3’ 5’-CCCCAAAAGTATCCTGCATC -3’ 
HAS2 5’-GATGCATTGTGAGAGGTTTC-3’ 5’-CCGTTTGGATAAACTGGTAG-3’ 
HAS3 5’-CTTGAAGATTAATGTAGGATGACAGGCT-3’ 5’-AAAGTTGACGACCACAGTGCAA-3’ 
UST 5’-GAACGTGAATGAAAACTTCC-3’ 5’-TCTGGGTCTTTGTAGATACTG-3’ 
CHST11 5’-TATTTCCAAATCATGCGGAG-3’ 5’-ATTGGGTTGTAGAGTTCCTG-3’ 
E. Housekeeping
β-Actin 5’-CCAACCGCGAGAAGATGA-3’ 5’-CCAGAGGCGTACAGGGATAG-3’ 
RESULTS
Clinical characteristics
Descriptive data are given for healthy individuals (donors, n=12) and kidney patients (recipients, 
n=12) in Table 2. The kidney patients in this study were younger compared to the healthy 
donors (p=0.05), and there were more male recipients compared to male donors (although 
not significantly different, p=0.23). Healthy individuals and kidney patients in this study are 
well matched for length (p=0.05) and weight (p=0.78). Blood pressure did not significantly 
differ between the two groups (systolic p=0.23 and diastolic p=0.25). Kidney patients suffered 
from various renal diseases and had more comorbidity, such as hypertension, coronary heart 
disease and diabetes mellitus. Therefore, they also used more anti-hypertensive, diuretic and 
anti-diabetic medication. In terms of kidney function eGFR (p<0.001), plasma sodium (p=0.006) 
and urine sodium (p=0.02) were significantly decreased in kidney patients compared to healthy 
individuals, while proteinuria was significantly higher in kidney patients compared to the healthy 
donors (p=0.001 ). 
No significant differences were found between kidney patients who were on dialysis (n=5) 
and patients in higher CKD stages  (preemptives, n=7) for the clinical characteristics. Compared 
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Variables All Preemptives Dialysis
(N=12) (N=7) (N=5)
Age (years) 61 [53-67] 52 [43-60]* 51 [48-64] 53 [41-60]
Sex (% male) 33 58 57 60
Length (cm) 166 [161-178] 176 [170-183] 176 [170-182] 175 [168-184]
Weight (kg) 81 [73-91] 77 [70-87] 73 [70-82] 84 [73-94]
BMI (kg/m2) 29 [25-31] 24 [22-28] 24 [22-25]* 26 [23-32]
Bloodpressure (mmHg)
Systolic 138 [129-150] 150 [131-158] 151 [122-165] 149 [136-152]
Diastolic 80 [72-85] 87 [71-95] 88 [69-98] 86 [63-89]
Time on dialysis (mos) - - - 13 [8-18]
Dialysis (%)
Hemodialysis - - - 80




Healthy donor 100 0 0 0
IgA Nephropathy 0 17 14 20
FSGS# 0 17 14 20
ADPKD# 0 33 29 40
Glomerulonephritis 0 25 29 20
Other 0 8 14 0
Comorbidities (%)
Hypertension 8 67 58 80
Malignancy 8 8 14 0
Coronary heart disease 8 17 14 20
Diabetes Mellitus 0 8 0 20
Other 8 17 14 40
None relevant 67 17 29 0
Drug use (%)
Anti-hypertensives 42 67 86 40
Diuretics 0 42* 43* 40*
Anti-diabetics 0 8 0 20
Dermal sodium content 
(µmol/mg protein) 0.68 [0.45-0.94] (n=8) 0.89 [0.59-1.01] (n=11) 0.98 [0.59-1.12] (n=7) 0.83 [0.45-0.89] (n=4)
Lab characteristics (day of OR)
eGFR (mL/min) 91 [81-95] 11 [8-14]*** 11 [10-14]*** 8 [6-X]** (n=3)
Serum creatinine (umol/L) 68 [63-84] 514 [447-646]*** 462 [442-516]*** 619 [399-1065]**
Serum albumin (mmol/L) 44 [43-46] 43 [41-46] 43 [42-50] 42 [40-45]
Plasma sodium (mmol/L) 141 (140-143] 139 [137-140]** 139 [138-142] 137 [137-140]**
Urine creatinine (mmol/L) 6.5 [4.2-11.9] 6.4 [3.8-8.9] 5.4 [3.2-8.2] 8.6 [6.4-13.1]
Proteinuria (g/L) 0.04 [0.03-0.06] 1.92 [0.26-2.35]** 0.39 [0.26-6.60]** 2.09 [0.54-2.33]**
Urine sodium (mmol/L) 85 [60-119] 62 [41-68]* 62 [56-68] 44 [22-77]
Sodium excretion (mmol/24h) 128 [20-192] 107 [40-140] 116 [54-166] 107 [17-X] (n=3)
*Significantly different compared to healthy donors (*p<0.05, **p<0.01, ***p<0.001). 
# Focal Segmental Glomerulo-sclerosis (FSGS) and Autosomal-Dominant Polycystic Kidney Disease (ADPKD)
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to healthy controls, there were no significant differences in age, sex, length, weight and blood 
pressure (Table 2, right column). The median time on dialysis prior to renal transplantation was 
13 (8-18) months. Twenty percent of the dialysis patients had been on peritoneal dialysis prior to 
hemodialysis. There was no significant difference in drug use between the groups, but the groups 
did show significant differences compared to the healthy individuals. While both groups showed 
a significantly lower eGFR compared to the eGFR values in the healthy controls (preemptive; 
p<0.001, dialysis; p=0.009), and significantly higher serum creatinine (preemptive; p<0.001, 
dialysis; p=0.002) and proteinuria (preemptive; p=0.003, dialysis; p=0.008), only the dialysis group 
showed significantly lower plasma sodium levels compared to the healthy individuals (p=0.006). 
Dermal sodium and sodium homeostasis
Plasma sodium was higher in healthy donors compared to kidney patients (p=0.006), especially with 
hemodialysis patients (p=0.006). Urinary sodium excretion values did not significantly differ between 
donors and kidney patients (Figure 1.A&B, p=0.77). The patients with CKD above stage 5 and the 
hemodialysis patients did not show any differences in sodium excretion (Figure 1.B, preemptive; 
p=0.87, dialysis; p=0.47). The dermal sodium concentration was not significantly different between 
donors and kidney patients (p=0.31). However, there were apparently slightly higher dermal sodium 
concentrations in the kidney patients, especially in the preemptive group (Figure 1.C ). 
Figure 1. Plasma sodium (A), urinary sodium excretion (B) and dermal sodium concentration 
(C) in healthy individuals (donors) and kidney patients (recipients). . Mann-Whitney and 
Kruskall Wallis were used to test differences between two or more groups. *p<0.01.
Dermal tissue remodeling
Dermal tissue remodeling events such as inflammation, fibrosis and lymphangiogenesis are 
shown in Figures 2, 3 and 4. Dermal inflammation was evidenced by a significantly increase 
of CD68+ macrophages throughout the dermal tissue in kidney patients compared to healthy 
donors (p=0.01). Both the preemptive kidney patients and the hemodialysis patients showed 
significantly higher expression of macrophages compared to the healthy renal transplant donors 
(Figure 2A, preemptive; p=0.04, dialysis; p=0.04). While monocyte chemoattractant protein-1 
(MCP-1) expression in the endothelium of dermal blood vessels was apparently slightly higher 
throughout the dermal tissue in kidney patients compared to healthy individuals, especially in 
the preemptive group, this difference was not statistically significant (Figure 2A, p=0.29). The 
influx of CD3+ T-cells also showed an apparent increase in kidney patients compared to healthy 
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donors (p=0.04). Hemodialysis patients showed a significantly higher amount of T-cells compared 
to the healthy donors, preferentially peri-vascular (Figure 2A, p=0.03). The mRNA expression of 
MCP-1 did not show any significant differences with a broad variance in the donor group (Figure 
2B, p=0,97). The expression of VCAM-1 also did not show any significant differences (Figure 2B, 
p=0.09). The data indicate that kidney disease is associated with an influx of macrophages and 
T-cells in the dermal layer of the skin, most outspoken in the hemodialysis patients.
Figure 2. Dermal inflammation in kidney patients (recipients) and healthy individuals 
(donors). Immunohistochemical expression and quantification of CD68+ macrophages, MCP-1 
and CD3+ T-cells. Magnification 200x. (A). The mRNA expression of MCP-1 and VCAM-1 by qRT-
PCR analysis (B). Values are expressed in fold increase compared to the mean of the donors. Mann-
Whitney and Kruskall Wallis were used to test differences between two or more groups. *p<0.05 
compared to donors. 
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Fibrotic changes in dermal tissue were not shown to be significantly different between healthy 
donors and kidney patients by immunohistochemical quantification of α-SMA+ dermal 
myofibroblasts (Figure 3A, p=0.94). The mRNA expression of collagen I was higher in kidney patients 
compared to the healthy individuals, but not statistically significant (Figure 3B, p=0.10). Hemodialysis 
patients, showed a significantly higher expression of collagen I compared to preemptives (p=0.02) 
and compared to the healthy donors (p=0.001). Preemptive patients did not have an increased 
expression of collagen I compared to healthy donors (p=0.81). Thus, patients with kidney disease 
show an increased dermal collagen I synthesis, most outspoken in the hemodialysis patients.
Figure 3. Dermal fibrosis in kidney patients (recipients) and healthy individuals (donors). 
Immunohistochemical expression and quantification of α-SMA+ myofibroblasts. Magnification 
200x. (A). The mRNA expression of collagen I on qRT-PCR analysis (B). Values are expressed in fold 
increase compared to the mean of the donors. Mann-Whitney and Kruskall Wallis were used to 
test differences between two or more groups. *p<0.05 and **p<0.01 compared to donors. 
Kidney patients did not show significant differences in dermal lymph vessel number compared 
to healthy donors (p=0.67), although the highest density was found in hemodialysis patients 
(Figure 4A). Also mRNA expression of Podoplanin tended to be higher in kidney patients 
compared to healthy individuals (p=0.14). Hemodialysis patients showed significantly higher 
mRNA expression of Podoplanin compared to preemptives (p=0.05) and compared to healthy 
donors (p=0.02). The mRNA expression of VEGF-C did not show any significant differences 
between healthy individuals and kidney patients due to the large variance (p=0.79). However, 
a number of hemodialysis patients showed a higher VEGF-C expression compared to healthy 
donors and preemptives (Figure 4B). The data suggest increased dermal lymphangiogenesis in 
kidney patients, most outspoken in hemodialysis recipients.
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Glycosaminoglycans
Differences in expression of GAGs were investigated for heparan sulfate (HS-GAG), chondroitin 
and dermatan sulfate (CS/DS-GAGs) and hyaluronic acid (HA-GAG) (Figure 5). JM403, a monoclonal 
antibody reacting to a low-sulfated epitope on HS-GAG, showed a slightly lower (non-significant) 
vascular and epidermal basement membrane expression in kidney patients compared to healthy 
controls (Figure 5A, p=0.38). On mRNA level, N-deacetylase, N-sulfotransferase-1 (NDST1), which 
is responsible for the N-sulfation in HS-GAG, showed to be significantly higher in kidney patients 
compared to healthy individuals (p=0.04) and dialysis patients in particular (Figure 5B; p=0.01) 
and is in line with loss of mAb JM403 stainability due to increased sulfation. No significant 
changes (p=0.12) were found in heparan sulfate 6-O-sulfotransferase-1 (HS6OST1), which is the 
most important enzyme for HS-GAG 6-O sulfation, neither were significant differences found for 
HSPE, coding for the HS-GAG degrading enzyme heparanase (Fig. 5B, p=0.63 ).
For CS/DS-GAG, we evaluated versican, a dominant dermal CS/DS proteoglycan. The dermal 
expression of versican in the tissue did not show any difference between the groups (Figure 5.C, 
p=0.83) and also on mRNA level, the expression of versican (p=0.55) and the major enzymes 
involved in CS/DS synthesis and sulfation, namely the chondroitin 4-O-sulfotransferase-1 or 
Figure 4. Dermal lymphangiogenesis in kidney patients (recipients) and healthy individuals 
(donors). Immunohistochemical expression and quantification of Podoplanin+ lymphvessels. 
Magnification 200x. (A). The mRNA expression of Podoplanin and VEGF-C on qRT-PCR analysis (B). 
Values are expressed in fold increase compared to the mean of the donors. Mann-Whitney and 
Kruskall Wallis were used to test differences between two or more groups. *p<0.05 compared to 
donors or compared to non-dialysis (preemptive) patients. 
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Figure 5. Dermal GAGs in kidney patients (recipients) and healthy individuals (donors). 
Immunohistochemical expression and quantification of GAGs and versican and mRNA expression 
of  enzymes involved in the synthesis of HS-GAG (A, B), CS/DS-GAG (C, D) and HA-GAG (E, F). 
Photos: magnification 200x. For qRT-PCR data, values are expressed in fold increase compared to 
the mean of the donors. Mann-Whitney and Kruskall Wallis were used to test differences between 
two or more groups. *p<0.05. 
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carbohydrate sulfotransferase-11 (CHST11, p=0.40), the chondroitin sulfate synthase 1 (CHSY1, 
p=0.09) and dermatan/chondroitin sulfate 2-sulfotransferase or uronyl 2-sulfotransferase (UST, 
p=0.13) did not differ (Figure 5D). However, it was striking that the mRNA expression of versican 
and all CS/DS-GAG enzymes were apparently a bit higher in the dialysis group compared to the 
healthy controls and the preemptives.
Reduced dermal expression of HA-GAG was found in hemodialysis patients compared to 
healthy donors (Figure 5E, p=0.04). mRNA expression of hyaluronan synthase 1, 2 and 3 (HAS1-
3) did not show significant differences between groups (Figure 5F, HAS1; p=0.18, HAS2; p=0.32, 
HAS3; p=0.10). 
Association studies
The relationship between dermal sodium concentrations, sodium homeostasis, tissue 
remodeling (inflammation, fibrosis, lymphangiogenesis, and GAGs) and kidney function, was 
investigated by correlating these parameters in donors (n=12) and preemptive recipients (n=7) 
together as one group. Hemodialysis recipients were excluded from this analysis because the 
preoperative dialysis might have influenced plasma and dermal sodium concentrations (see also 
Fig 1A and C preemptive patients versus hemodialysis recipients). Figure 6 and Table 3 show 
these correlations and their relation to each other. 
Figure 6. Diagram reflecting the number (indicated by black numbers) of associations 
(indicated by arrows) among clinical data, dermal sodium and tissue remodeling responses. 
Green arrows indicate positive associations, red arrows indicate negative associations.
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Table 3. Correlations between clinical data, tissue remodeling responses, and dermal sodium. 
Correlations are performed on the Z-scores of the values of donors and preemptive kidney patients. 
A. Dietary sodium intake and lymphangiogenesis
Variables R p-value
Plasma sodium vs. Podoplanin expression 0.656 0.028
Urine sodium vs. Podoplanin expression 0.709 0.022
        B. Dietary sodium intake and dermal sodium
Variables R p-value
Plasma sodium vs. dermal sodium concentration -0.619 0.042
        C. Obesity, age and proteoglycans
Variables R p-value
Age vs. mRNA expression of HAS3 0.530 0.042
Body weight vs. hyaluronan expression 0,503 0.047
BMI vs. versican expression 0.562 0.024
BMI vs. mRNA expression of CHST11 0.589 0.021
       D. Proteoglycans and lymphangiogenesis
Variables R p-value
mRNA expression of CHSY1 vs. mRNA expression of VEGF-C 0.571 0.026
mRNA expression of CHSY1 vs. mRNA expression of Podoplanin 0.546 0.035
mRNA expression of UST vs. mRNA expression of VEGF-C 0.679 0.005
mRNA expression of UST vs. mRNA expression of Podoplanin 0.625 0.001
mRNA expression of HAS2 vs. mRNA expression of VEGF-C 0.757 0.001
mRNA expression of VCAN vs. mRNA expression of Podoplanin 0.600 0.018
mRNA expression of NDST1 vs. mRNA expression of Podoplanin 0.704 0.003
mRNA expression of CHST11 vs. mRNA expression of Podoplanin 0.671 0.006
       E. Proteoglycans and fibrosis
Variables R p-value
mRNA expression of VCAN vs. mRNA espression of Collagen I 0.557 0.031
mRNA expression of NDST1 vs. mRNA espression of Collagen I 0.629 0.012
mRNA expression of CHST11 vs. mRNA espression of Collagen I 0.546 0.035
mRNA expression of UST vs. mRNA espression of Collagen I 0.589 0.021
mRNA expression of HS6ST1 vs. mRNA expression of Collagen I 0.514 0.050
 F. Proteoglycans and inflammation
Variables R p-value
mRNA expression of HSPE vs. CD68 expression 0.539 0.038
mRNA expression of HAS2 vs. MCP1 expression -0.554 0.032
mRNA expression of UST vs. MCP1 expression -0,621 0.013
Heparan sulfate expression (JM403) vs. CD3 expression 0.518 0.048
G. Renal failure and inflammation
Variables R p-value
Proteinuria vs. CD68 expression 0.730 0.007
Proteinuria vs. MCP-1 expression 0.614 0.034
Systolic blood pressure vs. CD68 expression 0.649 0.007
eGFR vs. CD68 expression 0.577 0.019
 H. Dermal sodium and inflammation
Variables R p-value
Dermal sodium storage  vs. mRNA expression of CCL2 -0.582 0.023
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Dermal sodium storage negatively correlated with the mRNA expression of CCL2, as a marker 
for inflammation (Figure 6; Table 3.A; r=-0.582; p=0.02). Next to this, dermal sodium storage 
also correlated negatively with one of the markers of sodium homeostasis, namely plasma 
sodium (Figure 6; Table 3.B; r=-0.619; p=0.04). Sodium homeostasis, reflected by plasma sodium, 
and increased sodium intake, reflected by increased sodium excretion values, shows positive 
correlations with parameters for lymphangiogenesis (Figure 6; Table 3.C; r=0.656; p=0.03 and 
r=0.709; p=0.02 respectively). We did not find a correlation between dermal sodium and 
lymphangiogenesis parameters (Figure 6). Parameters for renal function such as proteinuria and 
loss of GFR were positively correlated with markers for inflammation (Figure 6; Table 3.D). 
Age and body weight showed positive correlations with different GAGs (Figure 6; Table 3). 
GAGs showed mostly positive correlations with parameters for lymphangiogenesis, fibrosis and 
inflammation (Figure 6; Table 3).
DISCUSSION
In this study, we showed that dermal non-osmotic sodium storage is not increased in patients 
with chronic kidney disease, but that kidney disease plays a part in the interplay between dermal 
sodium storage, sodium homeostasis and dermal tissue remodeling. In the last decade, the 
classic paradigm of sodium handling has been questioned and widely investigated 2,4,19. These 
studies have shown that extra-renal non-osmotic sodium storage in skin, cartilage and bone 
plays an important role in maintaining a balanced plasma sodium level. Our data indicate that 
sodium homeostasis reflected by plasma sodium and increased sodium intake reflected by 
increased sodium excretion, associates with dermal lymph vessel formation and loss of dermal 
sodium storage capacity, whereas kidney failure associates with dermal inflammation. We also 
show that dialysis further influences dermal tissue remodeling. 
In this current study, human dermal sodium concentrations were determined by atomic 
absorption spectroscopy. However, we did not find significant differences in dermal sodium 
concentration between healthy individuals and kidney patients. Plasma sodium levels were 
significantly lower in kidney patients on hemodialysis compared to the healthy donors. This 
suggests that the lower plasma sodium levels were the result of hemodialysis prior to surgery. In 
a previous animal study in which rats received a high sodium diet during 4 weeks, we did show 
a significant increase in dermal sodium concentration compared to controls on a normal diet 
using the same spectroscopy technique 6. The fact that we were not able to show any significant 
differences during the current study might be explained by the fact that the donors and 
kidney patients were not on a high sodium diet in a controlled manner. Other research groups 
investigated sodium storage using a sodium-MRI technique in healthy volunteers, hypertensive 
patients and patients on hemodialysis 5,20.  Such studies have shown increased dermal sodium 
storage in elderly, males, hypertensive patients and patients on hemodialysis 1,20,21. Dahlmann 
et al. showed that hemodialysis treatment is able to mobilize sodium and water from the non-
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osmotic storage sites (skin and muscle), therefore lowering the dermal sodium concentration 
in these patients. They suggest that by reducing the intravascular volume during adequate 
hemodialysis, dermal sodium levels can be remained stable 21. The dialysis patients in our study, 
received hemodialysis prior to the OR, which makes it possible that the non-osmotic sodium had 
been mobilized already and therefore skin sodium concentrations returned to control values. 
Focusing on tissue remodeling, inflammatory markers showed significant differences between 
the donors and the kidney patients. There was an influx of macrophages in both the skin tissue 
of preemptives and of the patients on hemodialysis, while CD3+ T-cells increased only in the skin 
tissue of patients on hemodialysis. Furthermore, mRNA expression of podoplanin was increased in 
hemodialysis patients compared to healthy donors. Previous studies in high sodium animal models, 
have shown that a high sodium diet is associated with increased sodium storage in the skin, increased 
macrophage influx and MCP-1 levels, inducing the production of vascular endothelial growth factor 
C (VEGF-C) by these monocytes 11,22–24. VEGF-C mediaties lymphangiogenesis and several studies 
suggest that blocking VEGF-C has an increasing effect on blood pressure in relation to non-osmotic 
sodium storage 25,26. In our study we see an increase of podoplanin positive lymphvessel formation 
in the dialysis group. This underlines the hypothesis that macrophages are mediating lymphvessel 
formation in order to contribute in maintaining an adequate sodium balance. As described by others 
(18), patients on hemodialysis have increased skin sodium storage and are able to mobilize skin 
sodium during hemodialysis. The presence and maintenance of an adequate lymphatic network to 
accommodate this mobilization of sodium and water could therefore be beneficial. 
Next to inflammation and lymphangiogenesis, we also evaluated fibrotic changes in the 
skin. In the skin biopsies of patients on hemodialysis we saw an increased mRNA expression 
of collagen I. Interestingly, Kopp et al.  showed increased dermal sodium concentration in the 
fibrotic skin of systemic sclerosis patients 27. We suggest that the differences in dermal fibrosis 
might be too small to result in differences in sodium storage. 
Fibrosis emerges from the accumulation of extracellular matrix. Fibroblasts play a major role 
by releasing collagens, but also reasonable amounts of proteoglycans and glycosaminoglycans 
(GAGs). Because GAGs are suggested to bind sodium in a non-osmotic fashion, we therefore 
took a closer look to the involvement of GAGs in the skin of kidney patients 28–30. We investigated 
three groups of GAGS, namely heparin/heparan sulfate (HS-GAGs), chondroitin sulfate/dermatan 
sulfate (CS/DS-GAG) and hyaluronic acid (HA-GAG). For CS/DS-GAG we did not find any 
significant differences between healthy controls and kidney patients. For HS-GAG, the patients 
on hemodialysis showed increased mRNA expression of NDST1, an enzyme involved in the 
sulfation of heparan sulfate and therefore altering it’s biological properties and possibly their 
sodium binding capacity. For HA-GAG we found a significantly lower expression in patients on 
dialysis, which might be a direct effect of reducing the intravascular volume 21.
In order to unravel the possible interplay between all above described phenomena, we 
performed association studies. Our data indicates that kidney disease and dermal sodium 
associates with dermal inflammation, while sodium homeostasis and sodium intake (reflected 
by increased plasma sodium and sodium excretion respectively) is mainly associated with lymph 
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vessel density in the skin. We were not able to find a direct link between inflammation and 
lymphangiogensis in this study. Both loss of kidney function, as well as an increased sodium 
excretion, is associated with decreased dermal sodium storage. The mechanism behind this is 
still unclear and further research is needed. While previous studies suggest GAGs are involved in 
dermal sodium storage, we could not find this association in kidney patients despite the fact that 
the GAGs associated with all tissue remodeling phenomena 6,7,9,31,32. 
We acknowledge that the present study has its limitations. Firstly, the groups were very 
small, since we wanted to investigate if we were able to find any changes between the groups. 
While both the nitrogen and the sodium measurements are sensitive and robust, the margin of 
errors is increasing when using smaller size skin biopsies since both sodium and nitrogen are 
calculated per mg dry weight. Another disadvantage of the small group sizes is the inability 
to perform multivariable linear regression or Cox regression analyses. Next to this, we cannot 
rule out any effect of the immunosuppressive medication that has been given to the kidney 
patients pre-OR. While kidney patients did show more tissue remodeling and therefore 
inflammation, the differences with the healthy group might have been more outspoken 
without immunosuppressive medication. Jantsch et al. have shown previously that antibiotics 
(Gentamycin) reduces sodium storage in the skin by in vitro 33. In our study we used Cefalozin 
and Metronidazole in a in vivo model, namely humans, who were were all given profylactic 
antibiotic treatment prior to surgery (30 minutes before incision). While we do not expect the 
antibiotics to have such an direct effect on skin sodium concentrations whitin 30 minutes in 
a physiological model, in theory, we can not exclude that antibiotic profylaxis in all patients 
explains why there were no differences found in skin sodium concentrations. The same holds 
true for Mannitol, an osmotic diuretic, given maximum 30 minutes prior to incision. While it is 
theoretically possible that its diuretic properties increased urinary sodium excretion, we do not 
expect this to have major effects on non-osmotic sodium binding in the skin, in 30 minutes from 
infusion to taking the skin biopsies right after incision. 
The group of Titze have shown significant correlations between gender, age and skin sodium 
concentrations 34,35. In this study, we tried to age-match patients and donors as much as possible; 
however, in transplantation donors are selected based on HLA-type and health. We thus could 
not avoid patients to be significantly older compared to donors. However, Wang et al. showed 
a significant increase of skin sodium concentration in elderly people compared to younger 
people 34. Since we did not see a significant difference in skin sodium concentration of donors 
and patients, we do not expect that when corrected for age, patients would have lower skin 
sodium content compared to their healthy counterparts. There were no significant differences 
in age and gender between the patient groups themselves (preemptives and dialysis patients). 
Future studies should take into account the possible effects of gender and age on skin sodium 
concentration in transplant patients.
While we did not find a significant difference in skin sodium concentrations, we did find 
differences in lymphangiogenis and inflammation. Different pathways might explain these 
differences and other immunological pathways could be induced or tempered by years of 
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chronic kidney disease and/or dialysis 36. One interesting alternative factor of importance in 
CKD, is the pathway of uremic inflammation. Uremic specific causes such as abnormalities of 
the phosphate-Klotho axis play a crucial role in CKD, having a direct effect on cellular and tissue 
function 37,38. Furthermore, recent studies have shown indoxyl sulfate (IS) to be one of the most 
potent uremic toxins involved in CKD progression, by inducing inflammation and oxidative stress 
39,40. Nakano et al. even showed that clinically relevant concentrations of indoxyl sulfate induced 
proinflammatory responses of macrophages and the influenced the roles of organic anion 
transporters and organic anion transporting polypeptides 39. 
Next to uremic inflammation, the innate immune system is also known to play a crucial role in disease 
progression in CKD. While we hypothesise that glycosaminoglycans are able to bind sodium non-
osmotically, our group has also shown that they can interact with complement factors 41. Poppelaars 
et al. investigated the role of complement specifically in patients on hemodialysis. Their group 
showed a complement mediated increased cardiovascular risk in dialysis patients and experimental 
complement inhibition revealed a pro-inflammatory response secondary to complement activation 
16,42,43. This might explain why the most profound differences in skin lymphatic vessels, GAGs and 
inflammation in our study were found in the dialysis patients. Further research is warrented to 
investigate these alternative (or paralel) processes in renal transplant patients.
We used unique material of chronic kidney disease patients; both hemodialysis patients 
and preemptive patients before transplantation and their age-matched healthy donors. It’s the 
first study investigating differences in dermal sodium concentration, sodium homeostasis and 
tissue remodeling in these groups of ESRD patients. With our spectroscopy technique we were 
able to use small skin biopsies and objectively quantify the exact sodium concentration, finding 
a robust way to measure sodium in the skin. We performed an extensive analysis comparing 
dermal sodium concentrations, with tissue remodeling and different groups of GAGs, creating a 
starting point for further research. 
CONCLUSION
In conclusion, our data suggest that there is an interplay among dermal sodium storage, sodium 
homeostasis (reflected by plasma sodium) and sodium intake (reflected by sodium excretion), 
dermal tissue remodeling and kidney function, although the causal relationships and GAG 
involvement is not clear from our work. The exact mechanisms behind these phenomena 
warrant further research, and underscore the remote dermal effects observed in kidney patients. 
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ABBREVIATIONS
VEGFR3: Vacular Endothelial Growth Factor Receptor 3
S1P:  Sphingosine 1 Phosphate
FTY720:  Fingolimod ®
CKD:  Chronic Kidney Disease
ESRD:  End-Stage Renal Disease
RAAS:  Renin Angiotensin Aldosterone System
ACE: Angiotensin-Converting Enzyme
LECs:  Lymphatic Endothelial Cells
α-SMA:  Alpha-Smooth Muscle Actin
CL:  Clodronate Liposome
IMC-3C5:  Anti-VEGFR3 antibody
PBS/BSA:  Phosphate Buffer Saline/ Bovine Serum Albumin
Tris/EDTA:  Tris(hydroxymethyl)aminomethane/ Ethylenediaminetetraacetic Acid 
HCl:  Hydrochloric Acid
CD3:  Cluster of Differentiation 3 (T-cell)
ED1:  Pan-Macrophage Marker
Ig HRP:  Immunoglobulin Horseradish Peroxidase
DAB/AEC:  Aminoethylcarbazole/ Peroxidase Substrate 3,3’-Diaminobenzidine
PAS: Periodic Acid Schiff
LV:  Lymph Vessles
MCP-1/CCL: Monocyte Chemoattractant Protein-1 
VCAM-1:  Vascular Cell Adhesion Protein 1
TGF-β:  Transforming Growth Factor Beta
GAPDH:  Glyceraldehyde-3-Phosphate Dehydrogenase
CCR7:  C-C Chemokine Receptor Type 7
CCL21:  Chemokine (C-C motif) Ligand 21
UUO:  Unilateral Ureteral Obstruction
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ABSTRACT
Background. Proteinuria is an important cause of tubulointerstitial damage. Anti-proteinuric 
interventions are not always successful, and residual proteinuria often leads to renal failure. 
This indicates the need for additional treatment modalities by targeting the harmful 
downstream consequences of proteinuria. We previously showed that proteinuria triggers 
renal lymphangiogenesis before the onset of interstitial inflammation and fibrosis. However, 
the interrelationship of these interstitial events in proteinuria is not clear yet. To this end, we 
specifically blocked lymphangiogenesis (anti-VEGFR3 antibody), monocyte/macrophage 
influx (clodronate liposomes) and lymphocyte and myofibroblast influx (S1P agonist FTY720) 
separately to investigate the role and the possible interaction of each of these phenomena in 
tubulointerstitial remodeling in proteinuric nephropathy. 
Methods. Proteinuria was induced in three-month old male Wistar rats by adriamycin injection. 
After 6 weeks, when proteinuria had developed, rats were treated for another 6 weeks by anti-
VEGFR3 antibody, clodronate liposomes, and FTY720 up to week 12. 
Results. In proteinuric rats, lymphangiogenesis, influx of macrophages, T cells and myofibroblasts, 
and fibrosis significantly increased at week 12 vs. week 6. Anti-VEGFR3 antibody prevented 
lymphangiogenesis in proteinuric rats, however without effects on inflammation, fibrosis and 
proteinuria. Clodronate liposomes inhibited macrophage influx, partly reduced myofibroblast 
expression, however, neither
prevented lymphangiogenesis, fibrosis and proteinuria. FTY720 prevented myofibroblast 
accumulation and T cell influx, partially declined macrophage number and proteinuria, however, 
it did not influence lymphangiogenesis and fibrosis. 
Conclusion. We conclude that tubulointerstitial fibrosis, inflammation and lymphangiogenesis 
are rather independent tissue remodeling responses. Furthermore, proteinuria-induced 
interstitial fibrosis cannot be halted by blocking lymphangiogenesis or influx of macrophages, 
T-cells or myofibroblasts.
tubulointerstitial remodeling in proteinuric nephropathy
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INTRODUCTION
Proteinuria is a major challenge in clinical nephrology, as sustained proteinuria can lead to a 
progressive decline in kidney function, worsening to chronic kidney disease (CKD) and end-
stage renal disease (ESRD), and eventually the need for dialysis or renal transplantation 1–4. Many 
renal diseases are accompanied by proteinuria. Since proteinuria is independently associated 
with a decline in renal function, anti-proteinuric treatment (mainly RAAS intervention, eventually 
in combination with reduced salt intake) comprises a major cornerstone in renal medicine. 
Nevertheless, complete annihilation of proteinuria is practically not possible, and most patients 
slowly progress towards renal failure. Forced titration of proteinuria by dual RAAS intervention 
(ONTARGET trial) or ACE-inhibition under very low salt conditions worsened renal outcomes 5 or 
interstitial fibrosis 6. Even under rather low proteinuria values kidneys deteriorate over time. This 
indicates the need for additional treatment modalities: not only trying to reduce proteinuria even 
further, but also reduce the harmful effects downstream of proteinuria 7. It is well recognized 
that proteinuria (ultrafiltrated plasma proteins) activate tubular cells to secrete many chemokines 
and mediators that can elicit proinflammatory and profibrotic cascades 8–11, and leads to renal 
inflammation and fibrosis 12. An additional treatment option is thus to reduce tubulointerstitial 
changes secondary to proteinuria. 
We previously showed that proteinuria can promote renal lymphangiogenesis that 
concomitantly occurs with an increase of the profibrotic response and tubular activation 13. 
Several studies have proposed both a direct and an indirect link between lymphangiogenesis, 
inflammation and fibrotic reactions. Nevertheless, their causal interplay in tubulointerstitial 
remodeling in kidney diseases is not investigated yet 14. A wealth of evidence has shown a reciprocal 
interaction between inflammation and lymphangiogenesis 15,16. On one hand, leukocytes are 
able to produce mediators and growth factors that can promote lymphangiogenesis, and on 
the other hand, activated lymph endothelial cells (LECs) can secrete several mediators that 
recruit inflammatory cells and can further exacerbate this inflammatory microenvironment 17. 
Among inflammatory cells, macrophages have been shown to play a prominent role in inducing 
lymphangiogenesis, at least in two distinct ways: by producing lymphangiogenic growth factors 
and stimuli, and/or by directly trans-differentiating into LECs 18.
The direct link between inflammation and fibrosis has been well established as well 19. 
Despite many clinical and experimental investigations, effective treatment for fibrosis is still 
lacking in the clinic 20. FTY720, a S1P analogue, effectively inhibits the egress of T and B cells 
from lymph nodes 21,22, thereby reducing the number of antigen-primed/restimulated cells 
that recirculate to peripheral inflammatory tissues 23, and consequently halts inflammation. 
FTY720 can also directly block lymphangiogenesis 24, and has been reported to prohibit renal 
fibrogenesis 25–27. Taking these all into account, FTY720 seems to be a promising agent in 
targeting tubulointerstitial remolding. However, the exact interaction among these interstitial 
phenomena (inflammation, fibrosis and lymphatic remodeling) in proteinuric nephropathy is not 
clearly explored. Understanding of the detailed mechanisms of the complex interaction between 
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these proteinuria-induced downstream tubulointerstitial events might reveal their significance 
to the progression towards ESRD, and hence might have potential therapeutic values in patients. 
To mimic a clinically relevant situation a mild proteinuric model was chosen, thus a low 
amount of adriamycin to induce moderate proteinuria, without the development of nephrotic 
syndrome, however with chronic tubular epithelial cell activation and progressive interstitial 
remodeling. For this reason, we chose therapy aiming at reducing interstitial remodeling, thus 
not aiming at reducing proteinuria even further, but to target its downstream consequences. 
Therefore, in this interventional study we aimed to specifically block lymph vessel formation 
(antibody treatment with anti-VEGFR3), blocking monocyte/macrophage influx (clodronate 
liposomes, which selectively deplete monocytes/macrophages) and lymphocyte and α-SMA+ 
cells influx (by oral FTY720, as a S1P receptor agonist) separately to investigate the role of each 
of these phenomena in tubulointerstitial remodeling in proteinuric nephropathy. As read-out 
parameters we evaluated proteinuria and histological changes. 
MATERIALS AND METHODS
Animal experimental protocol and treatments
Proteinuria was induced in 78 three month-old male Wistar rats (weighing 180-200 gr) by single 
injection of adriamycin in the tail vein (1.8 mg/kg), and healthy rats served as controls. After 
6 weeks, when proteinuria was developed (~150 mg/24hrs), a kidney biopsy was taken via 
dorsolateral incision. After recovery, 60 rats were assigned randomly to one of the interventional 
or control groups. 18 rats did not develop sufficient proteinuria and were excluded from the 
study. Proteinuric rats were randomly divided into five groups; A proteinuric untreated group 
(n=8), and four interventional groups which were treated with FTY720 (n=8), anti-VEGFR3 
antibody (n=8), clodronate liposomes (n=8) or empty (PBS) liposomes (n=6) which served as 
a control for the clodronate liposomes. The healthy rats were randomly divided into a healthy 
untreated control group (n=6) and three different healthy control groups which were treated 
with FTY720 (n=6), anti-VEGFR3 antibody (n=4) or clodronate liposomes (n=6). The treatment by 
the above-mentioned agents then started from week 6 and was continued until week 12: anti-
VEGFR3 antibody (IMC-3C5, ImClone/Eli Lilly, USA) i.p. 40mg/kg, 3 times per week, clodronate 
liposomes (ClodronateLiposomes.org, The Netherlands) i.p. twice weekly 1 ml/rat, and FTY720 
(Novartis, Basel, Switzerland) 1 mg/kg BW/day in drinking water. At week 12, blood pressure was 
measured under general anesthesia with the Cardiocap/5 (Datex-Ohmeda, Newark, USA). Then, 
after saline perfusion, organs were harvested and some parts were preserved in liquid nitrogen 
for cryo sections and other parts in formaldehyde 10% for paraffin embedment. 
At the beginning of the study, at the time of the biopsy (6 weeks) and at the end of the 
experiment (12 weeks), body weight was measured, blood samples were collected and rats 
were placed in metabolic cages for 24 hours for urine collection and the measurement of food 
and water intake. Proteinuria was determined in urine samples by a turbidimetric assay (Roche 
tubulointerstitial remodeling in proteinuric nephropathy
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Modular P, Mannheim, Germany). Experimental procedures were carried out according to the 
national guidelines for the care and use of laboratory animals, and approved by the local Animal 
Ethic Committee of the University of Groningen.
Immunohistochemistry
Staining was performed on three-micron thick formalin-fixed paraffin sections after 
deparaffinization in xylene and rehydration in alcohol series. Antigen retrieval was done for 15 
minutes in a microwave oven for Tris/EDTA buffer PH:9 and citrate buffer PH:6, or overnight at 
80°C in Tris/HCl buffer PH:8. Endogenous peroxidase activity was blocked with 0.3% hydrogen 
peroxide. Sections were incubated for 1 hour or overnight 4°C with the following primary 
antibodies: mouse anti-human a-SMA (clone 1A4, Sigma-Aldrich, St. Louis, USA), goat anti-
Collagen III (cat.no. 1330-01, SouthernBiotech, Birmingham, USA), rabbit anti-rat CD3 (clone 
A0452, Dako, Glostrup, Denmark), mouse anti-rat CD68 (clone ED1, AbD Serotec, Oxford, UK) and 
mouse anti-rat podoplanin (cat.no. 11-035, Angio Bio, Del Mar, USA). After this step, the sections 
were incubated with secondary and tertiary antibodies diluted in PBS/BSA 1% and 1% normal 
rat serum. We used rabbit anti-mouse Ig HRP, goat anti-rabbit Ig HRP, goat anti-mouse Ig HRP, 
rabbit anti-goat Ig HRP, swine anti-rabbit HRP and anti-rabbit poly HRP (all from Dako, Glostrup, 
Denmark). As negative controls, the primary antibodies were replaced by PBS/BSA 1%. Bound 
antibodies were visualized by the aminoethylcarbazole (AEC) or by the peroxidase substrate 
3,3’-diaminobenzidine (DAB) (Sigma-Aldrich, St. Louis, USA) and then counterstained with 
diluted hematoxylin. Periodic Acid Schiff (PAS) also performed on series of sections in order to 
quantify the extent of structural changes (interstitial fibrosis). The sections were then scanned 
by a NanoZoomer HT (Hamamatsu Photonics K.K., Shizuoka Pref., Japan). The quantification was 
done using Aperio ImageScope software (version 9.1.772.1570, Aperio Technologies Inc, Vista, 
CA, USA) and Image J 1.46r (Rasband, W.S., U.S. National Institutes of Health).
Quantification of lymph vessels and renal histomorphology
For identification of LVs, we counted podoplanin-positive vessels in 30 cortical interstitial fields per 
kidney. Collagen III, myofibroblasts (a-SMA), ED1-positive macrophages and CD3 positive T-cells 
were measured as described previously 13. In short, the collagen III expression, myofibroblasts, the 
ED1-positive macrophages and the CD3 positive T-cells were evaluated in 30 (high or medium 
power field) cortical interstitial area of each kidney in a blinded fashion. The quantification was 
done using ImageJ 1.41 (Rasband, W.S., U.S. National Institutes of Health). PAS staining was semi-
quantitatively scored on a scale ranging from 1 to 5. The scoring indicates which part of renal 
cortical tissue was affected by tubulointerstitial fibrosis (broadening interstitial area in between 
the tubules). Score 1: <1%; Score 2: 1-5%; Score 3: 6-10%; Score 4: 11-20%; Score 5: 21-50%. 
Urine and plasma analysis
The sodium, potassium and chloride concentrations in both plasma and urine were analyzed 
by an electrolyte analyzer ISE (Roche Modular P, Mannheim, Germany). The urea and creatinine 
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in plasma and urine were measured by an enzymatic UV assay (Roche Modular P). For the 
measurement of total protein in plasma/serum we used a colorimetric assay (Roche Modular P).
RNA isolation and cDNA synthesis 
For RNA isolation from kidney tissue, we used the Favorprep RNA minikit (Favorgen Biotech Corp., 
Denmark). For each sample, we used 5 µm sections in total weighing approximately 30 mg (No 
DNase treatment during RNA isolation). Concentration measurement was done by Nanodrop 
and the integrity of the RNA was tested by running the samples on a 1% agarose gel in loading 
buffer. cDNA was synthesized using a QuantiTect Reverse Transcription Kit (Qiagen, Germany). 
Genomic DNA was eliminated during this procedure. 
RT-PCR
mRNA expression of osteopontin, MCP-1 (CCL2), VCAM-1, Collagen I (α1), Collagen III (α1) and 
TGF-β1 were determined by quantitative reverse transcriptase polymerase chain reaction 
(qRT-PCR). Primers were bought from QIAGEN, The Netherlands. Collagen I (α1) primer 
(agcctgagccagcagattga and ccaggttgcagccttggtta), MCP-1 primer (ccgactcattgggatcatctt and 
tgtctcagccagatgcagttaat). Other primers were ordered ‘on demand’ with the following order 
names: Rn_Col3a1_2_SG QuantiTect primer assay (QT01083537), Rn_Tgfb1_1_SG Quantitect 
primer assay (QT00187796), Rn-Vcam1-1-SG Quantitect primer assay (QT00178500) and Rat-Spp-1 
RT2 qPCR Primer assay (osteopontin) (PPR44222B).
 qRT-PCR was performed using the C1000 CFX384 from BioRad, using SYBR Green (SensiMix 
SYBR No-ROX kit, GC biotech). GAPDH was used as a housekeeping gene to normalize mRNA 
expression. GAPDH primers (catcaagaaggtggtgaagc and accaccctgttgctgtag). 6.7 ng cDNA per 
well were brought on a 384 wells plate (plateHard-Shell PCR plates, 384-well white well/CRL 
shell). Every sample was measured in triplo. The cycle procedure was as followed: 10 minutes 
at 95oC, with 40 repeats of a 15 second denaturation step at 95oC and a 15 seconds extension 
and annealing step at 60oC, followed with a 5 seconds extension step at 72oC. A dissociation 
stage was added to ensure that the desired amplification was detected. Results are expressed as 
2-deltaCT, and finally presented as relative expression to GAPDH.
White blood cell counting
The number of white blood cells, neutrophils, lymphocytes, monocytes, eosinophils and 
basophils were measured by the Sysmex XN9000 (Kobe Japan). 
Statistical analysis
Statistical analyses were performed using SPSS 20.0 (SPSS Inc. Chicago, IL), and GraphPad Prism 5.0 
(GraphPad Software Inc, La Jolla, CA) was used for making graphs and figures. Statistical differences 
were tested using Mann–Whitney U test. Since the PAS staining was scored semi-quantitatively into 
five categories, by Chi-square analyses we compared the number of kidneys without interstitial fibrosis 
(score 1) with those showing interstitial fibrosis (score >1). P<0.05 was considered statistically significant.
tubulointerstitial remodeling in proteinuric nephropathy
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Fig. 1 
Figure 1. Development of renal lymphangiogenesis, inflammation and fibrosis in adriamycin-
induced proteinuria model. Representative photomicrographs show the differences in several 
markers in the kidneys of healthy rats, and proteinuric rats at week 6 and week 12. A-C: podoplanin-
positive LVs, D-F: ED1+ macrophages, G-I: CD3+ T-cells, J-L: α-SMA+ myofibroblasts, M-O: collagen 
III deposition. All markers were significantly increased at week 12 in proteinuric rats compared 
to the healthy controls at week 12 and the proteinuric rats at week 6. For quantification of these 
data at 12 week between proteinuric rats with and without treatment: see figures 2, 4, and 6. 
Magnification: A-C and J-O: x 200; D-I: x 400. 
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RESULTS
Proteinuria developed over time in adriamycin-injected rats
Urinary protein excretion was significantly increased at week 6 in the adriamycin-injected 
rats compared to their saline-injected controls (146 (77-230) in adriamycin-injected rats versus 
18 (13-27) mg/24h in control rats; p<0.001). Except for proteinuria, however, at week 6 other 
clinical parameters, such as body weight, blood pressure and kidney function, evidenced by 
the creatinine clearance, were not significantly different between healthy and proteinuric rats, 
but heart rate was reduced in proteinuric rats (Table 1). Also, there was no difference in water 
intake between both groups of rats at that time. However, food intake was significantly higher 
in the proteinuria rats (Table 1). In this way, we developed a model of so-called pure proteinuria 
without signs of nephrotic syndrome.
Histological inspection of the kidneys revealed that at 6 weeks, a non-significant influx of 
α-SMA positive cells was observed in adriamycin-injected rats compared to healthy controls. 
Otherwise no changes were seen in week 6 proteinuric kidneys, neither for number of LVs, 
ED-1 positive macrophages and CD3-positive T-cells, nor for interstitial fibrosis evidenced by 
collagen III quantification (Fig. 1) and PAS staining (not shown at week 6). In contrast, at week 
12 tubulointerstitial tissue remodeling occurred. This was characterized by lymphangiogenesis 
measured by an increase in LV density (1C), increased numbers of ED-1 positive macrophages (1F) 
and CD3 positive T-cells (1I), increased α-SMA positive myofibroblasts (1L) and interstitial fibrosis 
measured by collagen III deposition (1O) and PAS staining (Fig. 2K ).  
Anti-VEGFR3 antibody totally prevented LV formation in proteinuric rats
Six consecutive weeks treatment by anti-VEGFR3 antibody (IMC-3C5) in proteinuric rats (week 
6-12) did not significantly alter proteinuria, compared to non-treated proteinuric controls. No 
noticeable changes were observed in body weight, blood pressure, heart rate, food and fluid 
intake, and creatinine clearance compared to untreated proteinuric rats (Table 1). On  histology, 
proteinuric kidneys at week 12 presented significantly more podoplanin-positive lymph vessels 
by immunohistochemistry in the cortical interstitium, compared to week 6, implying renal 
lymphangiogenesis between week 6 to 12 (Fig. 1A-C; p<0,05). IMC-3C5 treatment showed a 
robust and significant decrease in the amount of LVs, not only in the proteinuric rat kidneys, 
compared to non-treated proteinuric (p<0,001), but also in the kidneys of healthy rats upon 
treatment, compared to the non-treated healthy controls (Fig. 2A and B, p<0,001). Looking at 
macrophages and T-cells, although the proteinuric rats treated with IMC-3C5 showed a trend 
in reducing the ED1-positive macrophages, however, this was not statistically significant (Fig. 
2C,D). Rats treated with IMC-3C5 antibody, did not show any marked changes in T-cell number 
(Fig. 2E,F). a-SMA and collagen III expression and interstitial fibrosis (scored by PAS staining) did 
not show any marked changes after IMC-3C5 treatment (Fig. 2G-L). On mRNA level (qRT-PCR) 
IMC-3C5 treatment could decrease the collagen III (α1) mRNA level almost significantly, but not 
collagen I (α1) and TGF-β1. This intervention did not show significant effects on inflammatory 
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Figure 2. Effects of anti-VEGFR3 antibody treatment on renal lymphangiogenesis, 
inflammation, and fibrosis. Quantification of renal cortical podoplanin-positive vessel-like 
structures of the rats who received treatment with anti-VEGFR3 antibody (IMC-3C5) showed a 
significant reduction of LV number at 12 weeks (A, B - x400), while it showed a non-significant trend 
in reducing the number of macrophages in the cortical interstitium of proteinuric rats (C, D - x400), 
and did not influence T-cell influx (E, F - x400) at week 12. Anti-VEGFR3 antibody also did not show 
to have a significant effect on α-SMA (G, H - x200), collagen III deposition (I, J - x200) and interstitial 
fibrosis (K, L - x200). Grey bars represent week 6 before treatment, black bars represent week 12 after 
treatment. The PAS staining quantification (interstitial fibrosis) is showed at 12 weeks. HL=Healthy; 
PR= Proteinuric untreated; 3C5=anti-VEGFR3 antibody. *p<0,05 ** p<0,01 ***p<0,001.
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marker vascular cell adhesion molecule 1 (VCAM-1), monocyte chemoattractant protein-1 (MCP-
1/CCL2) and osteopontin (Fig. 3), although a tendency towards reduction of these inflammatory 
markers was suggestive. There were no significant differences for total white blood count, 
lymphocytes, neutrophils, basophils and eosinophils in IMC-3C5 treated groups (Fig. 8). Thus, 
treatment of proteinuric rats with anti-VEGFR3 completely prevented tubulointerstitial lymph 







Figure 3. Effects of anti-VEGFR3 antibody treatment on mRNA expression of fibrotic and 
inflammatory markers. Anti-VEGFR3 injections tended to reduce the proteinuria-induced 
expression of Collagen III (α1) and TGF-β1 mRNA, however, not with Collagen I (α1) (A-C). Likewise, 
anti VEGFR3 intervention tended to reduce the proteinuria-induced mRNA expression of MCP-
1, osteopontin and VCAM-1 (D-F). HL=Healthy; PR= Proteinuric untreated; 3C5=anti-VEGFR3 
antibody. *p<0,05 ** p<0,01 ***p<0,001.
FTY720 prevented the increase in myofibroblasts accumulation, T cells infiltration and 
interstitial fibrosis, but not collagen III deposition, macrophage influx and LVs number
Treatment of proteinuric rats with FTY720 did not affect body weight, food and water intake, 
blood pressure and heart rate, creatinine clearance or proteinuria (Table 1). FTY720 treatment 
had no effect on renal lymphangiogenesis (Fig. 4A,B ). The influx of ED1-positive macrophages 
showed a tendency to be reduced upon FTY720 treatment, however not significantly (Fig. 
4C,D). Since the number of white blood cells and leukocytes were strongly reduced by FTY720 
treatment (Fig. 8A and B, p<0,001), renal influx of CD3-positive T-cells was significantly reduced 
at 12 weeks (Fig. 4E,F, p<0.05). FTY720 completely prevented a-SMA positive myofibroblasts 
accumulation at week 12 compared to non-treated proteinuric rats (Fig. 4G,H, p<0.05), while 
did not show any marked effect on collagen III deposition by immunohistochemistry (Fig. 4I,J). 
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Figure 4. Effects of FTY720 treatment on renal lymphangiogenesis, inflammation, and 
fibrosis.
Quantification of the staining of kidneys from proteinuric rats treated with FTY720 did not show 
any effect on the increased number of LVs in proteinuric rats at week 12 (A, B). Although FTY720 
did not show a significant effect on the influx of macrophages (C, D), it did show a complete 
blocking of T cells influx at week 12 compared to the untreated proteinuric rats (E, F) and also 
of α-SMA positive cells at 12 weeks (G, H), while it did not show to have a significant effect on 
collagen III deposition (I, J). Nevertheless, interstitial fibrosis (PAS scoring) revealed that FTY720 
could markedly prevent the development of interstitial fibrosis in proteinuric rats compare 
to healthy controls at week 12 (K, L). Grey bars represent week 6 before treatment, black bars 
represent week 12 after treatment. PAS staining and quantification has been done at week 12. 
HL=Healthy; PR= Proteinuric untreated; FTY=FTY720. *p<0,05 ** p<0,01 ***p<0,001.
tubulointerstitial remodeling in proteinuric nephropathy
4
530678-L-bw-Hijmans
Processed on: 17-4-2019 PDF page: 88
88
Nevertheless, this intervention significantly reduced interstitial fibrosis scored by PAS staining 
(Fig. 4K,L, p<0.05). At mRNA level, FTY720 also could not prevent the increase in collagen I (α1), 
collagen III (α1), TGF-β1, MCP-1/CCL2 and osteopontin, while significantly prevented the increase 
of VCAM-1 mRNA expression (Fig. 5 ). In summary, in the kidneys of FTY720-treated proteinuric 
rats, accumulation of α-SMA positive myofibroblasts, CD3 positive T-cells and interstitial fibrosis 







Figure 5. Effects of FTY720 treatment on mRNA expression of fibrotic and inflammatory 
markers. Quantitative RT-PCR data showed that the mRNA expression of fibrotic and 
inflammatory markers which have been increased significantly upon proteinuria (A-F), was not 
reduced by FTY720 treatment (A-E), except for significant prevention of VCAM-1 mRNA increase 
(F). HL=Healthy; PR= Proteinuric untreated; FTY=FTY720. *p<0,05 ** p<0,01,***p<0,001.
Clodronate Liposome prevented macrophage influx in the kidney, however, did not show any 
major effect on other histological and clinical parameters
Targeting monocyte/macrophages by clodronate liposomes (CL) in proteinuric rats did not 
show changes in body weight, blood pressure and heart rate, food and water intake, creatinine 
clearance and proteinuria (Table 1 ). This treatment also did not prevent the formation of new 
lymphatic vessels in proteinuric rats compared to non-treated proteinuric control rats (Fig. 
6A,B). However, kidneys of proteinuric rats show a significant decrease in macrophage number 
upon CL treatment (Fig. 6C,D, p<0.05), while proteinuric rats treated by ‘placebo’ liposomes (PBS 
instead of clodronate) show a small non-significant reduction (Fig. 6D). Even in non-proteinuric 
healthy controls treated with CL, the number of kidney macrophages significantly decreased 
compared to non-treated healthy controls (Fig. 6D, p<0.01). CL did not influence the number 
of circulating white blood cells and lymphocytes in the blood (Fig. 8). Treatment of proteinuric 
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Figure 6. Effects of macrophages depletion by clodronate liposomes on renal 
lymphangiogenesis, inflammation and fibrosis. Quantification of immunohistochemical 
stainings of the kidneys of the clodronate-liposome (CL) treated proteinuric rats did not prevent 
the increase in LV number in proteinuric rats (A, B) despite a complete blocking of macrophage 
influx at week 12 (C, D). However, this treatment had no obvious effect of T-cells influx (E, F), and 
did not show to have a significant effect on α-SMA (G, H) or collagen III deposition (I, J). In the 
same line, the development of interstitial fibrosis was also not inhibited by CL intervention (K, L). 
Grey bars represent week 6 before treatment, black bars represent week 12 after treatment. The 
PAS staining quantification (interstitial fibrosis) is shown at 12 weeks. HL=Healthy; PR= Proteinuric 
untreated; CL=Clodronate Liposome; EL=Empty liposomes; *p<0,05 ** p<0,01 ***p<0,001.
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rats with clodronate liposomes, despite effective prevention of macrophage influx, neither 
significantly influenced on influx of T-cells and myofibroblasts accumulation, interstitial fibrosis 
and collagen III deposition (Fig. 6 E-L). At mRNA level, this treatment also did not show any marked 
effect on collagen I (α1), collagen III (α1), TGF-β1 and osteopontin, while inhibited the increase in 
mRNA expression of MCP-1/CCL2 and VCAM-1 (Fig. 7). Thus, despite effective reduction of renal 
inflammation by clodronate-liposomes treatment, interstitial fibrosis and lymphangiogenesis 






Figure 7. Effects of clodronate liposomes treatment on mRNA expression of fibrotic and 
inflammatory markers. Targeting macrophages by clodronate liposome (CL) did not markedly 
alter the mRNA expression of fibrotic markers Collagen I (α1), Collagen III (α1) and TGF-β1 compared 
to non-treated proteinuric rats (A-C). The CL intervention strongly prevented the increase of 
VCAM-1 mRNA expression in proteinuric rats (D, F). MCP-1 expression was non-significantly 
(p<0.06) reduced by CL treatment (E), whereas osteopontin expression was not influenced by the 
treatment (D).     HL=Healthy; PR= Proteinuric untreated; CL=Clodronate Liposome; EL=Empty 
liposomes. *p<0,05 ** p<0,01 ***p<0,001.
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DISCUSSION
In the adriamycin-induced proteinuria model, we targeted tubulointerstitial lymphangiogenesis 
(VEGFR3 blockade), monocyte/macrophage influx (depletion by clodronate liposomes), and pre-
fibrotic myofibroblast accumulation and interstitial fibrosis (by S1P agonist FTY720). Anti-VEGFR3 
antibody completely blocked renal lymphangiogenesis in proteinuric rats. Nevertheless, on a 
histological level, the anti-VEGFR3 antibody did not show any major effects on inflammatory 
(macrophages and T cells) or fibrotic (a-SMA, collagen III and interstitial fibrosis) markers 
despite some apparent reductions in fibrotic and inflammatory markers at mRNA level. FTY720 
considerably prevented α-SMA positive myofibroblasts accumulation and interstitial fibrosis, but 
not specifically collagen III deposition and lymphangiogenesis. The treatment of proteinuric rats 
with CL prevented the increase in tissue macrophage number in proteinuric kidneys, but did not 
show major changes on the clinical parameters, neither on tubulointerstitial lymphangiogenesis 
and fibrotic markers. This study thereby shows the dissociation of inflammatory (macrophages, 
T cells) or fibrotic (myofibroblasts, collagen III and interstitial fibrosis) responses from renal 
lymphangiogenesis, at least in this proteinuric-nephropathy model. Importantly, proteinuria-




Figure 8. Number of total white blood cells (WBCs) and lymphocytes in the blood in both 
healthy and proteinuric rats at week 12. Total WBCs did not show any difference in healthy 
non-proteinuric compared to proteinuric rats (A). However, upon treatment with FTY720, the 
total WBCs dramatically decreased at week 12, in both healthy (grey bars) and proteinuric (black 
bars) groups. CL and IMC-3C5 did not show any effect. In order to see the effect of treatments 
on specific subset of WBCs in the blood, we also measured the number of lymphocytes. FTY720 
markedly reduced the lymphocyte in the circulation, even in healthy rats who received the drug. 
However, again the other two interventions did not have any effect on lymphocyte number in the 
blood circulation (B).
HL=Healthy; PR= Proteinuric untreated; CL=Clodronate Liposome; EL=Empty liposomes; 
3C5=anti-VEGFR3 antibody; FTY=FTY720. *compared to healthy control, # compared to the 
proteinuric non-treated rats. *p<0,05 ** p<0,01 ***p<0,001.
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Tubulointerstitial remodeling is one of the key events in proteinuric nephropathy, which in 
the end, will cause massive renal fibrosis culminating into loss of renal function and ESRD 28,29. 
Although targeting proteinuria directly is the most commonly used and effective treatment in 
the clinic, nevertheless, complete annihilation of proteinuria is very difficult and attempts to do so 
resulted in increased mortality 28,30–32. Therefore, preventing and/or curing damage downstream 
of proteinuria in the kidney would be of high importance in order to preserve kidney function, 
and halt progression towards CKD and eventually ESRD.
Vascular remodeling plays a major role in tubulointerstitial homeostasis in the 
microenvironment of all organs, and specifically in the kidney 33,34. Lymphangiogenesis, the 
growth and formation of new LVs, has caught increasing attention over the last years due to 
its immense importance in many pathological conditions in the body 35. Lymphangiogenesis 
has been shown to be in close relation to fibrogenesis in different organs including the kidney 
36–38. Yet, the causal interplay between fibrosis and lymphangiogenesis is not clearly explored. 
Meinecke AK. et al. showed in an elegant study that LVs play central role in fibrogenesis, at least in 
pulmonary fibrosis 39. They meticulously showed that in the early stage of the disease, activated 
LECs stimulate PDGFR-ß receptor-expressing mural cells, by secretion of platelet derived growth 
factor-B (PDGF-B), recruiting them around LVs and then by attaching to LVs, impeding their 
drainage capacity. These defects then hamper the most important function of LVs, which is 
fluid drainage, and thereby leading to fibrotic processes in the lung. Although, it is not yet 
known whether this phenomenon holds true in renal fibrosis, however, this study proposed an 
important role of LVs in fibrogenesis. CCL21, by signalling CCR7 receptor-expressing cells, initiates 
a vital pathway in renal fibrogenesis 40. LECs of renal LVs also showed to be able to secrete CCL21 
41. As blocking of lymphangiogenesis by anti-VEGFR3 decreased CCL21 secretion 42, this strategy 
might be useful in targeting fibrosis. We previously showed that in the experimental unilateral 
proteinuric model, prolonged and sustained proteinuria triggers new LVs formation in the 
kidney and that renal lymphangiogenesis occurs before the influx of macrophages and collagen 
deposition 13. To explore the importance of LVs in tubulointerstitial damage and its potential 
roles in modulating the microenvironmental milieu, we targeted lymphangiogenesis distinctly. 
Anti-VEGFR3 antibodies have been extensively studied in experimental models, and are currently 
in the phase 1 clinical trial for the treatment of advanced malignant tumors (http://clinicaltrials.
gov/ct2/show/NCT01288989)http://clinicaltrials.gov/show/NCT01288989. Therefore, in this 
current study, by specific blocking of lymphangiogenesis in renal injury model, we aimed to 
explore more about its implication. In this study, IMC-3C5 perfectly blocked lymphangiogenesis 
in our proteinuric model in rats and also in the healthy controls, which indicates LVs regression 
43. This intriguing observation needs further studies to see what could be the consequence of 
this decrease in lymphatic vessels number, such as oedema formation or delaying in exit of 
inflammatory cells, etc. This intervention however failed in preventing renal inflammation (at least 
not macrophage and T-cell number) and fibrosis (at least not α-SMA and collagen III expression, 
and interstitial fibrosis scored by PAS staining), although some apparent effects on mediators of 
inflammation and fibrosis on mRNA level is suggested by qRT-PCR data. The reason might be 
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that in this model tubular epithelial cells which continuously encounter the ultrafiltered plasma 
proteins and are being activated, are the main source of many chemokines and mediators which 
induce tubulointerstitial remolding such as lymphangiogenesis, inflammation and fibrosis 11. 
LVs are an integral part of the inflammatory process, and they have been proposed as a 
therapeutical target in inflammation 15,16,44. Different leukocytes are capable of prompting 
lymphangiogenesis 45, however, among them the role of macrophages is far more highlighted 
18,46, and macrophage depletion or reduction has been shown to abolished lymphangiogenesis in 
several disease models 47,48. Still, the role of macrophages, specifically in renal lymphangiogenesis, 
is not distinguished clearly. Several groups, including ours, have shown that macrophages are 
actively involved in inducing lymphangiogenesis in kidney diseases 13,47, however, there are 
some conflicting findings in these studies. Lee AS. et al. 49 depleted macrophages by clodronate 
liposomes in UUO kidney damage in mice and found the striking blockage of lymphangiogenesis. 
In a rat UUO model, Suzuki Y. et al. 50 showed tubular epithelial cells to be the main inducer of renal 
lymphangiogenesis. It seems that, at least in this experimental model, macrophages are not the 
main lymphangiogenic inducer. We now showed, that complete prevention of tubulointerstitial 
macrophage influx, also reduced some markers of inflammation at mRNA level. However, neither 
interstitial fibrosis, nor lymphangiogenesis could be reduced by this intervention. Hence, the role 
of macrophages in inducing lymphangiogenesis seems to be very much context-dependent.
FTY720, a FDA-approved drug to treat multiple sclerosis, inserts different kind of effects in 
the body 51,52. One of the most well-known influences is the immunosuppression by blocking 
the egress of lymphocytes from the lymph nodes, thereby reducing inflammation 21,22. Several 
reports have shown the beneficial effect of FTY720 not only in a renal inflammatory reactions, but 
also in hampering renal profibrotic and fibrotic development such as myofibroblast activation 
and collagen deposition 25–27. By binding to the S1P1 receptor on LECs, FTY720 showed to be 
an effective drug in blocking lymphangiogenesis 53. In this current study, FTY720 treatment 
effectively reduced the number of lymphocytes in the blood circulation, and T cells in proteinuric 
kidneys, but did not show to have any impact on renal lymphangiogenesis. Interestingly, 
while FTY720 significantly prevented the increase of α-SMA positive myofibroblasts, it was not 
effective in decreasing collagen III deposition, however significantly reduced tubulointerstitial 
fibrosis (PAS scoring). Apparently, collagen III is not fully representative for interstitial fibrosis, 
which is a reflection of interstitial matrix accumulation of many different extracellular matrix 
molecules. Results also showed that α-SMA is not an ideal marker for collagen-secreting cells 
in interstitial injuries, as many (myo)fibroblasts which do not express α-SMA, have the ability of 
collagen deposition 54–56.
In summary, our study showed that tubulointerstitial fibrosis, inflammation and 
lymphangiogenesis are rather independent tissue remodeling responses, at least under 
proteinuric conditions. Our work also shows that blocking renal interstitial lymphangiogenesis 
or inflammation did not effectively reduce the development of renal fibrosis. It proposed that, 
for the treatment of the downstream consequences of proteinuria there is no specific target in 
just one of the tubulointerstitial changes that we investigated in this study. Data rather suggest 
tubulointerstitial remodeling in proteinuric nephropathy
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combination of intervention strategies to reduce proteinuria-driven tubulointerstitial tissue 
remodeling, eg by combining FTY720 or clodronate-liposomes with lymphangiostatic treatments 
to evaluate the effects on fibrosis and functional renal outcome parameters. Earlier data indicated 
that activated tubular epithelial cells trigger lymphangiogenesis, inflammation and fibrosis. Our 
group previously showed that specific targeting of Rho-kinase pathway in proximal tubular 
epithelial cells markedly reduced renal inflammation and renal lymphangiogenesis in an acute 
renal allograft rejection model 47. Although it warrants future studies, these findings suggest that 
strategies to preserve tubular epithelial cells or directly target their secreted chemokines and 




Proteinuria is a major challenge in clinical nephrology. Sustained proteinuria might lead to 
progressive loss of renal function, and finally the need for dialysis or renal transplantation. 
Routine anti-proteinuric treatment regimens are not always completely successful and residual 
proteinuria might cause irreversible tissue damage and ultimately loss of kidney function. 
This point towards the urgent need for other therapeutic strategies, not aiming at reducing 
proteinuria even further, but at preventing proteinuria-induced renal injury instead.
Results
In a well-established experimental rat model of proteinuria, authors targeted specifically 
three major tubulointerstitial remodeling events under sustained proteinuria. They blocked 
lymphangiogenesis (anti-VEGFR3 antibody), monocyte/macrophage influx (clodronate 
liposomes) and lymphocyte, myofibroblast influx and interstitial fibrosis (S1P agonist FTY720). 
Proteinuria was developed 6 weeks after the injection of Adriamycin in Wistar rats. The treatments 
then were started by above-mentioned compounds for another 6 consecutive weeks, up to 
week 12. Proteinuric rats showed significant increase of renal lymphangiogenesis, inflammatory 
cell influx (evidenced by macrophages and T cells number) and fibrosis markers (evidenced by 
myofibroblasts accumulation and collagen III deposition and scoring interstitial fibrosis) at week 12. 
Anti-VEGFR3 antibody completely inhibited lymphangiogenesis in proteinuric rats; however, had 
no significant effect on inflammatory cells, fibrotic markers and proteinuria. Clodronate liposomes 
reduced macrophage influx, and partly prevented myofibroblast increase; nevertheless, did not 
show any effects on renal lymphangiogenesis, fibrotic markers and proteinuria. FTY720 markedly 
declined myofibroblast accumulation and T cells infiltration and interstitial fibrosis (not collagen 
III deposition), partially reduced macrophage number and proteinuria, however, had no influence 
on lymphangiogenesis. Authors concluded that targeting any of these tubulointerstitial changes 
alone is not effective at least under proteinuric conditions.
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Implications and future directions
Despite all efforts, complete annihilation of proteinuria is practically not possible. Aiming 
at reducing proteinuria further in those patients is not only unsatisfactory, but is also life-
threatening. Hence, strategies targeting the downstream effects of proteinuria to preserve 
kidney function are highly desirable. In this study, authors targeted not the proteinuria, but the 
detrimental tissue remodeling secondary/downstream of proteinuria. They showed that none of 
the tubulointerstitial events investigated in this study is a promising target individually. Future 
treatments should aim for a combination of therapies. Alternatively, as activated tubular epithelial 
cells mediate tubulointerstitial tissue remodeling, future directions should aim at preventing the 
activation of tubular epithelial cells in proteinuric conditions, or aiming at blocking/inactivating 
the chemokines and mediators secreted by them.
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ABBREVIATONS
ACR:  Albumin to Creatinine Ratio
ACS:  Acute Coronary Syndrome
AKI:  Acute Kidney Injury
AuROC: Area under Receiver Operating Curve
BP:  Blood Pressure
CKD: Chronic Kidney Disease
COPD:  Chronic Obstructive Pulmonary Disease
CVD:  Cardio Vascular Disease
eGFR:  Estimated Glomerular Filtration Rate
EMA:  European Medicines Agency
ESKD: End-Stage Kidney Disease
FDA:  Food and Drug Administration
FGF-23 Fibroblast Growth Factor 23
GFR:  Glomerular Filtration Rate
HR:  Hazard Ratio
ICU:  Intensive Care Unit
IGFBP7:  Insulin-Like Growth Factor Binding Protein 7
IL-18:  Interleukin-18
KDIGO: Kidney Disease Improving Global Outcomes
KIM-1:  Kidney Injury Molecule-1
L-FABP:  Liver-Type Fatty Acid-Binding Protein
NGAL: Neutrophil Gelatinase-Associated Lipocalin
NIH: National Institutes of Health
PTH:  Parathyroid Hormone
RR:  Relative Risk
RRT:  Renal Replacement Therapy
sCr: Serum Creatinine
TER:  Treatment Effect Ratio
TIMP-2:  Tissue Inhibitor of Metalloproteinase-2
TmP-GFR:  Tubular maximum Reabsorption of Phosphate (TmP) to GFR
TRIBE-AKI:  Translational Research Investigating Biomarker Endpoint of AKI
WHO: World Health Organisation
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ABSTRACT 
This review provides an overview of the clinical value of the most relevant renal biomarkers, 
focusing on two main clinical conditions, namely acute kidney injury and chronic kidney disease. 
We categorize biomarkers according to their actionability, in terms of a documented response to 
treatment in relation to outcomes. Furthermore, we introduce a new category of renal biomarkers, 
namely metabolic biomarkers, and underscore their capacity to be highly actionable.
biomarkers of renal function
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INTRODUCTION
Medical professionals are probably familiar with Galen’s (129–201 AD) doctrine on using black 
bile, yellow bile, phlegm and blood to assess a patient’s health, or the tasting of a patient’s 
urine to diagnose diabetes mellitus, which was first described in 1675 1. It took until 1957 for 
the term “biological marker” to be introduced 2. The National Institutes of Health (NIH) defined 
a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” 3. According to the NIH definition, a biomarker can be used as a diagnostic tool for 
the identification of patients with a disease or abnormal condition, as an indicator of disease 
prognosis, or as a tool for monitoring of clinical response to an intervention. Hence, biomarkers 
can support the clinical management of patients in several ways. Furthermore, biomarkers can 
be of value in research by serving as surrogates of eventual clinical outcomes or as criterion for 
early enrollment in clinical trials. 
In order to validate the performance of biomarkers, available studies mainly focus on 
parameters such as specificity, sensitivity, robustness and reproducibility. While we underline 
the importance of these quality indicators, one important indicator is virtually lacking in the 
available literature, namely ‘actionability’. The term ‘actionable biomarker’ has been used in heart 
failure and rheumatology 4,5, and can be defined as ‘the extent to which a biomarker can be 
acted upon to improve clinical management’. 
Recent advances in (high- throughput) laboratory technologies have helped generate an 
expanding list of potential biomarkers and panels of biomarkers related to kidney (dys-)function. 
The number of patients suffering from chronic kidney disease (CKD) is substantial: in the 
general population, the prevalence of CKD at any stage is estimated at 3.31-17.3% 6. End-Stage 
Kidney Disease (ESKD) defined by the WHO as the requirement for life-saving dialysis or kidney 
transplantation is estimated at 1.4 million patients worldwide. The incidence of ESKD is growing 
each year by approximately 8%, driven by aging populations, hypertension and the increasing 
prevalence of type 2 diabetes mellitus (http://www.who.int/). The alarming demographic 
trends render the detection, monitoring and prediction of kidney disease increasingly relevant. 
The availability of specific biomarkers permits recognition of kidney damage separately from 
changes in kidney function. Therefore, biomarkers are often categorized as damage biomarkers, 
functional biomarkers, risk factors and tools for risk prediction. In line with the general trend 
in biomarker literature, however, only a few papers allow assessment of clinical utility and 
actionability. As a consequence, the impact of renal biomarkers on patient management in 
clinical practice is currently limited. 
To add to routine clinical practice, a biomarker should provide additional actionable 
information compared to standard methods. In this review we will summarize the current 
knowledge on the actionability of current and novel biomarkers in two main clinical conditions, 
namely acute kidney injury (AKI) and chronic kidney disease (CKD). We will categorize the 
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METHODS
The number of publications on novel candidate renal biomarkers in the setting of AKI or CKD is 
increasing steadily. Therefore, any list of renal biomarkers is probably incomplete by its time of 
publication. As many high quality reviews and meta-analysis are available already, and as the aim 
of the current review is to review the actionability of current and novel biomarkers, we searched 
for reviews, systematic reviews and meta-analyses and focused on actionability. 
Search strategy
In January 2017, a search was performed in PubMed using the following search terms: “biomarker”, 
“marker”, “biological marker”, “functional marker”, “urinary marker”, “serum marker”, or “urinary 
marker”, and; “renal damage, “renal function”, “chronic kidney disease”, “acute kidney injury” 
or “kidney function”. This search resulted in 6499 hits, of which only the 423 reviews and 78 
systematic reviews and meta-analyses published in the last five years were retained. The 5-year 
time period was chosen to include the most recent meta-analyses and systematic reviews, which 
in turn compile studies from a much longer time frame. Articles primarily regarding kidney 
transplantation, articles in pediatrics and animal studies were excluded. Three authors (SHB, RSH, 
GN) examined the references independently and 48 references were selected as being relevant 
by at least two authors (26 meta-analyses and 11 reviews). From these meta-analyses and reviews 
we selected 11 clinical trials to illustrate the best available evidence regarding the actionability 
of renal biomarkers.
Quality assessment
We used the PRISMA checklist to appraise the quality of reporting of the selected systematic 
reviews and meta-analyses (http://www.prisma-statement.org/). This checklist is currently the 
standard for investigators to report their findings and consists of 27 items. Each checklist item 
was assigned ‘yes’ for compliance or ‘no’ for non-compliance. Discrepancies were decided by 
consensus agreement.
Below we will summarize the current knowledge on biomarkers and their actionability in the 
setting of AKI and CKD. Both clinical conditions will be shortly introduced with a clinical scenario 
and three clinical questions to illustrate the settings where biomarkers can potentially add to 
clinical management, namely diagnosis, prognosis and monitoring response to treatment. 
biomarkers of renal function
5
530678-L-bw-Hijmans




A 73-year-old male is admitted to the ICU with pneumococcal sepsis. His past medical history is 
remarkable for hypertension and COPD Gold stadium II. He has a 30 pack-year history of smoking 
cigarettes. On admission he is intubated and hypotensive on vasopressors.
This patient is at risk for AKI, and biomarkers have the potential to support the clinical management 
of this patient in several ways:
Diagnosis: Which biomarkers should be used for the detection of AKI?
Monitoring: Which biomarkers can assess response to treatment?
Prognosis: Which biomarkers predict AKI-related outcome in terms of need for dialysis or AKI-
associated death?
Diagnosis: Detection of acute kidney injury  
AKI is currently diagnosed using the Kidney Disease Improving Global Outcomes (KDIGO) criteria, 
a consensus-based definition based on functional biomarkers, namely serum creatinine (sCr) 
level and urine output-based criteria 7. However, in early stages of AKI, sCr may still be normal, 
since there may not have been sufficient time for creatinine to accumulate. Therefore, urinary 
and serum damage biomarkers have been widely studied. Our search strategy resulted in eleven 
meta-analyses on the accuracy of damage biomarkers to detect acute kidney injury. The main 
findings of these meta-analyses are summarized in table 1 8–18. Some meta-analyses evaluated 
more than one biomarker: five analyses evaluated urinary neutrophil gelatinase-associated 
lipocalin (NGAL), five plasma NGAL, two serum cystatin C, one urinary cystatin C, two urinary 
kidney injury molecule-1 (KIM-1), three urinary interleukin (IL-18), two urinary liver-type fatty 
acid-binding protein (L-FABP) and one urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) 
multiplied by insulin-like growth factor binding protein 7 (IGFBP7). A schematic overview of renal 
biomarkers, organized by tissue source and renal cell type is provided in Figure 1.
Alge and Arthur gave a clear overview of the mechanistic relevance and function of renal 
biomarkers 19. After kidney injury, intrarenal NGAL production is dramatically upregulated in the 
thick ascending limb and the collecting duct. Plasma NGAL also increases as a result of increased 
hepatic production, and NGAL is filtered by the glomerulus and taken up by the proximal 
tubule. KIM-1 is a transmembrane protein that contains extracellular mucin and Ig domains. 
Basal expression of KIM-1 is low in the normal kidney. However, it is upregulated in proximal 
tubular epithelial cells after injury. IL-18 is a pro-inflammatory cytokine, which is upregulated in 
the kidney upon renal damage. L-FABP is a renoprotective protein and is localized predominantly 
in the proximal tubule. In addition to promoting the metabolism of long-chain and very long–
chain fatty acids, L-FABP also has antioxidant properties. TIMP-2 and IGFBP7 induce G
1
 cell cycle 
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Table 1. Quality of reporting and summary results of meta-analyses on the performance of 
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* Meta-analysis not conducted because of heterogeneity of included studies.
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arrest after an insult, which prevents ensuing cell death. TIMP-2 is secreted by the ureteric bud, 
and it has been proposed that injured tubular epithelial cells secrete IGFBP7. Finally, functional 
tubular markers may be of importance to estimate kidney damage. It has been proposed that, 
for example, the tubular handling of phosphate decreases with age, and the tubular maximum 
reabsorption capacity (TmP-GFR) may as such reflect tubular function. The prognostic significance 
of reduced functional tubular markers such as the TmP-GFR, however, remains unknown.
Quality of reporting of the selected meta-analyses was moderate to good and ranged from 
a score of 15/27 to 27/27 on the PRISMA checklist. Pooled sensitivity, specificity and area under 
receiver operating curve (AuROC) for almost all analyses were ≥0.70, except for the specificity 
of serum NGAL in two meta-analyses regarding patients with sepsis 17,18, the specificity of TIMP-
2 x IGFBP7 in one meta-analysis 15, the sensitivity of urinary IL-18 in two meta-analyses 12,13 and 
the AuROC of urinary IL-18, urinary cystatin C as well as serum cystatin C in one meta-analysis 
11. Neither the ideal cut-off point, nor the optimal timing was reported for any of the studied 
biomarkers. Furthermore, all meta-analyses were limited due to considerable heterogeneity 
between the included studies. Hjortrup et. al. even aborted their plans of conducting a meta-
analysis of the value of NGAL to predict AKI in patients with sepsis, because of the heterogeneity 
in included studies 10. They stated “The results of the included studies varied greatly, as did those 
of studies in general intensive care unit (ICU) patients only. Put another way, the results ranged 
from a predictive value equivalent to flipping a coin to NGAL being an excellent early marker 
of AKI.” Finally, none of the included studies in the meta-analyses focused on the actionability 
















































Figure 1. Schematic overview of renal biomarkers, organized by tissue source and renal cell type.
chapter 5
530678-L-bw-Hijmans
Processed on: 17-4-2019 PDF page: 109
109
guide clinical management. This illustrates that the currently available data are not sufficient to 
conclude that individual biomarkers should be used routinely for early detection of AKI. 
Other analyses investigated biomarker panels. The rationale behind panels of biomarkers 
over single biomarkers, would be that a combination of biomarkers may be less influenced by the 
underlying disease state. For instance, underlying infections may influence NGAL concentrations. 
This may have resulted in less diagnostic accuracy of NGAL in the two meta-analyses in patients 
with sepsis 17,18 compared to the meta-analysis in patients after cardiac surgery 9. However, if 
NGAL levels were elevated along with elevations of KIM-1 and L-FABP the diagnostic likelihood 
could be enhanced. In order to assess the quality of research on biomarker combinations in the 
setting of early AKI diagnosis, Meisner et. al. conducted a systematic review with focus on the 
statistical methods of the included articles 20. They found that each of the included articles was 
susceptible to at least one source of bias. Furthermore, in 6 out of 7 cases, the AuROC  decreased, 
varying from 14% to 35%, when they applied the published results to TRIBE-AKI data (Translational 
Research Investigating Biomarker Endpoint of AKI; one of the most carefully conducted cohort 
studies for early detection of AKI after major cardiac surgery). Again, none of the included studies 
investigated the potential benefit of biomarker-guided clinical interventions. 
A step towards clinical implementation of the use of a biomarker combination was made in 
2014, when the FDA approved marketing of NephroCheck (Astute Medical Inc., San Diego, CA, 
USA) 21. NephroCheck multiplies the urinary concentrations of TIMP-2 and IGFBP7 and divides 
this product by 1,000 to report a single test result with units of (ng/mL)2/1,000 to assess the risk 
of developing severe AKI (defined as KDIGO stage 2 or 3) within 12 hours after testing. The FDA’s 
review included two clinical studies to evaluate the test’s safety and effectiveness. With a cut-off 
of 0.3 (ng/ml)2/1,000, NephroCheck accurately detected 92% of AKI patients in one study and 
76% in the other 22,23. In both studies, NephroCheck incorrectly gave a positive result in about 
half of patients without AKI. TIMP-2 and IGFBP7 individually identified patients with early AKI with 
significantly greater accuracy than NGAL, KIM-1, IL-18, L-FABP, or cystatin C. The combination of 
the two markers performed best 24.
In 2016, the Acute Kidney Injury Advisory Group of the American Society of Nephrology 
published recommendations on the use of Nephrocheck in the clinical setting 25. They state 
that use of TIMP-2 x IGFBP7 is appropriate in patients ≥ 21 years old, who are admitted to 
the ICU and have undergone cardiac bypass or other major high-risk surgery, or have sepsis, 
or have 1 other risk factor for AKI. In this setting, a positive test implicates a 27% absolute risk 
for KDIGO stage 2 or 3 AKI within 12 hours and should prompt consideration of nephrology 
consultation and preventive strategies such as avoiding nephrotoxins, optimizing volume status 
and hemodynamics and close monitoring of urine output. Unapproved uses of NephroCheck 
and limitations include: low-risk patients in the hospital and emergency department, daily or 
serial measurements, proteinuria (urinary albumin > 125 mg/dL interferes with the NephroCheck 
result and >3000 mg/dL invalidates it) and bilirubinuria (urine bilirubin concentrations > 7.2 g/dL 
interfere with the result) 25. Our search strategy yielded one meta-analysis on TIMP-2 x IGFBP7 of 
good quality (table 1) 15. The summary AuROC and sensitivity of the ten included studies were 
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good (0.99 and 0.84, respectively), but specificity was relatively poor (0.57). Furthermore, it has 
not been demonstrated that NephroCheck-guided earlier start of supportive measures improves 
patients’ outcome and therefore future clinical trials are needed before routine measurements 
can be implemented in daily practice. Until now, to our knowledge, there are no registered 
ongoing trials investigating optimal NephroCheck-stratified patient management.
Monitoring: Response to treatment in AKI
A biomarker suitable to monitor response to treatment should reflect the efficacy or lack of 
efficacy of specific interventions and the change in biomarker level during effective treatment 
should be an adequate surrogate for clinical improvement. Currently, recovery of renal function 
is assessed with the functional markers sCr and creatinine-based estimated glomerular filtration 
rate (eGFR) 7. However, creatinine-based estimates of GFR will underestimate the true GFR during 
recovery of kidney function, because of a lag time in the decline of sCr concentration. Despite 
the known limitations of sCr, other biomarkers to monitor response to treatment in AKI are not 
widely investigated. Our search strategy yielded no meta-analyses or systematic reviews on the 
value of serial measurements of novel biomarkers to monitor response to treatment. This may 
well be due to the fact that treatment of AKI is mainly supportive and no therapeutic options 
have been shown to be effective 7 . 
Table 2. Quality of reporting and summary results of meta-analyses on the performance of 













All All OR dialysis requirement 2.34 (1.46-3.75)












All All Sensitivity dialysis requirement 0.69 
(0.35-0.91)
Specificity dialysis requirement 0.43 
(0.03-0.95)
Sensitivity in-hospital death 0.93 (0.66-
0.99)
Specificity in-hospital death 0.79 (0.27-
0.97)
* Meta-analysis not conducted because of insufficient data
Prognosis: Prediction of AKI related outcome 
A prognostic biomarker is most meaningful when the results of testing are clinically actionable 
and changes in the biomarker level reflect changes in prognosis. Serum creatinine fulfills both 
criteria since the event “AKI” itself, based on sCr derived criteria, is strongly associated with 
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an increased risk of CKD, end-stage renal disease (ESRD) and mortality, and a decline reflects 
improved prognosis 26,27. However, individual long-term follow-up studies have identified 
a subgroup of patients without AKI as defined by sCr, but with elevated biomarkers of renal 
damage, who are at increased risk of adverse outcomes 28,29. This suggests that novel biomarkers 
of AKI may provide additional prognostic information beyond that offered by sCr. Our search 
strategy resulted in only three meta-analyses studying the prognostic value of novel biomarkers 
on AKI-related outcome 13,30,31. These meta-analyses investigated serum cystatin C, urinary IL-18 
and urinary L-FABP, respectively (table 2). The studies’ performance to predict dialysis requirement 
or in-hospital death were either poor (urinary L-FABP) 30, acceptable (serum cystatin C) 31 or could 
not be determined due to insufficient data for pooling studies (urinary IL-18) 13. 
All meta-analyses included studies wherein the biomarker was measured prior to the onset 
of AKI, since the included studies aimed to validate the biomarker as an early AKI diagnostic. 
Furthermore, none of the meta-analyses included studies reporting on the added value of novel 
biomarkers to traditional baseline prognostic variables, such as sCr or eGFR. 
In addition to these meta-analyses, Schaub and Parikh, recently provided a clear overview of 
individual studies investigating the association of novel biomarkers with short- and long-
term outcomes in different clinical settings of patients with AKI 32. They conclude that there is 
extensive evidence showing that biomarkers are related to important patient outcomes, such as 
RRT and death. They underscore the importance of enrolling patients with elevated biomarkers 
in future clinical trials to investigate the possible benefit of biomarker-guided therapy. Most of 
the studies included in this review also collected biomarker specimens prior to the diagnosis 
of AKI. In contrast, below, we highlight three clinical studies in patients with established AKI, 
wherein the added value of biomarkers to baseline models with sCr was investigated. Hall et. al. 
measured urinary concentrations of NGAL, KIM-1 and IL-18 and determined fractional excretion 
of sodium, fractional excretion of urea and microscopy score for casts and tubular cells in a 
heterogeneous group of 249 hospitalized patients on the first day of meeting AKI criteria. There 
was an approximate three-fold increase in adjusted risk for worsened AKI stage from enrollment 
to peak sCr or in-hospital death for upper versus lower values of NGAL, KIM-1 and IL-18 and 
microscopy score. The net reclassification index (quantifies how well a new model reclassifies 
subjects to the observed outcome) improved after adding these biomarkers to a baseline 
clinical assessment (age ≥65 years, body mass index, male gender, non-Caucasian race, baseline 
eGFR, surgery before AKI, diabetes and hypertension) 33. Another prospective study in patients 
admitted for acute decompensated heart failure also showed that urinary NGAL and urinary IL-18 
predicted AKI progression and improved risk reclassification compared with the clinical model 
(including SCr-based eGFR) alone 34. In a third prospective cohort of cardiac surgery patients 
with stage I AKI, urinary IL-18 combined with percentage change in sCr or urinary KIM-1 had the 
best discriminative ability to identify patients at high risk for progressing to more advanced AKI 
or death within 30 days 35.
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Although these studies illustrate that there are novel biomarkers which provide prognostic 
information additional to sCr and eGFR, none of the studies has shown that these biomarkers 
are actionable, i.e. that therapy induced changes in the level of the specific biomarker in patients 
with established AKI reflect changes in outcome.
Table 3. Clinical value of biomarkers in AKI based on systematic reviews and meta-analyses, 
authority approval, and estimated assay costs. 
Biomarker Clinical value 







Diagnosis Monitoring Prognosis Actionability
uNGAL +++ - - - EMA $19.62
uCysC ++ - - - EMA/FDA $18.94
uKIM-1 +++ - - - - $19.72
uIL-18 +++ - - - - $17.65
uL-FABP ++ - + - - $24.38
sNGAL +++ - - - EMA $19.62
sCysC +++ - ++ - EMA/FDA $18.94
TIMP-2 x 
IGFBP7
+ - - - EMA/FDA $85.00
The green or red colors are indicative of good (green) or poor (red) performance of biomarkers in different settings of AKI 
based on systematic reviews and meta-analyses and whether there are mixed results (purple) or no data was found (grey). We 
use + or – to indicate the level of evidence found in literature. – indicates no meta-analyses have been found for this biomarker 
on their diagnostic, monitoring or prognostic value, + indicates one meta-analysis with a PRISMA-score <25, ++ indicates one 
meta-analysis with a PRISMA-score ≥25, and +++ indicates multiple meta-analyses with PRISMA-scores ≥25. The ‘approved’ 
column indicates whether a biomarker is approved by EMA and/or FDA for clinical use. Prices are indicative and expressed 
in US dollars, based on the cheapest human ELISA kit, per triplicate measurement. Prices are a gross underestimation of the 
true costs, because personnel expenses and costs for good laboratory practice setup etc. are not included in this estimation.
Conclusions and considerations regarding the clinical value of biomarkers 
in AKI 
In table 3, we put available data in the perspective of clinical applicability by providing an 
overview of the diagnostic, monitoring and prognostic value of biomarkers, as well as the 
European Medicines Agency (EMA) and/or FDA approval status and an estimation of the costs. 
Based on this table, urinary NGAL, urinary KIM-1, urinary L-FABP and serum cystatin C perform 
reasonable in early diagnosis of AKI across study populations. Combining biomarkers has the 
potential to give more accurate results, however, methodological issues may lead to bias in the 
development of biomarker combinations. TIMP-2 x IGFBP7 shows promising results, however, 
specificity is relatively poor and evidence that NephroCheck guided earlier start of supportive 
measures improve patients’ outcome is not available. On the contrary, the added-value 
of NephroCheck for future research is evident. Future intervention trials in AKI may consider 
using NephroCheck as a criterion for early enrollment, since a delay in the recognition of AKI 
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(resulting from the use of sCr level as entry criterion) may have attenuated the effect of various 
interventions in prior studies).
When appraising the clinical value of candidate biomarkers for AKI there are some issues to 
consider. First, it is difficult to compare the value of novel biomarkers with those of sCr, because 
sCr is almost always used in the reference standard (e.g. the AKI criteria as formulated by KDIGO). 
Second, it is also difficult to compare the value of novel biomarkers in separate studies, due to 
the heterogeneity between studies in terms of clinical setting, age, laboratory assays, timing of 
measurement, AKI criteria used etc. And third, the most important issue, in sharp contrast to the 
total number of studies focused on establishing their accuracy to detect renal damage, there 




A 69-year-old woman is seen at the outpatient clinic. She was diagnosed with type 2 diabetes 4 
years ago. Other medical problems include obesity and hypothyroidism. She is seen for routine 
follow-up and is noted to have a blood pressure of 168/105 mmHg. 
This patient is at risk for developing chronic kidney disease. Biomarkers can support the 
clinical management of this patient in several ways:
Questions:
• Diagnosis: Which biomarkers should be used for the detection of CKD?
• Monitoring: Which biomarkers can assess response to treatment in patients with CKD?
• Prognosis: Which biomarkers predict the onset of CKD and/or related outcome in terms of 
need for renal replacement therapy, cardiovascular complications and death?
Diagnosis: Detection of CKD 
CKD is defined as glomerular filtration rate < 60 mL/min/1.73 m2 or presence of ≥1 marker(s) 
of kidney damage (albumin to creatinine ratio (ACR) ≥30 mg/g, urinary sediment abnormality, 
electrolyte or other abnormality due to tubular disorder, abnormalities on histology, structural 
abnormalities detected by imaging, or history of kidney transplantation), or both, of at least 
three months duration 36. The CKD Prognosis Consortium conducted several meta-analyses, 
providing a solid basis for including eGFR and ACR measures to establish a CKD diagnosis, by 
showing that eGFR <60 ml/min/1.73 m2 and increased albuminuria (ACR >30 mg/g or dipstick 
>trace) are consistently associated with an increased risk for progressive renal function loss and 
ESRD across different populations (see Prognosis) 37–39. However, eGFR and albuminuria also have 
limitations. A limitation for the use of albuminuria to diagnose CKD is that urinary albumin levels 
are highly variable, and not all types of kidney disease lead to albuminuria 40. Furthermore, by 
biomarkers of renal function
5
530678-L-bw-Hijmans
Processed on: 17-4-2019 PDF page: 114
114
the time a change is observed in sCr (and hence, eGFR), a critical therapeutic window may have 
been missed, because increased sCr levels reflect a substantial loss of functioning nephrons, 
and so earlier detection may seem warranted 41. In this regard, several reviews reported on the 
peptidomic CKD marker panel CKD273 as a marker for early renal damage, preceding changes 
in eGFR and in ACR 42–45 and predicting renal function loss. This panel was identified during a 
comparison of healthy control patients and patients with various biopsy–proven renal diseases 
46. The CKD273 panel was better correlated to percentage change in eGFR in 522 patients during 
a follow-up of three years than percentage change in albuminuria. Furthermore, the CKD273 
panel identified 75% of the rapid progressors, whereas urinary albumin identified 65% of the 
rapid progressors. Net reclassification index analysis suggested that the urinary CKD273 panel 
improved the detection of rapid progressors by 30% compared with the use of albuminuria 
alone 47. Of note, the CKD273 risk classifier is currently applied in an ongoing trial that not only 
aims to confirm its ability to predict development of microalbuminuria in normoalbuminuric 
patients with type 2 diabetes mellitus, but also aims to determine whether early initiation of 
treatment with an aldosterone antagonist can reduce the risk of transition to microalbuminuria 
in designated ‘high-risk’ individuals. This is a rare example of a biomarker-directed therapy trial, 
that explicitly attempts to evaluate its actionability in a clinically relevant setting 48.
Table 4. Quality of reporting and summary results of meta-analyses on the performance of 
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Monitoring: Response to treatment in CKD 
The treatment objectives of all patients with CKD, regardless of the cause, include the 
prevention of cardiovascular events and a reduction in the rate of progression of renal 
function loss towards ESRD and other complications, such as anemia, mineral bone disorder, 
hyperkalemia, and metabolic acidosis. These objectives require pharmacological, as well as 
non-pharmacological measures (e.g. lifestyle and nutritional) interventions, preferably well 
aligned 36. Hence, we searched for biomarkers to assess the response to pharmacological as 
well as non-pharmacological interventions, but almost exclusively found studies focusing on 
pharmacological interventions assessed with the classical biomarkers Scr and proteinuria 49–52. 
The majority of included studies were studies of diabetic or hypertensive kidney disease and 
tested renin angiotensin system blockade.
The results of our search strategy are summarized in table 4. 
Inker et. al. showed that a drug-induced early reduction in proteinuria is consistently associated 
with slower progression of kidney disease and this association was stronger when baseline 
proteinuria was higher 50. Similar results were found by Heerspink et. al. and Jun et. al 49,51. Jun 
et. al. assessed the correlation between drug-induced changes in sCr and proteinuria and 
ESRD and determined the treatment effect ratio (TER) 51. TER was defined as the ratio of the 
treatment effects on ESRD and the effects on the change in surrogate outcomes. TERs close to 
1 indicate greater agreement between ESRD and the surrogate, and these ratios were pooled 
across interventions. The TER for sCr was excellent 0.98 (0.85-1.14) and for proteinuria was good 
0.82 (0.59-1.16). These results demonstrate the actionability of proteinuria and sCr as a marker to 
monitor for subsequent clinical outcomes, and they support the use of change in proteinuria 
and sCr to inform CKD prognosis in clinical practice.
Prognosis: Prediction of CKD related outcome 
We subsequently searched for meta-analyses focusing on the prediction of CKD-related outcome 
by renal biomarkers. Our search strategy resulted in 3 meta-analyses evaluating the usefulness 
of potential biomarkers for prediction of ESRD as individual outcome 37,53,54 (table 5) in general 
and high-risk populations and 9 meta-analyses evaluating the usefulness of potential biomarkers 
for prediction of CKD-related outcome (e.g. mortality, ESRD) in patients with established CKD 
38,39,53–59   (table 6). 
In the literature, the need for biomarkers that exclusively identify those patients who are at most 
risk of progressive renal function loss is emphasized, because of the assumption that better 
assessment of prognosis guides clinical management and early treatment could slow, stop, or 
possibly even reverse progression towards ESRD 36. It is well established that decreasing eGFR and 
increasing albuminuria predict progressive renal function loss across different populations 36. The 
CKD diagnostic framework encompasses different categories of eGFR and albuminuria (stages) 
in order to identify people who will go on to have poor renal outcomes 36. However, people 
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Table 5. Quality of reporting and summary results of meta-analyses on the performance of 

































































































Table 6. Quality of reporting and summary results of meta-analyses on the performance of 








aspect Outcome (when applicable with 95% CI)
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# variables used in risk equation: age, sex, sCR-based eGFR, ACR
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within the same CKD stage can have very different absolute risks for adverse renal outcome, and 
there is substantial overlap between the categories 60. It has also been suggested that an eGFR-
based definition of CKD with a threshold of <60 ml/min/1.73 m2 defines a considerable number 
of people who will never progress to symptomatic renal disease as CKD patients 61. 
Shlipak et. al. showed that eGFR on the basis of serum cystatin C provides stronger associations 
for ESRD (as well as for death from any cause and death from cardiovascular causes) than eGFR 
on the basis of creatinine 53. Indeed, the 2012 KDIDGO CKD guideline suggests the use of cystatin 
C based eGFR to validate the diagnosis of CKD in patients who are considered to have CKD solely 
on the basis of a creatinine-based eGFR of 45-59 ml/min/1.73 m2, without albuminuria or other 
markers of renal damage 36. The subgroup of patients which is reclassified to a cystatin C based 
eGFR of 60 ml/min/1.73 m2 or more has a substantially lower risk of death 53. In contrast, Inker 
et. al. showed that the filtration markers serum β-trace protein and β-2 microglobulin do not 
provide substantial additional information to traditional prediction models including sCr based 
eGFR and albuminuria 54. 
In line with results in general and high risk populations, Matsushita et. al. showed that ACR 
is one of the strongest predictors of cardiovascular mortality  and, although to a lesser extent 
than ACR, eGFR also improves cardiovascular risk prediction in patients with established CKD 39. 
The change in c-statistic by incorporating eGFR and/or ACR in prediction models was similar or 
superior to the contributions of most of the individual traditional risk factors including blood 
pressure, lipids, and smoking. Another meta-analysis, including 721,357 participants with CKD 
stages 3-5 showed that an original 4-variable kidney failure risk equation (age, sex, eGFR, ACR) 
achieved excellent discrimination (ability to differentiate those who developed kidney failure 
from those who did not); overall C statistic, 0.90 (95% CI 0.89-0.92) at two years and 0.88 (95% 
CI 0.86-0.90) at 5 years). Calibration (the difference between observed and predicted risk) was 
adequate in North American cohorts, however, in some non-North American cohorts the 
addition of a calibration factor was necessary 59. 
The studies summarized in almost all other meta-analyses in patients with established CKD 
generally did not study the value of the particular biomarker in addition to clinical models with 
eGFR and ACR, but predominantly used traditional regression models to show that the association 
between a candidate biomarker and outcome persisted after adjustment for clinical factors. 
Elevated cardiac troponin level was associated with a higher risk (approximately 2- to 4-fold) 
for all-cause mortality and cardiovascular death among CKD patients without suspected ACS 
56,57. One meta-analysis evaluated the value of urinary NGAL and urinary KIM-1 in predicting CKD 
stage 3, ESRD and overall mortality. Only the predictive value of uNGAL for ESRD was supported 
by level A evidence (RR 1.40, 95% CI 1.21-1.61), with the level of evidence for other findings being 
insufficient to recommend their utility in practice 55. Although not a meta-analysis, systematic 
review or review, a recent study by Hsu et. al. is of interest since it addressed the additional 
prognostic value of biomarkers KIM-1, NGAL and L-FABP compared to eGFR and ACR. Strikingly, 
none of these biomarkers improved the already high (0.89) C-statistic for the basic clinical model 
including age, sex, race, clinical center, ACR, eGFR, diabetes mellitus, cardiovascular disease, 
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systolic blood pressure, body mass index, angiotensin-converting enzyme inhibitor/angiotensin 
receptor blocker use, and education 62. 
Thus, overall, no biomarker so far seems able to out-perform sCr-based eGFR or albuminuria, 
except for serum cystatin C based eGFR. And again, none of the studies has shown that results of 
testing of other biomarkers are actionable and that changes in the level of the specific biomarker 
in patients with established CKD reflect changes in prognosis.
Table 7. Clinical value of biomarkers in CKD based on systematic reviews and meta-analyses, 
authority approval, and estimated assay costs. 
Biomarker Clinical value 







Diagnosis Monitoring Prognosis Actionability
eGFR (sCR) ++ ++ + ++ EMA/FDA $5.20
eGFR (sCysC) - - + - EMA/FDA $18.94
eGFR (β2-
microglobulin)
- - + - - $16.75
eGFR 
(sβ-trace protein)
- - + - - $12.50
Albuminuria ++ +++ + ++ EMA/FDA $18.04
uNGAL - - ++ - EMA $19.62
uKIM-1 - - ++ - - $19.72
CRP - - + - EMA/FDA $4.40
Cardiac troponin - - ++ - EMA/FDA $8.35
NT-proBNP - - ++ - EMA/FDA $20.04
The green or red colors are indicative of good (green) or poor (red) performance of biomarkers in different settings of AKI 
based on systematic reviews and meta-analyses and whether there are mixed results (purple) or no data was found (grey). We 
use + or – to indicate the level of evidence found in literature. – indicates no meta-analyses have been found for this biomarker 
on their diagnostic, monitoring or prognostic value, + indicates one meta-analysis with a PRISMA-score <25, ++ indicates one 
meta-analysis with a PRISMA-score ≥25, and +++ indicates multiple meta-analyses with PRISMA-scores ≥25. The ‘approved’ 
column indicates whether a biomarker is approved by EMA and/or FDA for clinical use. Prices are indicative and expressed in 
US dollars, based on the cheapest human ELISA kit, per triplicate measurement. Prices are a gross underestimation of the true 
costs, because personnel expenses and costs for GLP-setup (good laboratory practice) etc. are not included in this estimation.
Conclusions and considerations regarding the clinical value of biomarkers 
in CKD 
In table 7, we put available data in the perspective of clinical applicability by providing an 
overview of the diagnostic, monitoring and prognostic value of biomarkers in CKD, as well as the 
EMA and/or FDA approval status and an estimation of the costs. Based on this table, there are 
no well-validated biomarkers that outperform Scr-based eGFR and proteinuria, except for serum 
cystatin C based eGFR in predicting ESRD and mortality. Most promising is the biomarker panel 
CKD273, especially because of an ongoing trial testing the concept of biomarker-guided therapy 
initiation (PRIORITY) 48. 
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Towards better clinical applicability: role of metabolic markers
Based on the evidence summarized above, unfortunately the clinical actionability of novel 
biomarkers is not supported by empirical studies. This may well reflect the general difficulties in 
generating prospective trials, in terms of funding, organization and time. It has been argued that 
especially in nephrology there is a paucity of trials 63. Yet, biomarkers can potentially be highly 
useful when properly selected and tested. To this purpose, we propose to slightly broaden the 



































Figure 2. The availability of specific biomarkers permits recognition of kidney damage separately 
from changes in kidney function. Kidney damage and changes in function may precede each 
other or occur concurrently in response to a trigger. We propose a new subgroup of functional 
biomarkers, namely metabolic biomarkers. In contrast to damage biomarkers, metabolic 
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Biomarkers  used in nephrology are often classified as functional biomarkers, damage biomarkers, 
risk factors or tools for risk prediction. Functional biomarkers refer almost exclusively to biomarkers 
of glomerular filtration rate, neglecting the homeostatic and regulatory functions of the kidney, 
such as excretion of sodium, free water, potassium, phosphate and uric acid, control of blood 
pressure, acid-base balance and the humoral aspects of red blood cell production and bone and 
mineral metabolism. By neglecting these renal functions and their corresponding biomarkers, 
a whole dimension of actionable biomarkers is overlooked. An important reason to consider 
the role of such markers, which we propose to name ‘metabolic biomarkers’ (Figure 2), is their 
dynamic character, and hence their potential for actionability by lifestyle-related interventions, 
pharmacological interventions, or their combination. Metabolic biomarkers closely reflect a 
known (patho)physiological process for which (non-)pharmacological interventions are already 
available. In contrast, damage biomarkers do not evidently lead to direct therapeutic targets, 
except for albuminuria and urinary sediment abnormalities.
Some metabolic biomarkers, such as urinary sodium and urea excretion, and serum 
potassium, bicarbonate, calcium, phosphate and PTH, are already incorporated in clinical practice 
guidelines. Daily salt intake is adequately reflected by 24-hour urinary sodium excretion 64. Salt 
reduction reduces blood pressure and proteinuria considerably and consistently 65,66. Hence, in 
daily practice, 24-hour sodium excretion is an actionable metabolic biomarker and reflects the 
efficacy of adherence to a sodium-restricted diet. Moreover, lower sodium intake is associated 
with an enhanced renoprotective effect of renin-angiotensin system blockade 67,68. 
Daily 24-hour urea excretion can be used to estimate daily protein intake 69 and to counsel 
patients on adequate intake, weighing the potential benefits and dangers of varying dietary 
protein intake. 
Existing data support prevention of hyperphosphatemia and associated secondary 
hyperparathyroidism in CKD. Calcium/phosphate dysbalance, vitamin D deficiency or enhanced 
parathyroid hormone levels may be improved by reducing phosphate intake or using phosphate 
binders, vitamin D supplementation or calcium receptor sensitizer agents. Emerging data 
suggest that vitamin D deficiency, particularly when combined with high sodium intake, may 
contribute to the development of albuminuria 70, and that treatment with vitamin D analogues 
(along with limiting sodium intake) may reduce albuminuria in established CKD 71,72. However, 
in general, the evidence for recommended targets to restore mineral metabolism in CKD, and 
the strategies to achieve these targets, is merely observational 36. Hence, more clinical trials are 
needed, especially in patients with non-dialysis CKD, to substantiate the actionability of serum 
calcium, phosphate and PTH. 
A serum bicarbonate level <22 mmol/l has been associated with an increased risk of CKD 
progression and increased risk of death and serum bicarbonate levels guide treatment with oral 
bicarbonate supplementation 36. 
From these perspectives on metabolic biomarkers, there are several other candidate 
metabolic biomarkers, for which therapeutic interventions are already available. However, in 
these cases, future clinical trials are needed before routine measurements can be implemented 
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in daily practice. For example, functional vitamin K deficiency is common in patients with CKD 
and is independently associated with an increased risk of all-cause mortality 73–75. Given the 
potential to modulate vitamin K intake by dietary interventions and the availability of vitamin 
K supplements, vitamin K insufficiency seems an attractive target for therapeutic intervention. 
Furthermore, the KDIGO CKD guideline lists hyperuricaemia as a potential contributor to 
progression of CKD 36, based on evidence describing the association of hyperuricaemia with CKD 
and adverse cardiovascular outcomes. Hyperuricaemia can be reduced with xanthine oxidase 
inhibitors such as allopurinol. Furthermore, a recent meta-analyses showed that allopurinol 
therapy is associated with significantly improved endothelial function in subjects at risk of CVD 
risks, and the beneficial effects of allopurinol seemed not to be related to its uric acid lowering 
action 76.
However, further large trials are required to better understand the potential benefit of uric 
acid lowering agents for the specific purpose of delaying CKD progression or lowering the risk 
of cardiovascular events 36. 
Numerous reports have linked elevated fibroblast growth factor 23 (FGF23) to progression to 
ESRD, cardiovascular disease and death in patients with CKD. 
FGF23 levels may be improved by reducing phosphate intake or using phosphate binders, 
vitamin D supplementation or calcium receptor sensitizer agents. However, large randomized 
controlled trials are needed to evaluate if these therapeutic strategies lead to improved survival 77. 
In the less advanced CKD-stages, dietary interventions to increase potassium intake, while 
reducing salt intake, by stimulating the intake of fruit and vegetables, has the potential to 
improve cardiovascular risk management 78. Furthermore, dietary changes to reduce salt intake 
are accompanied by reduced phosphate intake. Therefore, it might be speculated that the blood 
pressure lowering effect observed with salt restriction is partly explained by this concomitant 
phosphate reduction 79. Both observations need to be further explored in randomized controlled 
trials.  
All the above mentioned examples illustrate the added value of clinical studies with actionable 
metabolic biomarkers, complementary to all the research done on damage biomarkers, risk 
stratificators and tools for risk prediction.
OVERALL CONCLUSION
Despite an increasing body of literature assessing the accuracy of biomarkers to detect kidney 
damage or to predict outcome, the question of how patients whose risk is stratified by a 
biomarker level should be treated remains mostly unanswered. In other words, knowledge 
on the actionability of novel biomarkers is mostly lacking. In this regard, most advances are 
expected in the near future from TIMP-2 x IGFBP7 in AKI and CKD273 in CKD. Furthermore, in 
CKD, we propose a different perspective on functional biomarkers by broadening this group 
with metabolic biomarkers, such as markers of bone mineral disorders, uric acid, urinary sodium 
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excretion, and vitamin K status, because these biomarkers are highly actionable and in contrast 
to damage biomarkers, therapeutic interventions are already available in most cases. Future 
studies should address whether interventions targeting these actionable biomarkers results in 
improved outcomes in AKI and chronic kidney disease.
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α-SMA: Anti-Human α-Smooth Muscle Actin
(u/p)C1M:  (Urinary/Plasma) Collagen Type I Degradation Fragments
(u/p)C3M:  (Urinary/Plasma) Collagen Type III Degradation Fragments
ECM:  Extracellular Matrix
HABP:  Hyaluronan Binding Protein
iColl3:  Interstitial renal collagen type III
MMP:  Matrix Metalloproteinases
PAS:  Periodic Acid Schiff
PDGF-βr:  Anti-Platelet-Derived Growth Factor Receptor β
FTY720 :  S1P-receptor modulator
S1P:  Sphingosine-1-Phosphate
IF:  Interstitial Fibrosis
CKD:  Chronic Kidney Disease
eGFR:  Estimated Glomerular Filtration Rate
Tris/EDTA:  Tris(hydroxymethyl)aminomethane/ Ethylenediaminetetraacetic Acid 
HCl:  Hydrochloric Acid
CD68/ED1:  Cluster of Differentiation 68, Pan-Macrophage Marker
PBS/BSA:  Phosphate Buffer Saline/ Bovine Serum Albumin
Ig HRP:  Immunoglobulin Horseradish Peroxidase
DAB/AEC:  Aminoethylcarbazole/ Peroxidase Substrate 3,3’-Diaminobenzidine
FITC:  Fluorescein Isothiocyanate
DAPI:  4’,6’-Diamidino-2-Phenylindole Hydrochloride 
Φs:  Macrophages
NS:  Not Significant
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ABSTRACT
Background: Renal fibrogenesis is associated with increased ECM remodeling and release of 
collagen fragments in urine in progressive renal disease. We investigated the diagnostic value 
of urinary collagen degradation products in a proteinuria-driven fibrosis rat model with and 
without anti-fibrotic S1P-receptor modulator FTY720 treatment. 
Methods: Proteinuria was induced in male Wistar rats by Adriamycin (ADR) injection (n = 16). 
Healthy rats served as controls (n = 12). Six weeks post-injection, all underwent renal biopsy, and 
FTY720-treatment started in ADR-rats (n = 8) and controls (n = 6). Others remained untreated. 
Rats were sacrificed after 12 weeks. Collagen type I (C1M) and III (C3M) degradation fragments 
were measured in blood and urine using ELISA. Kidneys were stained for various inflammatory 
and fibrotic markers. 
Results: Six weeks post-injection proteinuria increased (versus controls, P < 0.001) and although 
no accumulation of interstitial renal collagen type III (iColl3) was observed at this time, urinary 
C3M (uC3M) and C1M (uC1M) were significantly increased (both P < 0.001). At 12 weeks, uC3M 
(P < 0.001) and uC1M (P < 0.01) further increased in ADRrats versus controls, just as fibronectin, 
PDGF-β receptor, hyaluronan (all P < 0.01), iColl3, PAS, myofibroblasts, macrophages and T-cells 
(all P < 0.05). FTY720-treatment reduced accumulation of immune cells, α-SMA+ myofibroblasts 
and PAS-score, but not iColl3 and uC3M. Correlation analyses indicated that uC3M and uC1M 
reflected and predicted tubulointerstitial fibrogenesis. 
Conclusions: These data displayed urinary collagen breakdown products as sensitive early 
markers of interstitial fibrosis, preceding histological fibrotic changes, which might replace the 
invasive renal biopsy procedure to assess fibrosis. Anti-fibrotic FTY720 intervention reduced 
some fibrotic markers without affecting collagen type III metabolism.
urinary collagen degradation markers for renal fibrosis
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INTRODUCTION
Renal interstitial fibrosis (IF) is an important pathological feature of disease progression in 
chronic kidney disease (CKD) 1,2. Despite its importance as a marker of disease progression, 
early detection and quantitative analysis of IF remains a challenge, both in the clinical and in 
the experimental setting. The most widely used and accepted clinical markers to predict the 
progression of CKD are the estimated glomerular filtration rate (eGFR) and albuminuria 3–5. By the 
time these functional changes are detectable, advanced pathological structural changes have 
already taken place. Therefore it would be beneficial to be able to detect renal tissue remodeling 
earlier 6. 
Currently, the gold standard to assess renal IF in CKD is performing a renal biopsy followed by 
a semi-quantitative histological evaluation by a pathologist. This approach is however prone to 
sampling error and to intra- and inter-observer variability 7. Many studies have tried to find non-
invasive, more sensitive and IF specific alternatives. One of the most promising alternatives are 
urinary markers, which are consequent of the processes of extracellular matrix (ECM) production 
and degradation, thus reflecting fibrogenesis.6,8. 
Renal IF is characterized by an increased production and deposition of ECM, which eventually 
leads to a progressive loss of kidney function 9. For tissue homeostasis, it is important to maintain 
a balance between synthesis and degradation of ECM proteins. However, this equilibrium is 
delicate and when disrupted, it can lead to IF 10. 
In terms of synthesis, (myo)fibroblasts with an activated phenotype expressing smooth 
muscle actin (α-SMA) are considered to be the main source of the increased deposition of ECM 
11–15. Earlier studies showed that interstitial fibrosis is the result of an increase in important ECM 
components, namely collagen type I, collagen type III, fibronectin and proteoglycans 16–18. 
Collagen type I and III are major interstitial collagens and their turnover is determined by, 
among other enzymes, matrix metalloproteinases (MMP), which are zinc-dependent enzymes 
and are synthesized in many tissues including the kidney 19–22. During tissue remodeling, small 
protein fragments are released into the circulation, where these may be used as biomarkers. Two 
promising markers are generated by MMP-mediated collagen type I and III degradation (C1M 
and C3M, respectively) which have been shown to reflect renal IF 23–25. 
In this study, our aim was to assess the diagnostic value for fibrosis of different collagen 
degradation products in the urine (uC1M and uC3M) and plasma (pC3M), as compared to 
(immuno)histological markers of fibrosis in a rat model of Adriamycin-induced nephropathy 
(i.e. a model of proteinuria-induced tubulointerstitial fibrosis). S1P receptor modulator FTY720 
(FINGOLIMOD®) has been shown to have an inhibitory effect on fibrosis and on T-cell mediated 
inflammation 26–29. Therefore this intervention was used to distinguish the effects of anti-fibrotic 
treatment on different components of ECM remodeling pathways in the kidneys, as well as on 
collagen fragments in plasma and urine. 
In our well-established rat model proteinuria precedes fibrosis and allows prognostic 
evaluation of fibrotic markers in relation to the deposition and prevention of fibrosis. 
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MATERIALS AND METHODS
Animal experiment and treatments
The detailed experimental setting has been described previously 30. In short, twenty-eight three-
month old male Wistar rats were randomly divided in two groups. In the first group (ADR-rats; 
N=16) proteinuria was induced by injecting Adriamycin in the tail vein (2 mg/kg body weight). 
The rats in the second group received a saline injection in the tail vein and served as healthy 
controls (HC; N=12). Six weeks after the injections, renal biopsies were taken to evaluate renal 
structural damage as described before 31. After three days of recovery, treatment with S1P-
receptor modulator FTY720 (Novartis, Basel, Switzerland, 1 mg/kg body weight per day in 
drinking water) was started in the ADR group (ADR-FTY; N=8) and in the control group (C-FTY; 
N=6). Eight ADR-rats and six control rats remained untreated. 
At 12 weeks, blood pressure was measured under general anesthesia with the Cardiocap/5 
(Datex-Ohmeda, Newark, USA). Animals were then sacrificed and organs were harvested after 
saline perfusion. Renal tissue obtained from the biopsy (6 weeks) and at sacrifice (12 weeks) was 
collected and partly preserved in formaldehyde 10% for paraffin embedment, and also snap-
froze stored at -80°C for cryosectionting and qRT-PCR analyses.
At the beginning of the study, at the time of the biopsy (6 weeks), and at the end of the 
experiment (12 weeks), bodyweight was measured, blood samples were collected and rats were 
placed in metabolic cages for 24 h urine collection and the measurement of food and water 
intake. Proteinuria was determined in urine samples by a turbidimetric assay (Roche Modular P, 
Mannheim,Germany). Urea and creatinine in plasma and urine were measured by an enzymatic 
UV assay (Roche Modular P). 
The experiment was carried out under a protocol, which was approved by the Animal Care 
Committee of the University of Groningen (licencenumber 6318D). 
Immunohistochemistry
Immunohistochemical staining was performed on 4-μm-thick formalin-fixed paraffin sections 
after deparaffinization in xylene and rehydration in alcohol series, or on 4-μm-thick cryo sections 
with acetone fixation. For paraffin sections; antigen retrieval was done for 15 min in a microwave 
oven for Tris/EDTA buffer pH:9.0 and citrate buffer pH:6.0, or overnight at 80°C in Tris/HCl buffer 
pH:8.0. For paraffin and cryo sections; endogenous peroxidase activity was blocked with 0.3% 
or 0.03% hydrogen peroxide, respectively. Endogenous biotin binding sites were blocked by an 
Avidin/Biotin blocking step in case of biotin-labeled first antibodies. Sections were incubated 
for 1 h or overnight at 4°C with the following primary antibodies: mouse anti-human α-smooth 
muscle actin (SMA) (clone 1A4, Sigma-Aldrich, St Louis, USA), goat anti-collagen type III (cat. no. 
1330-01, Southern Biotech, Birmingham, USA), rabbit anti-rat CD3 (clone A0452, Dako, Glostrup, 
Denmark), biotinylated hyaluronan binding protein (HABP, Seikagaku, Tokyo, Japan), mouse anti-
rat CD68 (clone ED1, AbD Serotec, Oxford, UK), and rabbit mAb anti-platelet-derived growth 
factor (PDGF) Receptor β (28E1) (cat. No. 3169, Cell Signaling Technology, Danvers, USA). After 
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this step, the sections were incubated with secondary and tertiary antibodies diluted in PBS/1% 
BSA and 1% normal rat serum. We used rabbit anti-mouse Ig horseradish peroxidase (HRP), 
goat anti-rabbit Ig HRP, goat anti-mouse Ig HRP, rabbit anti-goat Ig HRP, swine anti-rabbit HRP 
and anti-rabbit poly HRP (all from Dako, Glostrup, Denmark). As negative controls, the primary 
antibodies were replaced by PBS/1% BSA. The negative controls were found to be negative. 
Bound antibodies were visualized by aminoethylcarbazole (AEC) or by the peroxidase substrate 
3,3-diaminobenzidine (DAB) (Sigma-Aldrich, St Louis, USA) and then counterstained with diluted 
hematoxylin. Biotinylated HABP was visualized using FITC-conjugated streptavidin (Invitrogen, 
Carlsbad, USA). DAPI (Vector laboratories, Burlingame, USA) was used to stain nuclei. The sections 
were scanned with a NanoZoomer HT digital scanner (Hamamatsu Photonics K.K., Shizuoka 
Pref., Japan). Fluorescence microscopy was performed using a Leica DMLB microscope (Leica 
Microsystems, Rijswijk, the Netherlands) equipped with a Leica DC300F camera and Leica 
Qwin 2.8 software. The quantification was done using Aperio ImageScope software (version 
9.1.772.1570, Aperio Technologies Inc., Vista, CA, USA) and ImageJ 1.46r (Rasband, W.S., U.S. 
National Institutes of Health). ED1-positive macrophages and CD3-positive T cells were manually 
counted in 30 cortical interstitial fields per kidney. The expression of collagen type III, hyaluronan, 
PDGF-β receptor and myofibroblasts (α-SMA) was measured by using an automatic quantification 
method using ImageJ 1.41 (Rasband, W.S., U.S. National Institutes of Health) and expressed as a 
% of positively stained area. 
Renal morphology
Sections (4 μm) of formalin-fixed paraffin embedded kidneys were stained with Periodic Acid 
Schiff (PAS). Renal damage was semi-quantitatively scored on a scale ranging from 1 to 5. The 
scoring indicates which part of total renal cortical tissue was affected by tubulointerstitial fibrosis 
(PAS-positive broadening interstitial area in between the tubules): score 1: <1%; score 2: 1-5%; 
score 3: 6-10%; score 4: 11-20%; score 5: 21-50%. 
Use of published data by our group
The data on collagen III, alpha-SMA and PAS from figure 2 were published before (Yazdani, S., 
Hijmans, R. S., et al. (2015). Targeting tubulointerstitial remodeling in proteinuric nephropathy in 
rats. Dis. Model. Mech. 8, 919–930), however are necessary for comparison with the new stainings 
and quantifications of the other markers of fibrosis, namely fibronectin, PDGF Receptor beta and 
hyaluronan (see Figure 2). Since the same authors are involved in both the previous as well as in 
the writing of this manuscript, permission was granted to use the data. 
Plasma and urinary collagen degradation products 
Supernatant from antibody producing hybridoma was collected and the monoclonal antibody 
was purified using HiTrap affinity columns (GE Healthcare Life Science, Little Chalfront, 
Buckinghamshire, UK) and labeled with HRP using Lightning-LinkTM HRP Conjugation Kit (Innova 
Biosciences, Babraham, Cambridge, UK), according to the manufacturer’s instructions.
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The competitive ELISA procedures have been described in detail before 23,24. In short, procedures 
were as follows: Streptavidin coated plates were incubated with 100 µl biotinylated-peptide for 
30 min at 20 °C. Plates were washed five times in washing buffer (20 nM TRIS, 50 mM NaCl, pH 
7.2). Sample/standard/control (20 µl) was added and followed immediately by addition of 100 µl 
HRP labeled monoclonal antibody and incubated for 1h at 20 °C (pC3M), 3h at 4 °C (uC1M), or 20h 
at 4 °C (uC3M). After incubation, plates were washed five times in washing buffer. A volume of 
100 µl 3,3’,5,5’ -Tetramethylbenzidine (TMB) was added and incubated for 15 min at 20 °C in the 
dark. To stop the enzyme reaction of TMB, 100 µl 0.1% sulphuric acid was added and the plate 
was analyzed in the ELISA reader at 450 nm with 650 nm as the reference (Molecular Devices, 
SpectraMax M, CA, USA). A calibration curve was plotted using a 4-parametric mathematical 
fit model. Each ELISA plate included kit controls to monitor inter-assay variation. All samples 
were measured within the range of the specific assay. All samples below the lower limit of 
quantification (LLOQ) were assigned the value of LLOQ. The urinary markers were normalized 
for urinary creatinine.
Statistical analyses
Statistical analysis was performed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA) or Statsdirect 3.0 
(Cheshire, UK), and GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA) was used to 
construct graphs and figures. Statistical differences between all groups at the same time-point 
were tested using the non-parametric unpaired Kruskall-Wallis test (with Dwass-Steel-Critchlow-
Fligner post-test) and differences over time by using the non-parametric paired Friedmann 
test (with Iman and Davenport post-test). Correlations were tested using the non-parametric 
Spearmann Rank test on the Z-scores of the variables used. Correlations between collagen 
degradation markers at 12 weeks and histological markers at 6 weeks were tested using data 
of untreated ADR-rats only (N=8). For correlations at between variables at the same time-point 
(12 weeks), we paired the FTY720-treated ADR-rats and the untreated ADR-rats (N=16). Statistical 
differences of p<0. 05 were considered significant. 
RESULTS
Adriamycin induced proteinuria and tubulointerstitial remodeling
The effects of ADR on proteinuria and tubulointerstitial remodeling have been described in 
detail before 30. In short a summary of the relevant results for our study: six weeks after ADR 
injection proteinuria was increased 8-fold up to 146 [77-230] mg/24h (p<0.001) compared to 
controls (18 [13-27] mg/24h). At this early time-point, tubulointerstitial myofibroblasts started to 
appear, however, no interstitial collagen type III deposition was observed yet. Twelve weeks after 
ADR injection, proteinuria further increased up to 338 [176-535] mg/24h, which was associated 
with an increase in tubulointerstitial fibrosis (PAS), increased collagen type III deposition, and 
accumulation of myofibroblasts, macrophages (MΦ) and T-cells (all p<0.05). Treatment of ADR-
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Figure 1. Effects of Adriamycin with or without FTY720 treatment on collagen degradation 
markers. Effects of Adriamycin are shown without (left panels) and with FTY720 treatment 
(right panels) on pC3M (A, B), uC3M (C, D), and uC1M (E, F). uC3M and uC1M concentrations 
were expressed per mg urinary creatinine. Open boxes represent controls, dark grey boxes ADR-
rats. *P<0.05, **P<0.01, ***P<0.001. Statistical differences between all groups at the same time-
point were tested using the Kruskall-Wallis test (Dwass-Steel-Critchlow-Fligner post-test) and 
differences over time by using the Friedmann test (Iman and Davenport post-test).
chapter 6
530678-L-bw-Hijmans
Processed on: 17-4-2019 PDF page: 137
137
rats from week six to week twelve with FTY720 neither reduced proteinuria nor reduced renal 
collagen type III expression (both at protein and mRNA level). However, renal accumulation of 
myofibroblasts and T-cells were significantly lower after FTY720 treatment (both p<0.05) and 
apparently MΦ (NS). FTY720 also significantly reduced tubulointerstitial fibrosis score (PAS; 
p<0.05).
Longitudinal  analysis of plasma and urinary collagen degradation fragments.
To assess the diagnostic and predictive value of non-invasive collagen degradation fragments, 
we time-dependently analysed the markers of ECM remodeling in healthy control rats and ADR-
injected rats, both untreated and treated with S1P-receptor modulator FTY720. 
The timecourse of untreated ADR-rats (Fig. 1. Left panels), showed a transient increase of 
pC3M six weeks after ADR injection (baseline vs week 6: p<0.01), that returned to baseline values 
at twelve weeks (Fig. 1A; week 12 vs week 6: p<0.001). uC3M values showed an ongoing increase 
at week six and twelve in ADR-rats compared to control values (Fig. 1C; both p<0.001). uC1M levels 
were significantly higher both at week six (p<0.001) and twelve (p<0.01) in ADR-rats compared to 
their healthy controls at the same time-points (Fig. 1E). These data showed increased excretion 
of uC1M and uC3M upon progression of proteinuria-induced tubulointerstitial fibrosis.
Treatment of healthy controls with FTY720 (Fig. 1. Right panels) showed a decreasing trend in 
pC3M over time, while FTY720-treated ADR-rats showed a significant decrease at twelve weeks 
compared to baseline (p<0.01) and six weeks (Fig. 1B; p<0.001). uC3M levels in the FTY720-
treated ADR-rats (Fig. 1D) increased significantly over time at both six weeks (p<0.01) and twelve 
weeks (p<0.001) compared to baseline values. uC1M levels in healthy controls treated with 
FTY720 showed a significant decrease over time at six (p<0.05) and twelve weeks (p<0.001). At 
twelve weeks, FTY720-treated ADR-rats showed significantly higher uC1M values compared to 
their controls at twelve weeks (Fig. 1F; p<0.05). Importantly, FTY720 treatment did not reduce 
excretion of both uC3M and uC1M in ADR-rats.
To dissect different fibrotic pathways, we also looked at specific fibrotic markers in the renal 
tissue and if these markers are affected by treatment with FTY720. At six weeks, we did not 
see any significant changes for collagen type III expression, α-SMA positive myofibroblasts and 
tubulointerstitial fibrosis (PAS) in the renal tissue, which has been published before by our group 
and is needed to interpret our most recent findings 30.
At twelve weeks, ADR-rats showed an increase in collagen type III expression (Fig. 2 first row; 
p<0.05), α-SMA positive myofibroblasts (Fig. 2 third row; p<0.05) and tubulointerstitial fibrosis 
by PAS staining (Fig. 2 fifth row; p<0.05) compared to controls, while treatment with FTY720 
showed a (non-significant) decrease of the expression of α-SMA positive myofibroblasts and 
tubulointerstitial fibrosis (PAS score), which can no longer be differentiated from FTY720-treated 
control rats. The expression of fibronectin showed the same trend as collagen type III expression 
increased significantly in ADR-treated rats compared to controls (Fig. 2 second row; p<0,01). 
Treatment with FTY720 did not have an effect on the expression of fibronectin. 
In order to investigate α-SMA positive myofibroblasts as a possible pro-fibrotic marker, we 
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Figure 2. Effects of FTY720 treatment on tubule-interstitial remodeling at week 12. 
Expression of interstitial collagen type III (400x), fibronectin (200x), α-SMA positive myofibroblasts 
(200x), PDGF-β receptor (200x), interstitial fibrosis (PAS; 200x) and hyaluronan (400x) at week 12. 
Data of collagen type III, α-SMA and PAS have been published before 30). Permission to show data 
was granted by the authors and publishers.  *P<0.05, **P<0.01, ***P<0.001. Statistical differences 
between groups were tested using the Kruskall-Wallis test (Dwass-Steel-Critchlow-Fligner post-test).
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compared these findings to the expression of the PDGF-β receptor as an alternative phenotypic 
fibroblast marker. The expression of PDGF-β receptor was increased in ADR-rats compared to 
controls (Fig. 2 fourth row; p<0,01), whereas α-SMA positive myofibroblasts influx decreased 
under treatment with FTY720, there was no significant difference in PDGF-β receptor expression 
between untreated ADR-rats and FTY720-treated ADR-rats. 
To investigate if the apparent reduction in tubulointerstitial fibrosis (PAS) between 
untreated and FTY720-treated ADR-rats might be an effect of FTY720 on the accumulation of 
glycosaminoglycans instead of reflecting the collagen metabolism, a staining for hyaluronan 
was done. This staining showed the same non-significant decrease in the FTY720-treated ADR 
group as was shown by the PAS (Fig. 2 sixth row), corroborating that positive PAS staining 
represents glycosaminoglycans rather than collagens. Based on the quantification of various 
(immuno)histochemical markers we conclude that the FTY720 intervention tended to reduce 
accumulation of a-SMA positive myofibroblasts, hyaluronan and the fibrosis score based on 
PAS-staining. However, FTY720 treatment did not reduce the (myo)fibroblast marker PDGF-β 
receptor, interstitial collagen type III and fibronectin . 
uC3M forebodes the development of renal fibrosis
uC3M and uC1M at week 6 did not show any correlation with histological markers at the 
same time-point in all ADR-rats (not shown). However, uC3M at six weeks was associated with 
hyaluronan at 12 weeks and borderline with the PAS fibrosis score at 12 weeks in the untreated 
ADR-rats, but not with the other renal fibrosis markers (Table 1A). In addition, uC1M at six weeks 
associated borderline significance with the PAS-score at 12 weeks in untreated ADR-rats. 
At 12 weeks, after pooling of both the ADR-untreated as well as in FTY720-treated ADR-rats 
(N=16), uC3M was strongly associated with renal collagen type III, myofibroblast density, PDGF-b 
receptor, tubulointerstial fibrosis (PAS) and hyaluronan. uC1M showed the same associations, 
except for collagen type III (Table 1B). These associations indicate that uC3M and uC1M represent 
and predict early development of renal fibrosis, at least in this experimental model of proteinuria-
driven renal fibrosis . 
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Table 1. Predictive value of uC3M and uC1M at 6 (A) weeks and correlation at 12 weeks (B) with 
histological fibrotic markers at week 12 in untreated ADR-rats and FTY720-treated ADR-rats.
A. uC3M/Cr 6 weeks
uC1M/Cr
6 weeks
rs P-value rs P-value
ADR untreated rats
Histological markers – 12 weeks
Collagen type III 0.381 0.352 0.262 0.531
Fibronectin 0.238 0.570 0.190 0.651
Myofibroblasts(α-SMA) 0.333 0.420 0.310 0.456
PDGF-b receptor 0.524 0.183 0.405 0.320
Tubulointerstitial fibrosis (PAS) 0.687 0.060 0.674 0.067
Hyaluronan 0.810 0.015 0.571 0.139
B. uC3M/Cr 12 weeks
uC1M/Cr 
12 weeks
rs P-value rs P-value
ADR-rats (pooled)
Histological markers – 12 weeks
Collagen type III 0.529 0.035 0.403 0.122
Fibronectin 0.074 0.787 0.194 0.471
Myofibroblasts(α-SMA) 0.600 0.014 0.497 0.050
PDGF-b receptor 0.841 <0.0001 0.656 0.006
Tubulointerstitial fibrosis (PAS) 0.831 0.000 0.694 0.003
Hyaluronan 0.807 0.000 0.654 0.006
Significant differences are highlighted in bold. Spearmann rank correlation was done on Z-values of all variables. 
DISCUSSION
The novel finding in this study is that uC3M is measurable prior to being histologically detectable, 
making it an early non-invasive predicting marker for renal fibrosis. Furthermore, collagen type 
I and III degradation (C1M and C3M) are late urinary markers reflecting the extent of established 
renal fibrosis. Dissection of different fibrotic pathways using S1P-modulator FTY720 showed that 
uC3M was more specific in reflecting renal fibrosis, in terms of collagen deposition, compared to 
the more commonly used PAS or α-SMA staining. 
Proteinuria developed six weeks after Adriamycin injection in rats but collagen type III 
deposition was not observed at this time-point 30. uC3M and uC1M were significantly elevated 
compared to the controls at six weeks. The uC3M results were profoundly elevated and therefore 
we measured plasma C3M as well and found a significant transient peak at six weeks compared 
to baseline and twelve-week values. These data suggest that at 6 weeks, tissue remodeling had 
started and although no collagen deposition could be demonstrated at this early time-point, 
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both urinary and plasma values of C1M and C3M were increased. This suggests active tissue 
remodeling, which most likely reflects a pre-fibrotic event. From week 6 to week 12, interstitial 
fibrosis developed, uC1M remained elevated and uC3M increased even further. The reduction 
in the levels of uC3M and uC1M in the control untreated animals could be due to an age effect 
which has been described previously by Karsdal et al 32. Anti-fibrotic treatment with S1P modulator 
FTY720 (FINGOLIMOD®) yielded mixed results for the various fibrotic markers quantified in the 
kidneys. It appears that the kinetic response of the various fibrotic pathways varies with anti-
fibrotic therapy. uC3M appears to be an early and sensitive marker of renal tissue remodeling.
In order to dissect different fibrotic pathways, we looked at the effect of anti-fibrotic treatment 
with FTY720 on different histological markers, which are frequently used (both in the clinic or 
for research purposes) to address renal fibrosis 7. Previously published results on collagen type III 
expression, a-SMA positive myofibroblasts and tubulointerstitial expression (PAS), showed that 
treatment with FTY720 had different effects on these markers, even though all are known to 
reflect renal fibrosis 30. The role of the extracellular matrix as a mere scaffold to uphold tissue 
integrity is being questioned, and it is becoming increasingly clear that it may be considered as 
a complex paracrine/endocrine entity 33. Previous studies showed that structural proteins, such 
as collagens, do not only have organizational properties, but might also have other effects. For 
example, collagen type I, collagen type III and fibronectin are involved in signaling pathways 
during fibrosis and inflammation by activating hepatic stellate cells (reviewed in 33). The dissection 
of the different components of ECM remodeling by anti-fibrotic and anti-inflammatory FTY720-
treatment allows us to have a more specific look at the roles of the most important involved 
structural proteins.
To investigate these different outcomes and in order to define what kind of fibrotic pathway 
is reflected by increased uC3M, we furthermore performed staining for fibronectin (as a ECM 
marker which is able to bind to collagen), for the PDGF-b receptor (as an alternative fibroblast 
marker) and for hyaluronan (as a matrix glycosaminoglycan, GAG) 34–36. Interestingly, fibronectin 
showed the same pattern as collagen type III. Findings were confirmed by previously published 
qPCR results, where treatment with FTY720 did not have a significant effect on collagen type 
I, collagen type III or TGF-β mRNA expression 30. The expression of the PDGF-β receptor was 
unchanged after FTY720 treatment and clearly deviates from a-SMA positive myofibroblasts. 
There are different subpopulations of myofibroblasts and the finding that FTY720 lowered a-SMA 
positive myofibroblasts and did not have an effect on PDGF-β receptor-expressing fibroblasts 
suggests that there might be a shift in the population of fibroblasts or that the myofibroblasts 
lose a-SMA expression upon FTY720 treatment. PAS staining also showed a contrasting pattern 
compared to collagen type III expression after FTY720 treatment. PAS is used as a fibrotic marker, 
and specifically stains acid groups 37. Therefore, we investigated if the decrease of PAS could be 
explained by a decreased glycosaminoglycan expression which are ECM compounds containing 
acid carboxyl groups. Staining was done for hyaluronan, which showed the same decrease after 
FTY720 treatment as PAS, confirming our hypothesis that the decrease of PAS staining after 
FTY720 treatment reflects a direct effect of FTY720 on the level of proteoglycans/GAGs.
urinary collagen degradation markers for renal fibrosis
6
530678-L-bw-Hijmans
Processed on: 17-4-2019 PDF page: 142
142
The data suggest that treatment with FTY720 influences the differentiation of myofibroblasts 
by loss of α-SMA expression, without affecting the expression of the PDGF-β receptor. This 
showed no effect on the collagen and fibronectin metabolism. It however does influence GAGs 
as hyaluronan expression decreases and this consequently reduces the PAS fibrosis-score.
We were interested in the diagnostic and predictive value of uC3M and uC1M. At six weeks 
uC3M in the untreated ADR-rats showed a positive correlation with hyaluronan at six and at 
twelve weeks. At six weeks uC1M and uC3M were borderline significantly correlated with the PAS 
fibrosis score at 12 weeks. At twelve weeks uC1M and uC3M were associated with most of the 
fibrotic kidney markers at 12 weeks. These data indicated that early uC3M, and to a lesser extent 
uC1M, precede and reflect renal fibrosis.
The strength of this study is the well-established time course in which we were able to 
follow changes in both histological renal remodeling responses, as well as in urinary/plasma 
degradation products at different time-points. This allowed us to show that uC3M is elevated 
at an earlier time-point compared to histological collagen type III expression 6,25. Another 
strength is the dissection of the different fibrotic pathways by using FTY720 treatment, showing 
a deviation in collagen and hyaluronan tissue responses. We were thus able to show that uC3M 
reflects the level and predicts future deposition of type III collagen. Our data showed that uC3M 
is an early fibrotic marker for collagen type III deposition, but not representative for other ECM 
components. 
During physiological conditions remodeling of the ECM is very low but increases during 
injury. Increased degradation is promoted by a rise in protease activity such as by MMPs 38. 
Protease-generated fragments of a protein have been suggested to be more specific for 
pathological ECM turnover during fibrosis than total protein content since it is dependent on 
the local protease activity 39. The C1M and C3M assays are highly specific which allows us to 
assess collagen degradation by MMPs, a process believed to be associated with the pathological 
turnover of the ECM during fibrosis 40. To our knowledge, no comparable assay is currently 
available or published. Commercial assays for measurements of collagens in serum or urine are 
not directed against specific epitopes, but rather utilize polyclonal antibodies. 
Possible limitations of this study are the previously used data, the pre-dominant interest in 
C3M in comparison to C1M, and the disease model. We have limited the re-use of our previously 
published data to the IHC data on collagen type III, PAS and α-SMA. However, we need this data 
to understand the new findings better. In our previous study 30 we first found these contrasting 
findings on collagen type III metabolism and the effects of anti-fibrotic FTY720 treatment on 
PAS and myofibroblasts. In this study, where we investigated if urinary collagen degradation 
fragments could be a good alternative for these invasive histological diagnostic markers for renal 
fibrosis, we found this very interesting novel finding that these urinary collagen degradation 
markers can be shown in the urine prior to any visible histological changes. While the need for 
good diagnostic, prognostic and next to this clinical applicable biomarkers is growing, we tried to 
investigate the different fibrotic pathyways to further detail in order to get a better understanding 
of the specifity of the collagen degradation markers and the prognostic properties. 
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We found the most profound differences in the urinary C3M levels and the urinary C1M levels 
showed the same trends as urinary C3M. We choose to add the C1M data on urine to underline 
that the possibility of collagen degradation markers in the urine during renal fibrosis is not 
limited to collagen type III degradation fragments, but can also be found for collagen type I 
degradation fragments. At least in this study. 
Next to this, we realize that the Adriamycin nephropathy model is driven by proteinuria. 
We therefore can not be absolutely certain whether the increased levels of uC1M and uC3M 
are due to increased glomerular filtration or if it is an effect of an increased turnover of renal 
type I and III collagen. However, in a previously published study collagen degradation fragments 
C1M and C3M were measured in three different rat models for nephropathy, namely renal mass 
reduction (5/6 nephrectomy), progressive glomerulonephritis (chronic anti-Thy1.1 nephritis) and 
adenine crystal-induced nephropathy. All three treatments caused significant renal fibrosis on a 
histological level and showed a significant increase of both uC3M and uC1M. Interestingly, while 
the adenine model caused the most profound increasing effect on the levels of uC3M and uC1M 
compared to the other models, it was not accompanied by proteinuria 25. This underlines our 
hypothesis that the urinary collagen degradation fragments primarely reflect renal fibrogenesis 
and makes it unlikely that the increase in uC3M is mainly attributable to the proteinuria. 
CONCLUSIONS
In conclusion we described the greater diagnostic and predictive value of urinary collagen 
degradation markers C3M and C1M compared to the more conservative histological markers in 
a rat model of Adriamycin-induced nephropathy. We investigated the specificity of uC3M as a 
marker for renal fibrosis, by dissecting the collagen fibrotic pathway from other fibrotic pathways 
using anti-fibrotic S1P-receptor modulator FTY720. Although further research is needed to 
investigate the predictive value of the urinary collagen degradation markers, we propose that 
the diagnostic and predictive use of urinary collagen degradation markers to assess renal fibrosis 
can be used in early stages during disease progression of different etiologies. It might be used 
as a better, safer and more patient-friendly alternative than the renal biopsy, which is an invasive 
way of assessing histological markers of fibrosis. 
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SUMMARY, GENERAL DISCUSSION AND FUTURE PERSPECTIVES
Tissue remodeling as a signature of renal damage provides the opportunity to detect, monitor 
and prevent disease progression. In this thesis, we focused on tissue remodeling and its 
triggers such as blood pressure, sodium intake and proteinuria (Chapter 2 and 3), dissecting 
components of tissue remodeling such as fibrosis, inflammation and lymphangiogenesis and 
investigating their interplay (Chapter 4), and finally we investigated ways to clinically monitor 
tissue remodeling in order to prevent disease progression (Chapter 5 and 6). 
Triggers of tissue remodeling 
In Chapter 2, we reviewed the effects of a high sodium diet as a trigger for tissue remodeling 
in normotensive rats. To this end normotensive healthy male rats were fed with a high sodium 
diet and compared to sex- and age-matched rats on control diet, followed by evaluation of renal 
heparan sulfate (HS) proteoglycans, sodium content and renal tissue remodeling. 
In previous studies, we have shown that critical pro-inflammatory modifications of renal HS 
proteoglycans result in tissue remodelling responses (inflammation and fibrosis) after ischemia/
reperfusion, renal transplantation and proteinuria 1–3. Furthermore, scarce information suggests 
that the amount and type of cations bound to glycosaminoglycans modulate its 3D-structure 
and biological properties 4–6. We assume that HS changes also might occur upon high dietary 
sodium intake. We therefore hypothesized that high dietary sodium intake convert renal HS into a 
pro-inflammatory phenotype, able to bind more sodium and orchestrate influx of inflammatory 
cells, fibrosis and lymphangiogenesis. 
For the first time, we have shown that a high sodium diet increases sulfation of renal HS 
in salt-insensitive, normotensive healthy rats, and is associated with renal tissue remodelling 
events. Interestingly, these tubulo-interstitial changes are not associated with increased sodium 
content of the kidneys. 
There was a transient peak in blood pressure in the first week, which might possibly have 
induced the tissue remodeling responses. This might suggest that high sodium diet-induced 
changes in renal HS structure and tubulo-interstitial remodeling which can be transient in 
normotensive rats, as we showed that the rats could compensate for a rise in blood pressure by 
increasing their sodium excretion and their non-osmotic dermal sodium storage. Importantly 
however, this also suggests that if this process is disturbed in salt-sensitive rats or patients, 
high dietary salt intake could lead to progressive renal damage from 2 to 4 weeks onwards. 
This finding can have important clinical consequences for salt-sensitive patients, underlining the 
importance of sodium restriction in specifically this category of patients. 
To evaluate a direct sodium effect on renal HS and tissue remodeling, we conducted an in 
vitro study on precision-cut mouse kidney slices and titrated different sodium concentrations 
into the medium 7. We did not see any changes in damage markers, which suggests that the 
sodium effect on these markers as observed in vivo thus might be influenced by intermediate 
physiological processes. We speculate that high working load of proximal tubular epithelial cells, 
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increased RAAS and/or sympathetic activity, increased release of vasoactive mediators such as 
endothelin and vasopressin, or cytokine release by inflammatory cells might play a role, however 
this has not been studied in detail yet. 
Therefore, in Chapter 2, we deliver a first detailed description of a mechanistic pathway, in 
which a high sodium intake by healthy normotensive rats converts renal HS into high sulfated 
pro-inflammatory glycans and therefore triggers tissue remodeling. HS is not involved in sodium 
binding, however the modifications to HS caused by the high sodium diet are associated with 
tubulo-interstitial remodeling in the kidney. We also provide further evidence to the emerging 
view that blood pressure independent mechanisms also play an important role in aggravation 
of renal diseases by high dietary sodium intake. 
In Chapter 3, we tried to translate our previous findings to the clinic. We investigated tissue 
remodeling, glycosaminoglycans and dermal sodium storage in healthy human subjects and 
kidney patients, while trying to unravel their interactions. In this chapter, we showed that dermal 
non-osmotic sodium storage is not increased in patients with chronic kidney disease, but that 
kidney disease plays a part in the interplay between dermal sodium storage, sodium homeostasis 
and dermal tissue remodeling. Our data indicate that sodium homeostasis reflected by plasma 
sodium and increased sodium intake reflected by increased sodium excretion, associates with 
dermal lymph vessel formation and loss of dermal sodium storage capacity, whereas kidney 
failure associates with dermal inflammation. We also show that dialysis further influences dermal 
tissue remodeling. 
We used unique material of chronic kidney disease patients; both hemodialysis patients and 
preemptive patients before transplantation and their age-matched healthy donors. It is the first 
study investigating differences in dermal sodium concentration, sodium homeostasis and tissue 
remodeling in these groups of ESRD patients. 
In the last decade, the classic paradigm of sodium handling has been questioned and widely 
investigated 8–10. These studies have shown that extra-renal non-osmotic sodium storage in 
skin, cartilage and bone plays an important role in maintaining a balanced plasma sodium level. 
In this study we used atomic absorption spectroscopy as an objective technique to quantify 
dermal sodium storage in human skin. While both the nitrogen and the sodium measurements 
are sensitive and robust, the margin of errors is increasing when using smaller size skin biopsies 
since both sodium and nitrogen are calculated per mg dry weight.  
In conclusion, our data, albeit based on a small number of patients, suggest that there is an 
interplay among dermal sodium storage, sodium homeostasis (reflected by plasma sodium) and 
sodium intake (reflected by sodium excretion), dermal tissue remodeling and kidney function, 
although the causal relationships and GAG involvement is not clear from our work. The exact 
mechanisms behind these phenomena warrant further research, and underscore the remote 
dermal effects observed in kidney patients. 
In conclusion, part A of this thesis describes the triggers of tissue remodeling such 
as proteinuria, high sodium intake, blood pressure and disease progression itself. While 
summary, general discussion and future perspectives
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inflammation, fibrosis and lymphangiogenesis seem to be independent components under 
proteinuric conditions (see below), a high sodium diet can induce all these components by using 
glycosaminoglycans as pro-inflammotory mediators, at least in rats. Finally, sodium handling 
by the body is investigated in renal patients by assessment of dermal sodium storage. Dermal 
sodium storage appeared not to be affected, despite signs of inflammation and lymph vessel 
formation. However, in both rats and humans, we showed that there is a complex interplay 
between dermal sodium storage, sodium intake, plasma sodium, tissue remodeling and kidney 
function. 
Dissecting tissue remodeling in kidney disease
Many renal diseases are accompanied by proteinuria, which is defined as the presence of proteins, 
usually albumin, in the urine. In healthy persons, the glomerular capillary wall forms a barrier 
against larger molecules (such as albumin), where a small amount of protein passes through the 
capillary wall into the glomerular filtrate and will be reabsorbed and degraded by the proximal 
tubules. A small amount is excreted in the urine (upper limit of normal protein excretion is 150 
mg/day and for albumin it is 30 mg/day). 
Sustained proteinuria can be a trigger of a progressive decline in kidney function, worsening 
to chronic kidney disease (CKD) and end-stage renal disease (ESRD), and eventually the need for 
dialysis or renal transplantation 11–14. Even under rather low proteinuria values kidneys deteriorate 
over time. Proteins in the glomerular filtrate activate tubular cells to secrete many chemokines 
and mediators that can elicit proinflammatory and profibrotic cascades 15–18, which might lead to 
renal inflammation and fibrosis 19. 
Therefore, in Chapter 4, we targeted not the proteinuria itself, but the detrimental tissue 
remodeling downstream of proteinuria. In our adriamycin-induced proteinuria model, we 
targeted tubulointerstitial lymphangiogenesis (VEGFR3 blockade), monocyte/macrophage 
influx (depletion by clodronate liposomes), and pre-fibrotic myofibroblast accumulation and 
interstitial fibrosis (by S1P agonist FTY720). First, by blocking VEGFR3, we perfectly blocked 
lymphangiogenesis in both the proteinuric rats, as in the healthy controls. Although this finding 
might open therapeutic possibilities for patients with cancer, it did not affect inflammation or 
fibrosis in our proteinuria model20. 
Next, multiple studies (including from our group) have shown that macrophages are 
actively involved in inducing lymphangiogenesis in kidney diseases, however showing 
conflicting results21–24. In this chapter, we showed that depleting macrophages could reduce 
neither interstitial fibrosis, nor lymphangiogenesis. Hence, the role of macrophages in inducing 
lymphangiogenesis seems to be very much context-dependent. Indeed, in our model we found 
proximal tubular cells to be the major source of VEGF-C, which might explain why depletion of 
macrophages did not reduce tubulo-interstitial lymphangiogenesis.
Finally, FTY720 treatment effectively reduced the number of lymphocytes in the blood 
circulation, and T cells in proteinuric kidneys, but did not show to have any impact on renal 
lymphangiogenesis or macrophage influx. Interestingly, while FTY720 significantly prevented 
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the increase of α-SMA positive myofibroblasts, it was not effective in decreasing collagen III 
deposition, however significantly reduced tubulointerstitial fibrosis (PAS scoring), suggesting 
that α-SMA does not seem to be an ideal marker for collagen-secreting cells in interstitial injuries, 
as many (myo)fibroblasts which do not express α-SMA, have the ability of collagen deposition 
25–27. The reduction in PAS positivity in the FTY720 treated animals might be related to a reduced 
proteoglycan/glycosaminoglycan production by the (myo-)fibroblast, which might be differently 
regulated form collagen synthesis.
While effective targeting of all the tissue remodeling phenomena was proven histologically, 
targeting one of these phenomena did not affect the others. Therefore, Part B and Chapter 
4 show independency of inflammatory (macrophages, T cells) or fibrotic (myofibroblasts, 
collagen III and interstitial fibrosis) responses from renal lymphangiogenesis, at least in this 
proteinuric-nephropathy model. The reason might be that in this model tubular epithelial cells 
which continuously encounter the ultrafiltered plasma proteins and are being activated, are the 
main source of many chemokines and mediators which induce the various tubulointerstitial 
remodeling programs such as lymphangiogenesis, inflammation and fibrosis 18 (Figure 1 ). 
Figure 1. In healthy 
persons, glomerular 
capillary wall is able to 
form a barrier against 
larger molecules (such as 
albumin), where a small 
amount of protein passes 
through the capillary 
basement membranes 
into the glomerular filtrate 
and will be degraded and 
reabsorbed by the proximal 
tubules (upper figure). In 
kidney patients, the leakage 
of proteins through the 
glomerular capillary wall is 
increased and the epithelial 
cells in the proximal tubule 
are activated, resulting 
in lymphangiogenesis, 
fibrosis and inflammation 
(lower figure). 
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Clinical monitoring of tissue remodeling
In Chapter 5, an overview of all available biomarkers for acute kidney injury (AKI and chronic 
kidney disease (CKD) is provided. Over the last years, a lot of research has been done on finding 
the best biomarker to detect kidney disease. However, while a lot of biomarkers were marked 
as ‘promising’, remarkably little attention has been paid to their ‘actionability’28,29, thus can 
assessment of the biomarker guide treatment? We defined actionability as ‘the extent to which 
a biomarker can be acted upon to improve clinical management’. We performed a PRISMA 
analysis and concluded that despite the large amount of literature on biomarkers, the question 
of how patients whose risk is stratified by a biomarker level should be treated remains mostly 
unanswered, albuminuria being the sole exception. Therefore, the actionability of the biomarkers 
is unknown. The most promising biomarkers were TIMP-2 x IGFBP7 in AKI and CKD273 in CKD30,31, 
which all are related to tissue remodeling programs. Furthermore, in CKD, we propose a different 
perspective on functional biomarkers by broadening this group with metabolic biomarkers, 
such as markers of bone mineral disorders, uric acid, urinary sodium excretion, and vitamin K 
status, because these biomarkers are highly actionable and in contrast to damage biomarkers, 
therapeutic interventions are already available in most cases.
In Chapter 6, we investigated another class of biomarkers, namely urinary collagen degradation 
fragments. We found that urinary degradation fragments of collagen 3 (uC3M), are measurable 
even prior to being histologically detectable, making it an early non-invasive predicting marker 
for renal fibrosis. Dissection of different fibrotic pathways using S1P-modulator FTY720 showed 
that uC3M was more specific in reflecting renal fibrosis, in terms of collagen deposition, compared 
to the more commonly used PAS or α-SMA staining in renal specimens. 
When we compare our results to what was found in humans, we found that uC3M decreases 
in humans with increasing disease severity, while it increases in rats 32. The process of fibrosis 
exists of both fibrogenesis and collagen degradation. In the early disease stages (as been shown 
in our animal model), fibrogenesis and collagen degradation balance each other out and only 
when the disease progresses, fibrogenesis become more apparent compared to degradation 
and fibrotic lesions start to appear 33. The fact that during disease progression the balance 
tips towards fibrogenesis can be explained by the fact that collagens are known to crosslink 
34–36 and can become inaccessible for cleavage of collagens by MMPs 37–39. Next, Di Donato et 
al. investigated the renal expression of lysyl oxidase and its effects on collagen cross-linking 
at various stages of chronic Adriamycin nephropathy in rats 40. They showed that mRNA levels 
of lysyl oxidase increase up to 3 times in the ADR-rats compared to controls between 8 and 
12 weeks, and the levels reduced to normal levels at 16 weeks. They demonstrated that an 
increased expression of lysyl oxidase in the kidney precedes the development of diffuse fibrotic 
lesions and that, at this stage, collagenic structures contain highly cross-linked components, 
the final product of lysyl oxidase activity. In our study, we only measured levels of collagen 
degradation markers between 6 and 12 weeks after injection with Adriamycin, the period when 
lysyl oxidase levels are increasing, but collagen crosslinking has just begun and is not at his final 
stage. Lysyl oxidase has also been shown to be involved in fibrosis in humans 41,42. In patients 
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with CKD the disease is present for longer than 6 to 12 weeks and collagen crosslinking is already 
occurring in abundance, making it hard for MMPs to degrade the collagens. This is reflected by 
the decreasing urinary C3M levels during disease progression 32. In this study we were looking 
for a possible early marker for renal fibrosis, which could be the collagen degradation fragments 
in the urine, since they can already be found before the balance between renal fibrogenesis and 
collagen degradation is lost.
In summary, in Part C, we focus on clinically monitoring tissue remodeling in order to prevent 
progression of the renal disease. Most biomarker studies lack information on their actionability 
and are therefore not frequently used in the clinic. Next, collagen degradation products seem to 
be a promising early marker for renal fibrosis, and are possibly very actionable. Further research 
is warranted. 
Future perspectives
This thesis has shown that tissue remodeling can be used in order to detect and monitor renal 
damage and renal function decline. Therefore, clinical guidelines should add markers of tissue 
remodeling as the signature of renal damage besides measures of renal function. While we 
made an effort to understand triggers of tissue remodeling, it’s different components/pathways 
and their interplay, and finally how tissue remodeling can be used to clinically monitor renal 
damage, new challenges for the researcher, clinician and patient warrant further research as will 
be outlined below.  
Over the last decade, there can be seen an interesting shift in the way we think about 
sodium homeostasis. For many years sodium homeostasis was explained in terms of transport 
and osmosis related to osmotic active sodium. Multiple studies have shown now that sodium 
can be stored in cartilage, bone and even skin, thereby becoming osmotically inactive. Our 
findings underline these findings, however, the exact mechanisms remain unknown and form a 
very interesting field of investigation for the next years.  For patients and their medical doctors, 
it still remains unclear, why anti-proteinuric medication has beneficial effects in some patients, 
while lacking therapeutic advantages in others. While sodium restriction has long since been 
one of the cornerstone dietary measures in guidelines on preventing worsening of the kidney 
disease, its benefit has traditionally been limited to blood pressure control. Its role may become 
even more prominent when the exact mechanisms will become clear in which a high intake of 
sodium induces kidney damage, independent of blood pressure.  Therefore, intervention studies 
in both animal studies as in humans is needed to thoroughly investigate what is the possible 
missing link in understanding the exact mechanisms behind non-osmotic sodium storage and 
its damaging effects on both kidney and other organs. 
Dietary interventions are not only important in understanding the disease; they also play a 
key role in detecting renal damage. Next to the commonly used functional biomarkers, markers 
such as urinary sodium excretion, vitamin K status, bone minerals, and uric acid are highly 
actionable and can be treated easily when found. The future diagnosis and treatment of renal 
patients will focus not only on classifying type and severity of kidney disease, but also on their 
dietary habits, as a modifiable target for intervention. 
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NEDERLANDSE SAMENVATTING, ALGEMENE DISCUSSIE EN 
TOEKOMSTPERSPECTIEVEN
Remodellering van weefsel als kenmerk van nierbeschadiging biedt de mogelijkheid om 
ziekteprogressie te detecteren, te bewaken en te voorkomen. In dit proefschrift hebben we ons 
gericht op het remodelleren van weefsel en de triggers hiervan, zoals bloeddruk, natriuminname 
en proteïnurie (hoofdstuk 2 en 3), waarbij componenten van weefselremodellering zoals fibrose, 
ontsteking en lymfangiogenese werden ontleed en hun wisselwerking werd onderzocht 
(hoofdstuk 4). Uiteindelijk hebben we manieren onderzocht om weefselremodellering klinisch 
te monitoren om zo ziekteprogressie te voorkomen (hoofdstuk 5 en 6).
Triggers van weefselremodellering. 
In hoofdstuk 2 hebben we de effecten van een hoog natriumdieet als trigger voor het 
remodelleren van weefsels bij normotensieve ratten onderzocht. Hiertoe werden normotensieve 
gezonde mannelijke ratten gevoed met een hoog natriumdieet en vergeleken met geslachts- 
en leeftijdsgematchte ratten op controledieet, gevolgd door evaluatie van renale heparansulfaat 
(HS) proteoglycanen, natriumgehalte en remodellering van het nierweefsel. In eerdere studies 
hebben we aangetoond dat kritische pro-inflammatoire veranderingen van renale HS-
proteoglycanen resulteren in remodellerende reacties van het weefsel (ontsteking en fibrose) 
na ischemie / reperfusie, niertransplantatie en proteïnurie 1–3. Bovendien suggereren schaarse 
bronnen dat de hoeveelheid en het type aan glycosaminoglycanen gebonden kationen de 
3D-structuur en biologische eigenschappen moduleren 4–6. We nemen aan dat HS-veranderingen 
ook kunnen optreden bij een hoge inname van natrium in de voeding. We stelden daarom 
de hypothese dat een hoge natriuminname door de voeding renale-HS omzet in een pro-
inflammatoir fenotype, in staat om meer natrium te binden en de instroom van ontstekingscellen, 
fibrose en lymfangiogenese te regelen. Voor het eerst hebben we aangetoond dat een hoog 
natriumdieet de sulfatering van renaal HS in zoutongevoelige, normotensieve gezonde ratten 
verhoogt en dat dit geassocieerd is met remodellering van renaal weefsel. Interessant is dat deze 
tubulo-interstitiële veranderingen niet geassocieerd zijn met een verhoogd natriumgehalte van 
de nieren zelf. Er was sprake van een voorbijgaande piek in de bloeddruk in de eerste week, die 
mogelijk de reacties op het remodelleren van het weefsel had geïnduceerd. Dit zou kunnen 
suggereren dat hoge natriumdieet-geïnduceerde veranderingen in renale HS-structuur en 
tubulo-interstitiële remodellering van voorbijgaande aard kunnen zijn bij normotensieve ratten, 
aangezien we hebben aangetoond dat de ratten een verhoging van de bloeddruk konden 
compenseren door hun natriumuitscheiding te verhogen en door niet-osmotische dermale 
natriumopslag. Belangrijk is echter ook dat wanneer dit proces wordt verstoord in zoutgevoelige 
ratten of patiënten, een hoge inname van zout door de voeding kan leiden tot progressieve 
nierbeschadiging binnen 2 tot 4 weken. Deze bevinding kan belangrijke klinische gevolgen 
hebben voor zoutgevoelige patiënten, wat het belang van natriumbeperking onderstreept, in 
het bijzonder voor deze categorie patiënten.
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Om het directe effect van natrium op renale HS en weefselremodellering te evalueren, hebben 
we een in vitro onderzoek uitgevoerd met ‘precision cut’ plakjes muizennier en daarbij 
verschillende natriumconcentraties in het medium getitreerd 7. We hebben geen veranderingen 
in de markers waargenomen, wat erop wijst dat het effect van natrium op deze markers zoals 
waargenomen in vivo, zou kunnen worden beïnvloed door fysiologische tussenproducten. We 
denken dat een hoge werkbelasting van proximale tubulaire epitheelcellen, verhoogde RAAS 
en / of sympathische activiteit, verhoogde afgifte van vasoactieve mediatoren zoals endotheline 
en vasopressine, of cytokine-afgifte door ontstekingscellen een rol zouden kunnen spelen, 
maar dit is nog niet door ons in detail bestudeerd. In hoofdstuk 2 geven we daarom een 
eerste gedetailleerde beschrijving van een mogelijke mechanistische route, waarbij een hoge 
natriuminname door gezonde normotensieve ratten renale HS omzet in hoog gesulfateerde pro-
inflammatoire glycanen en zo de remodellering van het weefsel triggert. HS is niet betrokken bij 
de binding van natrium, maar de wijzigingen in HS veroorzaakt door het hoge natriumdieet zijn 
geassocieerd met tubulo-interstitiële remodellering in de nier. We bieden ook aanvullend bewijs 
voor de opkomende opvatting dat bloeddruk-onafhankelijke mechanismen ook een belangrijke 
rol spelen in de verergering van nierziekten door hoge inname van natrium in de voeding.
In hoofdstuk 3 hebben we geprobeerd onze eerdere bevindingen naar de kliniek te vertalen. 
We onderzochten weefselremodellering, glycosaminoglycanen en dermale natriumopslag 
bij gezonde proefpersonen en nierpatiënten, terwijl we probeerden de interacties tussen 
deze fenomenen te ontrafelen. In dit hoofdstuk hebben we aangetoond dat niet-osmotische 
dermale natriumopslag niet verhoogd is bij patiënten met chronische nieraandoeningen, 
maar dat nierziekte wel een rol speelt in het samenspel tussen dermale natriumopslag, 
natriumhomeostase en remodellering van het huidweefsel. Onze gegevens wijzen erop dat 
zowel natriumhomeostase, gereflecteerd door plasma-natrium, en verhoogde natriuminname, 
weerspiegeld door verhoogde natriumuitscheiding, associeert met de vorming van dermale 
lymfevaten en het verlies van dermale natriumopslagcapaciteit, terwijl nierfalen associeert 
met huidontsteking. We laten ook zien dat dialyse de remodellering van huidweefsel verder 
beïnvloedt. We gebruikten uniek materiaal van patiënten met chronische nierziekten; zowel 
hemodialysepatiënten als preëmptieve patiënten vóór transplantatie en hun gezonde donoren 
van ongeveer dezelfde leeftijd. Het is het eerste onderzoek naar verschillen in dermale 
natriumconcentratie, natriumhomeostase en remodellering van het weefsel bij deze groepen 
patiënten met eind stadium nierfalen. In het laatste decennium is het klassieke paradigma 
van natriumhomeostase in twijfel getrokken en uitgebreid onderzocht 8–10. Deze onderzoeken 
hebben aangetoond dat extra-renale niet-osmotische natriumopslag in huid, kraakbeen en 
bot een belangrijke rol speelt bij het handhaven van een uitgebalanceerd natriumgehalte in 
het plasma. In deze studie gebruikten we atomaire absorptiespectroscopie als een objectieve 
techniek om dermale natriumopslag in de menselijke huid te kwantificeren. Hoewel zowel de 
stikstof- als de natriummetingen gevoelig en robuust zijn, neemt de foutenmarge toe bij het 
gebruik van kleinere huidbiopten, omdat zowel natrium als stikstof worden berekend per mg 
nederlandse samenvatting, algemene discussie en toekomstperspectieven
A
530678-L-bw-Hijmans
Processed on: 17-4-2019 PDF page: 158
158
droog gewicht. Concluderend suggereren onze gegevens, zij het op basis van een klein aantal 
patiënten, dat er een wisselwerking bestaat tussen dermale natriumopslag, natriumhomeostase 
(gereflecteerd door natrium in het plasma) en natriuminname (weerspiegeld door 
natriumuitscheiding), remodellering van het huidweefsel en nierfunctie hoewel de causale 
relaties en GAG-betrokkenheid niet duidelijk zijn uit ons werk. De exacte mechanismen achter 
deze verschijnselen rechtvaardigen nader onderzoek en onderstrepen de op afstand gelegen 
huideffecten waargenomen bij nierpatiënten.
Concluderend beschrijft deel A van dit proefschrift de triggers van remodellering van het weefsel 
zoals proteïnurie, hoge natriuminname, bloeddruk en ziekteprogressie zelf. Hoewel ontsteking, 
fibrose en lymfangiogenese onafhankelijke componenten lijken te zijn onder proteïnurische 
omstandigheden (zie deel B), kan een hoog natriumdieet al deze componenten induceren 
door glycosaminoglycanen te gebruiken als pro-ontstekingsmediatoren, tenminste bij ratten. 
Ten slotte wordt de behandeling van natrium door het lichaam bij nierpatiënten onderzocht 
door beoordeling van dermale natriumopslag. Opslag van dermaal natrium bleek niet te zijn 
aangetast, ondanks tekenen van ontsteking en vorming van lymfevaten. Bij zowel ratten als 
mensen hebben we echter laten zien dat er een complex samenspel bestaat tussen dermale 
natriumopslag, natriuminname, natrium-plasma, remodellering van het weefsel en nierfunctie.
Ontleden van weefselremodellering bij nieraandoeningen. 
Veel nieraandoeningen gaan gepaard met proteïnurie, wat wordt gedefinieerd als de 
aanwezigheid van eiwitten, meestal albumine, in de urine. Bij gezonde personen vormt de 
glomerulaire capillaire wand een barrière tegen grotere moleculen (zoals albumine), waar een 
kleine hoeveelheid eiwit door de capillaire wand in het glomerulaire filtraat passeert en opnieuw 
wordt geabsorbeerd en afgebroken door de proximale tubuli. Een kleine hoeveelheid wordt 
uitgescheiden in de urine (de bovengrens van de normale eiwituitscheiding is 150 mg / dag 
en voor albumine is dit 30 mg / dag). Aanhoudende proteïnurie kan een trigger zijn voor een 
progressieve afname van de nierfunctie, verergering van chronische nierziekte en terminale 
nierziekte, en uiteindelijk voor de noodzaak voor dialyse of niertransplantatie 11–14. Zelfs onder 
tamelijk lage proteïnurie waarden verslechteren de nieren na verloop van tijd. Eiwitten in 
het glomerulaire filtraat activeren tubulaire cellen om veel chemokinen en mediatoren af te 
scheiden die pro-inflammatoire en profibrotische cascades kunnen activeren 15–18, wat kan leiden 
tot nierontsteking en fibrose 19.
Daarom richtten we ons in hoofdstuk 4 niet op de proteïnurie zelf, maar op de nadelige 
weefselremodellering stroomafwaarts van de proteïnurie. In ons adriamycine-geïnduceerde 
proteïnurie-model focussen we ons op tubulo-interstitiële lymfangiogenese (VEGFR3-
blokkade), instroom van monocyten / macrofagen (depletie door clodronaatliposomen) en 
pre-fibrotische myofibroblast-accumulatie en interstitiële fibrose (door S1P-agonist FTY720). Ten 
eerste blokkeerden we door het blokkeren van VEGFR3 perfect de lymfangiogenese in zowel 
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de proteïnurische ratten als in de gezonde controles. Hoewel deze bevinding therapeutische 
mogelijkheden voor kankerpatiënten zou kunnen bieden, had het geen invloed op ontsteking of 
fibrose in ons proteïnurie-model20. Vervolgens hebben meerdere onderzoeken (inclusief van onze 
groep) aangetoond dat macrofagen actief betrokken zijn bij het induceren van lymfangiogenese 
bij nierziekten, hoewel ze tegenstrijdige resultaten laten zien21–24. In dit hoofdstuk toonden we aan 
dat het inactief maken van macrofagen (middels clodronaatliposomen) noch interstitiële fibrose, 
noch lymfangiogenese kon verminderen. Vandaar dat de rol van macrofagen bij het induceren 
van lymfangiogenese erg contextafhankelijk lijkt te zijn. In ons model hebben we inderdaad 
gevonden dat proximale tubulaire cellen de belangrijkste bron van VEGF-C zijn, wat zou kunnen 
verklaren waarom de depletie van macrofagen de tubulo-interstitiële lymfangiogenese niet 
heeft verminderd. 
Tenslotte verminderde de FTY720-behandeling effectief het aantal lymfocyten in de 
bloedcirculatie en T-cellen in proteïnurische nieren, maar dit bleek geen enkele invloed te hebben 
op de lymfangiogenese van de nier of de influx van macrofagen. Interessant is dat FTY720 de 
toename van α-SMA-positieve myofibroblasten aanzienlijk kon voorkomen en niet effectief was 
in het verlagen van collageen III-depositie, maar wel de tubulo-interstitiële fibrosering (PAS-
scoring) significant verminderde. Dit suggereert dat α-SMA geen ideale marker lijkt te zijn voor 
collageen producerende cellen in interstitiële letsels, omdat veel (myo) fibroblasten die geen 
α-SMA tot expressie brengen, het vermogen van collageenafzetting hebben 25–27. De verlaging 
van de PAS-positiviteit in de met FTY720 behandelde dieren kan verband houden met een 
verminderde productie van proteoglycanen / glycosaminoglycanen door de (myo-) fibroblast, 
die mogelijk op een andere manier wordt gereguleerd dan via collegeen synthese. Hoewel 
het effectief targetten van al deze fenomenen van weefsel remodellering histologisch werd 
bewezen, had het targetten van een van deze fenomenen geen effect op andere karakteristieke 
fenomenen van weefsel modellering. 
Daarom tonen Deel B en Hoofdstuk 4 de onafhankelijkheid van inflammatoire (macrofagen, 
T-cellen) of fibrotische (myofibroblasten, collageen III en interstitiële fibrose) reacties van renale 
lymfangiogenese, althans in dit proteinurische-nefropathie-model. De verklaring hiervoor 
zou kunnen zijn dat in dit model tubulaire epitheliale cellen die continu de ultragefilterde 
plasmaproteïnen tegenkomen en zo worden geactiveerd, de belangrijkste bron zijn van veel 
chemokinen en mediatoren die de verschillende tubulo-interstitiële remodelleringsprogramma’s 
induceren, zoals lymfangiogenese, ontsteking en fibrose 18 (Figuur 1 ). 
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Figuur 1. Bij gezonde personen kan de glomerulaire capillaire wand een barrière vormen tegen 
grotere moleculen (zoals albumine), waar een kleine hoeveelheid eiwit door de capillaire basaal 
membranen het glomerulaire filtraat binnendringt en wordt afgebroken en weer geabsorbeerd 
door de proximale tubuli ( bovenste figuur). Bij nierpatiënten is de lekkage van eiwitten door de 
glomerulaire capillaire wand toegenomen en worden de epitheelcellen in de proximale tubulus 
geactiveerd, wat resulteert in lymfangiogenese, fibrose en ontsteking (lagere figuur). 
Het klinisch monitoren van weefsel remodellering 
In Hoofdstuk 5 wordt een overzicht gegeven van alle beschikbare biomarkers voor acuut 
nierfalen en chronische nierziekte. De laatste jaren is er veel onderzoek gedaan naar het vinden 
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van de beste biomarker voor het opsporen van nieraandoeningen. Terwijl veel biomarkers 
als ‘veelbelovend’ werden gemarkeerd, werd opmerkelijk weinig aandacht besteed aan hun 
‘actionability’ (vrij vertaald: de mogelijkheid verlenend om te handelen), ofwel, kan de bepaling 
van een biomarker richting geven aan de behandeling van de ziekte 28,29. We definieerden 
‘actionability’ als ‘de mate waarin volgens een biomarker kan worden gehandeld om het 
klinische management te verbeteren’. We voerden een PRISMA-analyse uit en concludeerden 
dat, ondanks de grote hoeveelheid literatuur over biomarkers, de vraag hoe patiënten moeten 
worden behandeld van wie het risico wordt gestratificeerd door een biomarkerniveau, 
grotendeels onbeantwoord blijft, waarbij albuminurie de enige uitzondering is. Daarom is de 
‘actionability’ van de biomarkers onbekend. De meest veelbelovende biomarkers waren TIMP-2 
x IGFBP7 voor acuut nierfalen en CKD273 voor chronische nierziekte. Biomarkers die gerelateerd 
zijn aan weefselremodellering 30,31. Bovendien, stellen we voor CKD een ander perspectief op 
functionele biomarkers voor door deze groep te verbreden met metabole biomarkers, zoals 
markers van botmineraalstoornissen, urinezuur, natriumuitscheiding in de urine en vitamine 
K-status. Deze biomarkers zijn zeer uitvoerbaar en in tegenstelling tot biomarkers voor nierschade, 
zijn therapeutische interventies in de meeste gevallen al beschikbaar.
In Hoofdstuk 6 hebben we een andere klasse van biomarkers onderzocht, namelijk 
afbraakfragmenten van collageen in de urine. We ontdekten dat urinaire afbraakfragmenten van 
collageen 3 (uC3M) meetbaar zijn zelfs voordat ze histologisch detecteerbaar zijn, waardoor het 
een vroege niet-invasieve voorspellende marker voor nierfibrose is. Dissectie van verschillende 
fibrotische routes met behulp van S1P-modulator FTY720 toonde aan dat uC3M specifieker was 
in het weergeven van renale fibrose, in het geval van collageenafzetting, vergeleken met de 
meer algemeen gebruikte PAS- of α-SMA-kleuring in nierspecimens. 
Wanneer we onze resultaten vergelijken met wat werd gevonden bij mensen, ontdekten we 
dat uC3M afneemt bij mensen met progressie van ziekte, terwijl het toeneemt bij ratten 32. 
Het proces van fibrose bestaat uit zowel fibrogenese als afbraak van collageen. In de vroege 
ziektestadia (zoals aangetoond in ons diermodel), zijn fibrogenese en collageenafbraak met 
elkaar in balans en alleen wanneer de ziekte voortschrijdt, wordt fibrogenese sterker aanwezig in 
vergelijking met afbraak en beginnen fibrotische laesies te verschijnen 33. Het feit dat tijdens ziekte 
progressie de balans doorslaat naar fibrogenese kan worden verklaard door het feit dat bekend 
is dat collagenen kruislings met elkaar verbinden 34–36 en ontoegankelijk kunnen worden voor 
splitsing van collagenen door matrixmetelloproteases (MMP’s) 37–39. Vervolgens onderzocht Di 
Donato et al. de renale expressie van lysyloxidase en de effecten ervan op collageen crosslinking 
in verschillende stadia van chronische Adriamycine-nefropathie bij ratten 40. Ze toonden aan dat 
de mRNA-niveaus van lysyloxidase tot 3 maal toenamen in de Adriamycine-ratten in vergelijking 
met controles tussen 8 en 12 weken, en de niveaus teruggebracht werden tot normale niveaus na 
16 weken. Ze toonden aan dat een verhoogde expressie van lysyl-oxidase in de nier voorafgaat 
aan de ontwikkeling van diffuse fibrotische laesies en dat in dit stadium collageenstructuren 
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sterk gecrosslinkte componenten bevatten, het eindproduct van lysyl-oxidase-activiteit. In 
onze studie hebben we alleen de niveaus gemeten van collageenafbraakmarkers tussen 6 
en 12 weken na injectie met Adriamycine, de periode waarin lysyloxidaseniveaus toenemen, 
maar de crosslinking van collageen net is begonnen en bevindt zich niet in zijn laatste fase. Van 
lysyloxidase is ook aangetoond dat het betrokken is bij fibrose bij mensen 41,42. Bij patiënten met 
chronische nierziekten is de ziekte langer dan 6 tot 12 weken aanwezig en collageen crosslinking 
is dan al in overvloed aanwezig, waardoor MMP’s moeilijk de collagenen kunnen degraderen. 
Dit wordt weerspiegeld door de afnemende C3M-niveaus in de urine tijdens ziekteprogressie 
32. In deze studie zochten we naar een mogelijke vroege marker voor nierfibrose, wat de 
collageenafbraakfragmenten in de urine kunnen zijn, omdat ze al kunnen worden gevonden 
vóór de balans tussen renale fibrogenese en collageenafbraak verloren gaat.
Samenvattend concentreren we ons in Deel C op het klinisch monitoren van weefsel 
remodellering om progressie van de nierziekte te voorkomen. De meeste biomarkeronderzoeken 
missen informatie over hun ‘actionability’ en worden daarom niet vaak in de kliniek gebruikt. 
Vervolgens lijken collageenafbraakproducten een veelbelovende vroege marker voor nierfibrose 
te zijn en zijn mogelijk zeer ‘actionable’. Verder onderzoek is geboden.
Toekomst perspectieven
Dit proefschrift heeft aangetoond dat weefselremodellering kan worden gebruikt om 
nierschade en nierfunctieverlies te detecteren en te controleren. Daarom moeten klinische 
richtlijnen markers van weefselremodellering meenemen als de signatuur van nierbeschadiging 
naast metingen van de nierfunctie. Hoewel we duidelijkheid hebben proberen te krijgen 
over triggers van weefselremodellering, over de verschillende componenten / pathways van 
weefselmodellering en hun interactie, en tot slot hoe het remodelleren van weefsel kan worden 
gebruikt om nierschade klinisch te bewaken, rechtvaardigen nieuwe uitdagingen voor de 
onderzoeker, clinicus en patiënt nader onderzoek zoals hieronder beschreven. 
In het afgelopen decennium is er een interessante verschuiving waar te nemen in de manier 
waarop we denken over natriumhomeostase. Gedurende vele jaren werd natriumhomeostase 
uitgelegd in termen van transport en osmose gerelateerd aan osmotisch actief natrium. Meerdere 
studies hebben aangetoond dat natrium kan worden opgeslagen in kraakbeen, botten en zelfs 
de huid, waardoor het osmotisch inactief wordt 43–45. Onze bevindingen onderstrepen deze 
bevindingen, maar de exacte mechanismen blijven onbekend en vormen een zeer interessant 
onderzoeksgebied voor de komende jaren. Voor patiënten en hun artsen is het nog steeds 
onduidelijk waarom anti-proteinurische medicijnen bij sommige patiënten gunstige effecten 
hebben, terwijl ze in anderen geen therapeutische voordelen hebben. Hoewel natriumbeperking 
al lang een van de belangrijkste voedingsmaatregelen is in richtlijnen over het voorkomen 
van verergering van de nierziekte, is het voordeel ervan traditioneel beperkt gebleven tot 
bloeddrukbeheersing. De rol van natriumbeperking kan nog prominenter worden wanneer de 
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exacte mechanismen duidelijk worden, waarbij een hoge inname van natrium nierbeschadiging 
induceert, onafhankelijk van de bloeddruk. Daarom zijn interventiestudies in zowel dierstudies 
als bij mensen nodig om grondig te onderzoeken wat de mogelijke ontbrekende schakel is in 
het begrijpen van de exacte mechanismen achter de niet-osmotische natriumopslag en de 
schadelijke effecten ervan op zowel nieren als andere organen. 
Dieetinterventies zijn niet alleen belangrijk voor het begrijpen van de ziekte; ze spelen ook een 
belangrijke rol bij het opsporen van nierbeschadiging. Naast de vaak gebruikte functionele 
biomarkers, zijn markers zoals natriumuitscheiding via de urine, vitamine K-status, botmineralen 
en urinezuur zeer uitvoerbaar en kunnen ze gemakkelijk worden behandeld als afwijkingen 
worden gevonden. De toekomstige diagnose en behandeling van nierpatiënten zal niet alleen 
gericht zijn op het classificeren van het type en de ernst van de nierziekte, maar ook op hun 
voedingsgewoonten, als een aanpasbaar doelwit voor interventie.
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